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Abbreviations 
The following abbreviations are used in the text: 
 
Compounds 
Abbreviation Systematic name  Common name 
5-FC 5-fluorocytosine  
5-FdUMP 5-fluoro-2’deoxyuridine 5’-monophosphate  
5-FdUTP 5-fluoro-2’-deoxyuridine 5’-triphosphate  
5-FU 5-fluorouracil  
5-FUri 5-fluorouridine  
5-FUTP  5-fluorouridine 5’-triphosphate  
aKG alpha-ketoglutarate, 2-oxoglutarate  
BAL beta-alanine  
BUP N-carbamoyl-beta-alanine beta-ureidopropionate 
DBAIB D-2-methyl-beta-alanine beta-aminoisobutyrate 
DBUIB 2-methyl-N-carbamoyl-beta-alanine beta-ureidoisobutyrate 
DHO 5,6-dihydroorotate dihydroorotate 
DHT 5,6-dihydrothymine dihydrothymine 
DHU 5,6-dihydrouracil dihydrouracil 
FBAL alpha-fluoro-beta-alanine  
GABA 4-amino-n-butyric Acid gamma-aminobutyrate 
LBAIB L-2-methyl-beta-alanine beta-aminoisobutyrate 
MMSA methylmalonic semialdehyde  
MSA malonic semialdehyde, 3-oxopropanoate  
PLP pyridoxal-5’-phosphate  
PRPP 5’-phosphoribosyl-1’-pyrophosphate  
SSA succinic semialdehyde, 4-oxobutanoate  
UDP uridine diphosphate  
UMP uridine monophosphate  
UTP uridine triphosphate  
 
  
Enzymes 
Abbreviation Systematic name  EC Other name(s) 
ATC carbamoyl-phosphate:L-aspartate 
carbamoyltransferase 2.1.3.2 
aspartate transcarbamoyltransferase, 
Ura2p 
BAL-AT I beta-alanine:2-oxoglutarate aminotransferase 2.6.1.19 beta-alanine transaminase, Pyd4p 
BAL-AT II beta-alanine:puryvate aminotransferase 2.6.1.18 beta-alanine transaminase, DBAIB-AT 
BAA barbiturate amidohydrolase 3.5.2.1 barbiturase 
CD cytosine aminohydrolase 3.5.4.1 cytosine deaminase, Fcy1p 
CDD cytidine aminohydrolase 3.5.4.5 cytidine deaminase, Cdd1p 
CPSII carbon-dioxide:L-glutamine amido-ligase (ADP-forming, carbamate-phosphorylating) 6.3.5.5 
Carbamoylphosphate synthase II, 
Ura2p 
CAA cyanuric amidohydrolase   
DHODH (S)-dihydroorotate:oxygen oxidoreductase 
1.3.1.14 
1.3.3.1 
1.3.99.11 
dihydroorotate dehydrogenase, Ura1p 
DHOT (S)-dihydroorotate amidohydrolase 3.5.2.3 dihydroorotase, Ura4p 
DHP 5,6-dihydropyrimidine amidohydrolase 3.5.2.2 dihydropyrimidinase, Pyd2p 
DHPDH 5,6-dihydrouracil:NADP+ 5-oxidoreductase 1.3.1.2 dihydropyrimidine dehydrogenase (NADP+) 
GABA-AT 4-aminobutanoate:2-oxoglutarate 
aminotransferase 2.6.1.19 
gamma-aminobutyrate transaminase, 
Uga1p 
MMSADH methylmalonate semialdehyde dehydrogenase (acylating) 1.2.1.27  
MSAD malonic semialdehyde decarboxylase   
MSADH malonate semialdehyde dehydrogenase (acylating) 1.2.1.18  
OMPD Orotidine-5'-phosphate carboxy-lyase 4.1.1.23 Ura3p 
OPRT orotidine-5'-phosphate:diphosphate phospho-
alpha-D-ribosyltransferase 2.4.2.10 
orotate phosphoribosyltransferase, 
Ura5p, Ura10p 
SSADH succinic semialdehyde dehydrogenase 1.2.1.24 Uga2p 
TS thymidylate synthase 2.1.1.45  
UDH uracil dehydrogenase 1.1.99.19  
UM beta-ureidomalonase   
UP N-carbamoyl-beta-alanine amidohydrolase 3.5.1.6 beta-ureidopropionase, beta-alanine 
synthase, Pyd3p 
UPRT UMP:diphosphate phospho-alpha-D-
ribosyltransferase 2.4.2.9 
uracil phosphoribosyltransferase, 
Fur1p 
URH uridine ribohydrolase 3.2.2.3 uridine nucleosidase, Urh1p 
URK ATP:uridine 5'-phosphotransferase 2.7.1.48 uridine kinase, Urk1p 
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ABSTRACT 
It is generally believed that pyrimidine degradation is initiated by either a reductive or an 
oxidative step! Are there really no alternatives? Degradation of pyrimidines is of a great 
importance in humans. Defects in the genes involved in the corresponding pathway cause 
severe symptoms, and especially in cancer patients a combination of gene defects and 
chemotherapy with e.g. 5-fluorouracil (a widely used anti-cancer drug) can have fatal 
consequences. The first step in the catabolic pathway performed by dihydropyrimidine 
dehydrogenase (DHPDH), has been found in mammals, insects, plants and bacteria. This first 
step has so far not been found in the fungi kingdom, but two genes (PYD2 and PYD3) 
encoding the two subsequent steps in the catabolic pathway, have previously been 
characterized in the yeast, Saccharomyces kluyveri. In this thesis, the origin of the uracil 
degradation pathway in yeast, and the genetic background for uracil and beta-alanine (BAL) 
catabolism in S. kluyveri, were investigated. 
The ability to use uracil, dihydrouracil (DHU), beta-ureidopropionate (BUP) and BAL as 
nitrogen source was studied in thirty-eight yeast species selected to cover the ”Saccharomyces 
complex”, which originated more than 200 mill. years ago. Uracil, DHU and BUP 
degradation were found to be linked in almost all the thirty-eight yeast species tested, and the 
pathway was apparently lost after the whole genome duplication. The ability to use BAL as 
sole nitrogen source was not linked to the three others, and was lost more or less randomly. In 
order to study the genetic background of uracil degradation in S. kluyveri a number of mutants 
defective in uracil degradation were isolated, and the defects were found to belong to six loci 
(PYD11,12,13,14,15,16). None of these loci were allelic to the previously described PYD2 
and PYD3 loci, and all of the mutants could use DHU and BUP as sole nitrogen source. 
Targeted disruption of all eight loci showed that uracil is degraded by a pathway consisting of 
the PYD1X genes, while DHU is degraded by a pathway consisting of PYD2 and PYD3. 
Surprisingly, uracil is degraded via UMP, and urea is an intermediate. A new gene, termed 
PYD4, found to be involved in DHU degradation was isolated. PYD4 encodes a pyridoxal-5’-
phosphate-dependent aminotransferase, which shows similar activity and substrate specificity 
as mammalian BAL/gamma-aminobutyrate aminotransferase (BAL/GABA-AT) [EC 
2.6.1.19]. S. kluyveri also has an UGA1 encoded GABA-AT [EC 2.6.1.19], which is specific 
for GABA. The original gene was apparently duplicated, thus giving PYD4 and UGA1, less 
than 200 mill. years ago.  
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DANSK RESUME 
Det første skridt i nedbrydningen af pyrimidiner er enten en reduktiv eller en oxidativ 
reaktion! Er der virkelig ingen alternativer? Nedbrydningen af pyrimidiner har stor betydning 
i mennesket. Genetiske defekter i den tilhørende pathway medfører alvorlige symptomer og 
specielt i for kræftpatienter, som får pyrimidinbaseret kemoterapi (f.eks. 5-fluorouracil, som 
er et meget anvendt kræfthæmmende stof), kan disse defekter få letale konsekvenser. The 
første trin i den katabolske pathway udført af dihydropyrimidine dehydrogenase (DHPDH), er 
blevet fundet i pattedyr, insekter, planter og bakterier. Dette første skridt er dog endnu ikke 
blevet fundet i svampe riget, men to gener (PYD2 og PYD3), som koder for de efterfølgende 
trin i den katabolske pathway, er tidligere blevet karakteriseret i gæren, Saccharomyces 
kluyveri. I denne afhandling, bliver oprindelsen af uracil nedbrydningspathway’en i gær og de 
genetiske forudsætninger for uracil og beta-alanine (BAL) katabolisme i S. kluyveri 
undersøgt. 
Evnen til at bruge uracil, dihydrouracil (DHU), beta-ureidopropionate (BUP) og BAL som 
nitrogenkilde blev studeret i 38 gær arter. Disse var udvalgt, så de dækkede “Saccharomyces 
komplekset”, som opstod for mere end 200 mill. år siden. Evnen til at nedbryde uracil, DHU 
og BUP var sammenkædet i næsten alle 38 gær arter, som blev testet, og pathway’en blev 
tilsyneladende tabt efter genom duplikationen. Evnen til at bruge BAL som eneste 
nitrogenkilde var uafhængig af de tre andre, og blev tabt mere eller mindre tilfædigt. For at 
studere de genetiske forudsætninger for nedbrydning af uracil i S. kluyveri, blev et antal 
mutanter, som var defekte i nedbrydningen af uracil, isoleret, og defekterne tilhørte seks loci 
(PYD11,12,13,14,15,16). Ingen af disse var identiske med de to tidligere beskrevne, PYD2 og 
PYD3 loci og alle mutanterne kunne bruge DHU samt BUP som eneste nitrogenkilde. 
Målrettet ødelæggelse af alle otte loci viste, at uracil bliver nedbrudt via en pathway 
bestående af PYD1X generne, mens DHU bliver nedbrudt via en pathway bestånde af PYD2 
og PYD3. Overraskende nok, så blev uracil nedbrudt via UMP og urea var et intermediat. Et 
nyt gene, kaldet PYD4, som er involveret i nedbrydningen af DHU, blev isoleret. PYD4 koder 
for en pyridoxal-5’-fosfat-afhængig aminotransferase, som har sammenlignelig aktivitet og 
substratspecificitet som pattedyr BAL/gamma-aminobutyrate aminotransferase (BAL/GABA-
AT) [EC 2.6.1.19]. S. kluyveri har også en UGA1 kodet GABA-AT [EC 2.6.1.19], som er 
specifik for GABA. Det oprindelige gen blev tilsyneladende duplikeret for mindre end 200 
,ill. år siden, hvilket resulterede i PYD4 og UGA1. 
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GENERAL INTRODUCTION 
Pyrimidines are the key components or precursors in many biomolecules. The 
metabolism of pyrimidines (and purines) and their intercellular pool sizes greatly 
influence a number of normal cellular metabolic pathways, and are therefore central 
for proper functioning of the cell (Reviewed in Bianchi, 1998). 
Pyrimidine metabolism is split into three parts: anabolic, salvage and catabolic 
(Reichard, 1988). Figure 1 is an illustration of the pyrimidine metabolism around the 
central metabolite, uridine-5’-monophosphate (UMP).  
 
The anabolic pathway, where UMP is synthesized from simple organic compounds 
via six enzymatic steps involving carbamyl phosphatesynthase II (CPSII), aspartate 
transcarbamylase (ATC), dihydroorotase (DHOT), dihydroorotate dehydrogenase 
 
Figure 1: Pyrimidine metabolism. The three major pathways involved in pyrimidine metabolism, 
biosynyhesis, salvage and degradation are indicated. UMP synthesized or salvaged gets further 
metabolized and incorporated into DNA, RNA and phospholipids, and is directly involved in 
polysaccharide formation. The intermediate, beta-alanine, of pyrimidine degradation, is a constituent 
of pantothenate.  
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(DHODH), orotate phosphoribosyltransferase (OPRT) and orotidine 5’-phosphate 
decarboxylase (OMPDC) is ubiquitous in the biosphere, while the salvage pathway, 
where premade nucleobases and nucleosides are transported (via specific 
transporters), phosphoribosylated by uracil phosphoribosyltransferase (UPRT) or 
phosphorylated by uridine kinase (URK) to the UMP level, is found in higher 
eukaryotes, plants and several microorganisms. While the genes of the anabolic and 
salvage pathways seems to be conserved, the ability to catabolize pyrimidines has 
evolved in two alternative routes; (I) the reductive pathway employing the three 
consequetive activities of dihydropyrimidine dehydrogenase (DHPDH), 
dihydropyrimidinase (DHP) and beta-ureidopropionase (UP), or (II) the oxidative 
pathway employing the three consequetive activities of uracil dehydrogenase (UDH), 
barbiturase (BAA) and beta-ureidomalonase (UM). These catabolic pathways, which 
both use uracil or thymine as first compound, has been found in much fewer 
organisms than the de-novo and salvage pathways. The reductive is by far the most 
abundant of the two, and it has been fully or partly described in mammals, insects, 
plants, yeast and bacteria. With the expanding repertoire of genome sequences 
avaliable the number of organism possessing this pathway is ”growing”. The 
oxidative pathway has only been found in a few bacteria, and only two genes 
belonging to this pathway have been cloned. These genes have no homologs in any 
other sequenced organism, but share some identity to enzymes involved in other 
metabolic pathways. Beside the role as a nitrogen source for microorganisms, the end-
product of uracil degradation, beta-alanine (BAL), is a crucial component in the 
biosynthesis of pantothenate in many organisms (excluding mammals). Several other 
pathways are found in nature which provide BAL. Further degradation leads to 
malonic semialdehyde (MSA) and methylmalonic semialdehyde (MMSA), which in 
turn gets coupled to CoA. 
The reductive catabolic pathway has recieved a lot of attention since it has been found 
to be of clinical interest. It’s a key determinant in the cytotoxicity of some pyrimidine 
based anti-cancer drugs, and inborn errors in the enzymes of the catabolic pathway 
has been identified from a number of patients leading to primarily neurological 
defects and a lot of research is focusing on optimizing the drug administration by 
determining the patients susceptibility to the drug pretreatment.  
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Yeast has for a long time been used as a model organism to study basic cellular 
processes. Fundamental things like telomeres and aging, DNA replication/repair 
mechanisms and function of peroxisomes have been studied intensely in yeast, and 
brought much insight for the rest of the eukaryotic world (Aylon and Kupiec, 2004; 
Goldman and Kafer, 2004; Teixeira and Gilson, 2005; van Roermund et al., 2003). 
With the growing number of yeast genome sequences comparative genomics and 
evolution of not just genes or pathways but chromosome and genome dynamics can 
now be studied by global approaches. Information about intergenic sequences can be 
explored. There are still new areas, where yeast are becoming an important source of 
new information. Like fx. pyrimidine catabolism as mentioned before, where the yeast 
S. kluyveri is being developed as a model organism to study this pathway.  
For many years it has been attempted to describe the catabolism of pyrimidines in the 
fungi kingdom. It was evident that members of the group could degrade pyrimidines 
(by using them as sole nitrogen sources), but the way it was degraded did not always 
match with either of the two known catabolic pathways, so some rather exotic 
pathways were postulated. It was first in 1998, when the non-conventional yeast, 
Saccharomyces kluyveri, was used in a systematic study, that a clear evidence of the 
reductive pathway was found (Gojkovic et al., 1998). 
AIMS AND OUTLINE 
The idea of this Ph.D. project was to elucidate the pyrimidine degradation in yeast. 
The primary goal was identification of the first enzymatic step in the pathway, since 
the two subsequent steps had already been relatively well characterized (Gojkovic et 
al., 2000; Gojkovic et al., 2001). As it will be evident from Chapter 4, things have 
been taking a turn and some new and exciting discoveries have been made. Also 
questions like BAL degrading enzyme(s), the diversity of the pathway within the 
yeast species and the evolutionary relationship between the anabolic and catabolic 
pathways were in focus. 
In the following chapter (Chapter 2) the present status on pyrimidine catabolism and 
end-product metabolism is summarized. The de-novo pathway is interesting in this 
context, because the three enzymes in this pathway, namely ATC, DHO and DHODH 
share a great deal of identity with the three enzymes of the reductive pathway, UP, 
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DHP and DHPDH, respectively, and it seems the two pathways share the same origin. 
Since the organism studied in this work is a yeast, a section on yeast phylogeny, 
genomics and nitrogen metabolism is presented, and another part is dedicated 
specifically to S. kluyveri and the historical background of pyrimidine degradation in 
yeast/fungi.The following three chapters are the results obtained from this Ph.D.-
project. Chapter 3 describes the degradation of uracil and intermediates of the 
reductive pathway by thirty-eight yeast strains, representing the whole Saccharomyces 
complex including the genera Saccharomyces, Arxiozyma, Kluyveromyces, Candida, 
Zygosaccharomyces, Torulaspora and Hanseniaspora. The work has been accepted 
for publication: Andersen, G., Merico, A., Björnberg, O., Andersen, B., 
Schnackerz, K.D., Dobritzsch, D., Piškur, J. & Compagno, C. (2006) Catabolism 
of pyrimidines in yeast: a tool to understand degradation of anti-cancer drugs. 
Nucleosides Nucleotides Nucleic Acids. Chapter 4 is a presentation of a novel uracil 
degrading pathway found in yeast and bacteria. It is based on mutagenesis and gene 
knockout studies of the uracil pathway, and the results from the work done at 
Department of Medical Biochemistry and Biophysics, Umeå University in A. Hofer’s 
lab. In Chapter 5, the identification and cloning of the SkPYD4 and SkUGA1 genes, 
which encodes a BAL and gamma-aminobutyrate (GABA) aminotransferase (BAL-
AT, GABA-AT) respectively. The gene products were overexpressed, purified and 
characterized with newly developed coupled enzymatic assay. Also Uga1p (GABA-
AT) from S. cerevisiae and Schizosaccharomyces pombe were overexpressed, purified 
and partly characterized. This chapter will be submitted as a manuscript in may, 2006. 
Finally, in Chapter 6 is a general discussion with a summary of the results obtained 
and some concluding remarks on pyrimidine degradation in yeast. 
REFERENCES 
 
Aylon, Y. and Kupiec, M. (2004). DSB repair: the yeast paradigm. DNA Repair 
(Amst) 3, 797-815. 
Bianchi, V. (1998). Regulation of deoxynucleotide pools by substrate cycles. Adv. 
Exp. Med. Biol. 431, 501-506. 
Chapter 1 
8 
Gojkovic, Z., Jahnke, K., Schnackerz, K. D., and Piskur, J. (2000). PYD2 encodes 
5,6-dihydropyrimidine amidohydrolase, which participates in a novel fungal 
catabolic pathway. J. Mol. Biol. 295, 1073-1087. 
Gojkovic, Z., Paracchini, S., and Piskur, J. (1998). A new model organism for 
studying the catabolism of pyrimidines and purines. Adv. Exp. Med. Biol. 431, 
475-479. 
Gojkovic, Z., Sandrini, M. P., and Piskur, J. (2001). Eukaryotic beta-alanine synthases 
are functionally related but have a high degree of structural diversity. Genetics 
158, 999-1011. 
Goldman, G. H. and Kafer, E. (2004). Aspergillus nidulans as a model system to 
characterize the DNA damage response in eukaryotes. Fungal Genet. Biol. 41, 
428-442. 
Reichard, P. (1988). Interactions between deoxyribonucleotide and DNA synthesis. 
Annu. Rev. Biochem. 57, 349-374. 
Teixeira, M. T. and Gilson, E. (2005). Telomere maintenance, function and evolution: 
the yeast paradigm. Chromosome. Res. 13, 535-548. 
van Roermund, C. W., Waterham, H. R., Ijlst, L., and Wanders, R. J. (2003). Fatty 
acid metabolism in Saccharomyces cerevisiae. Cell Mol. Life Sci. 60, 1838-
1851. 
 
Introduction 
9 
 
 
CHAPTER 2 
 
INTRODUCTION 
 
 
DE NOVO UMP BIOSYNTHESIS .............................................................................10 
SALVAGE OF PYRIMIDINES..................................................................................11 
Transporters .......................................................................................................................................13 
REDUCTIVE CATABOLISM OF PYRIMIDINES...................................................14 
Dihydropyrimidine dehydrogenase....................................................................................................15 
Dihydropyrimidinase .........................................................................................................................16 
beta-Ureidopropionase.......................................................................................................................17 
OXIDATIVE CATABOLISM OF PYRIMIDINES....................................................17 
METABOLISM OF BETA-ALANINE AND D-AMINOISOBUTYRATE ..............18 
Biosynthesis.......................................................................................................................................20 
Catabolism .........................................................................................................................................21 
CLINICAL ASPECTS OF DEFECTS IN PYRIMIDINE DEGRADATION IN MAN
......................................................................................................................................24 
Genetic deficiencies...........................................................................................................................24 
Pharmacological influence.................................................................................................................25 
INTRODUCTION TO YEAST ...................................................................................26 
Phylogeny ..........................................................................................................................................26 
Nitrogen metabolism and regulation..................................................................................................27 
Pyrimidine degradation in yeast/fungi ...............................................................................................29 
Saccharomyces kluyveri.....................................................................................................................31 
REFERENCES ............................................................................................................32 
Chapter 2 
10 
DE NOVO UMP BIOSYNTHESIS 
The de novo biosynthesis of uridine monophosphate is composed of 6 enzymatic 
activities (Figure 1). Actually the first step, by carbamoyl phosphate synthase II 
(CPSII, EC 6.3.5.5), is composed of two catalytic activities, a glutamine-dependent 
amidotransferase and a synthetase, but is usually considered as one enzymatic unit 
(Simmer et al., 1990). CPSII catalyze the formation of carbamoyl phosphate from 
glutamine, ATP, CO2 and H2O. Carbamoyl phosphate and aspartate are by aspartate 
transcarbamylase (ATC, EC 2.1.3.2) turned into ureidosuccinate, which then gets 
dehydrated and circularized by dihydroorotase (DHOT, EC 3.5.2.3) to form 
dihydroorotate (DHO). In higher eukaryotes, this part of the pathway has evolved in  
a way that individual enzymatic steps have become physically linked in a multi-
funtional enzyme (Figure 2). In prokaryotes these enzymatic steps are encoded by 
four different genes, (pyrAa, pyrAb, pyrB, pyrC). In Dictyostelium discoideum, 
Drosophila melanogaster and mammals, the multi-functional enzyme, (called PYR1-
3, rudimentary and CAD, respectively), performs the first three enzymatic activities, 
CPSII, ATC and DHOT. In yeast this enzyme is called Ura2p, but even though it has  
 
Figure 1: Pyrimidine de-novo biosynthesis. The figure is showing the enzymatic reactions involved in UMP 
biosynthesis. Abbreviations used are, CPSII: Carbamoyl phosphate synthase II, ATC: Aspartate transcarbamoylase, 
DHOT: Dihydroorotase, DHODH: Dihydroorotate dehydrogenase, OPRT: Orotate phosphoribosyltransferase, 
OMPDC: Oridine-5’-monophosphate decarboxylase.  
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high identity to CAD, it contains an inactive DHOT, and instead has a separate 
enzyme performing the DHOT activity (Ura4p) (Denis-Duphil, 1989; Souciet et al., 
1989).  
 
The enzyme containing the inactive DHOT is believed to be ubiquitous in the fungal 
kingdom (Aleksenko et al., 1999). The fourth step, oxidation of DHO to orotate, is 
performed by dihydroorotate dehydrogenase (DHODH, EC 1.3.3.1). This is in 
eukaryotes done either within the mitochondrial matrix or in the cytoplasm, and the 
localization is dependent on two different types of DHODH (mtDHODH and 
cytDHODH). Apparently the cytoplasmic type is involved in the ability of a 
microorganism to grow under anaerobic conditions, where the respiratory chain is 
uncoupled (Gojkovic et al., 2004). Also some bacteria have two different types of 
DHODH enzymes (reviewed in Kilstrup et al., 2005). The orotate is 
phosphoribosylated by orotate phosphoribosyltransferase (OPRT, EC 2.4.2.10) to 
orotidine monophosphate (OMP), which in turn is decarboxylated to UMP by OMP-
decarboxylase (OMPDC, EC 4.1.1.23). These last two steps are again organized in the 
same protein in D. melanogaster and mammals (UMP synthase), while yeast have 
them separated (Ura5p,Ura10p and Ura3p respectively) (Figure 2). Ura5p and Ura10p 
are isoenzymes and both are functional (de Montigny et al., 1990). 
SALVAGE OF PYRIMIDINES 
The pyrimidine de novo pathway is found in almost all known organisms, and it is 
efficient enough to supply the needed pyrimidines (UMP) for growth, although a lot 
of organisms have a system for salvaging premade pyrimidines from the 
 
Figure 2: Evolution of multi-functionality within pyrimidine anabolic enzymes. E.coli has six genes, encoding (from left to 
right) CPSII, ATC, DHOT, DHODH, OPRT and OMPDC, respectively, while the more advanced organisms has evolved 
gene fusions.  
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surroundings, and thereby saving time, energy and building materials. This salvage 
pathway is composed of elements that sense and transport extracellular pyrimidines 
into the cytosol, where they quickly get transformed to the riboside monophosphate 
level (Figure 3). Some of the first identifications of genes involved in yeast 
pyrimidine salvage was done on the basis of 5-fluoropyrimidine resistance (Jund and 
Lacroute, 1970).  
 
The cytotoxic activity of the analog is exerted by the salvage pathway. This selectivity 
offered by the 5-fluoropyrimidines has been used to identify all enzymes involved in 
the pyrimidine-base salvage in yeast. Seven alleles were found to be involved in 
resistance to one or more of the three tested analogs, 5-fluorouracil (5-FU), 5-
fluorocytosine (5-FC) and 5-fluorouridine (5-FUri). Now eight genes involved in 
pyrimidine salvage pathway in yeast are known (Table 1), and it has been shown that 
the pathway primarily leads to UMP formation (Kurtz et al., 1999). The only 
exception is in the case of cytidine, where a limited amount is converted to CMP via 
Urk1p, while the majority is converted to UMP. Cytidine transport is dependent on 
the FCY2 encoded purine/cytosine transporter.  
 
Figure 3: Pyrimidine salvage pathway in S. cerevisiae. The figure shows the 
transport and conversion of different pyrimidines into UMP. Fur4p: uracil 
permease, Fui1p: uridine permease, Fcy2p: cytosine/cytidine permease, Fcy1p: 
cytosine deaminase, Cdd1p: cytidine deaminase, Urh1p: uridine hydrolase, 
Urk1p: uridine kinase, Fur1p: uracil phosphoribosyl transferase. (Kurtz et al., 
1999). 
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Transporters 
There are three pyrimidine transporter encoding genes in S. cerevisiae, FUR4 (uracil 
permease), FUI1 (uridine permease) and FCY2 (cytidine and cytosine permease) , 
which belong to a large family of microbial purine-related transporters (PRT) (de 
Koning and Diallinas, 2000). The FUR4 subfamily has 24 highly conserved amino 
acid residues, while the FCY2 subfamily has ten. Of these ten, only one (N374) is 
conserved in FCY2. This asparagine residue is located at the cell surface and involved 
in substrate recognition (Bloch et al., 1992). The uracil permease is present in the cell 
membrane at very low concentrations and the FUR4 mRNA has a half-life of 2 min 
(Chevallier, 1982). Upon arrival at the plasma membrane the protein gets 
phosphorylated, and in exponentially growing cells the Fur4p is rather stable (Volland 
et al., 1992; Volland et al., 1994). Under adverse conditions (high temperature, 
nutrient starvation), Fur4p is rapidly degraded, but also an increase in the internal 
uracil concentration has the same effect (Seron et al., 1999; Volland et al., 1994). The 
degradation pathway of Fur4p has been studied intensely, and it involves 
ubiquitination, endocytosis and subsequent proteolysis in the vacuole (Blondel et al., 
2004; Galan et al., 1994; Galan et al., 1996; Marchal et al., 2000; Volland et al., 
1994). Recently two uracil transporters (UPS1 and UPS2) from the plant, Arabidopsis 
thaliana, were characterized (Schmidt et al., 2004), but no other pyrimidine 
transporters from higher eukaryotes have been identified.  
Table 1: Pyrimidine salvage genes and gene products in S. cerevisiae. 
Gene Function Source 
FUR1 uracil phosphoribosyltransferase JUND 1970 
FUR4 uracil transporter CHEVALLIER 1982 
FUI1 uridine transporter WAGNER 1998 
URK1 uridine/cytidine kinase KERN 1990 
URH1 uridine/cytidine ribohydrolase KURTZ 2002 
FCY1 cytosine deaminase JUND 1970 
FCY2 purine/cytosine/cytidine transporter CHEVALLIER 1975 
CDD1 cytidine deaminase KURTZ 1999 
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REDUCTIVE CATABOLISM OF PYRIMIDINES 
The reductive pathway (Figure 4) starts with the reduction of the pyrimidine ring of 
uracil or thymine (but not cytosine) at the C5-C6 bond yielding either dihydrouracil 
(DHU) or D-dihydrothymine (DHT). This is done by the NAD+/NADP+-dependent 
dihydropyrimidine dehydrogenase (DHPDH, EC 1.3.1.1/1.3.1.2, respectively). The 
next step is hydrolytic cleavage of the dihydropyrimidine ring at the N3-C4 bond by 
dihydropyrimidine amidohydrolase (DHP, EC 3.5.2.2). The products are beta-
ureidopropionate (BUP) or D-beta-ureidoisobutyrate (DBUIB), respectively.  
 
 
 
Figure 4: Reductive pyrimidine degradation. First a 
NAD+/NADP+-dependent reduction is carried out by DHPDH. 
Then a hydrolysis of the dihydropyrimidines is done by DHP, 
and lastly a hydrolysis of the beta-ureido group by UP, 
results in ammonia, CO2 and the beta-amino acids, DBAIB 
and BAL.  
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Third step is also an amidohydrolytic reaction carried out by beta-ureidopropionase 
(UP, EC 3.5.1.6), which produces ammonia, carbondioxide and beta-alanine (BAL) or 
D-beta-aminoisobutyrate (DBAIB) respectively. The degradation pathway is said to 
stop at this level, but two more steps are involved in the full metabolism of the six 
pyrimidine atoms. The last nitrogen is removed from BAL and DBAIB inside the 
mitochondrial matrix by pyridoxal 5´-phosphate (PLP) dependent aminotransferases, 
producing malonic semialdehyde (MSA) and methylmalonic semialdehyde (MMSA), 
respectively. These become activated by coupling to coenzymeA (CoA) as acetyl-
CoA and propionyl-CoA. This will be presented in more detail later. In humans the  
pyrimidine nucleosides are cleaved by thymidine phosphorylase (TP) and uridine 
phosphorylase (URP) to free pyrimidine bases and ribose-1’-monophosphate, and 
then the free pyrimidine base is degraded (Johansson, 2003). 
 
Dihydropyrimidine dehydrogenase 
The enzyme activity has been identified in a large number of different organisms, but 
it is the mammalian enzyme that is the most well-studied. Rat and pig liver enzymes 
have been purified, and found to be homodimers of 220 kDa and 206 kDa, 
respectively (Podschun et al., 1989; Shiotani and Weber, 1981). They are both 
NADPH dependent enzymes containing both flavin molecules and iron-sulfur 
clusters. The pig DHPDH has been suggested to be following a two-site ping-pong 
mechanism (Podschun et al., 1990). First flavin molecules in site 1 gets reduced by 
electrons from NADPH, which then leaves as NADP+, then the electrons are 
transferred via the iron-sulfur clusters to flavin at site 2, where uracil binds and gets 
reduced to DHU and then leaves. The Km values were 10 ± 1 and 1.1 ± 0.1 µM for 
NADPH and uracil, respectively.  
Cloning of the pig and human DHPDH cDNA, showed that the enzymes consists of 
1025 amino acids with calculated Mw of 111416 and 111398 dalton, respectively 
(Yokota et al., 1994). The sequences revealed (based on homology to known motifs) 
the locations of the different motifs, but with the crystal structure of pig DHPDH it 
has been possible to pinpoint the residues in much more details (Dobritzsch et al., 
2001; Dobritzsch et al., 2002; Schnackerz et al., 2004).  
The promoter region of the human DHPDH gene has been characterized, and two 
regulatory elements located in the -121/+7 upstream region (Shestopal et al., 2000).  
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The only bacterial DHPDH that has been succesfully purified and characterized is 
from Alcaligenes eutrophus (Schmitt et al., 1996). The native enzyme was termed a 
homotetramer with a molecular mass of approx 210 kDa, even though SDS-PAGE 
showed two subunits sizes (47.5 kDa and 52 kDa) with different N-terminal 
sequences. From Brevibacillus agri strain NCHU1002 the first pyrimidine degrading 
gene cluster was reported, containing three closely spaced genes designated pydABC 
encoding putative DHPDH, DHP and UP, respectively (Kao and Hsu, 2003). 
Recombinant DHP and UP were characterized, but the DHPDH, could not be purified, 
and no activity could be measured. It was discovered that pyrimidines does not serve 
as a sole nitrogen source, while DHU, BUP and BAL do. Apparently it is only DHP 
and UP which are transcribed as a polycistronic mRNA, and the transcript is induced 
by dihydrouracil specifically. This type of regulation has also been shown in the yeast 
Saccharomyces kluyveri, where PYD2 and PYD3 mRNA is induced by DHU, and to 
some degree BUP, but not uracil (Gojkovic et al., 2000; Gojkovic et al., 2001). 
 
Dihydropyrimidinase 
This zinc-dependent DHP has been purified to homogeneity from bovine, calf, pig 
and rat liver (Brooks et al., 1983; Jahnke et al., 1993; Kautz and Schnackerz, 1989; 
Kikugawa et al., 1994). They are homotetrameric proteins with monomer sizes of 56.5 
kDa for bovine, and 54 kDa for the remaining three. The natural substrates for calf 
liver DHP are DHU and DHT, but glutarimide, thiohydantoin and barbiturate could 
also be hydrolyzed at 20 %, 1 % and 0.02 % of the DHT velocity, respectively. 
Diethylbarbiturate or DHO could be used as substrate or inhibit the enzyme. The 
forward reaction has a pH optimum between 8-10 with approx. 20 % of maximum 
Vmax/Km at pH 6. This pH dependency could indicate the presence of a charged amino 
acid active in substrate binding and/or catalysis (Kautz and Schnackerz, 1989).  
The genes encoding DHP’s have been cloned from mammals (Hamajima et al., 1996; 
Matsuda et al., 1996), nematodes (Li et al., 1992), insects and molds (Gojkovic et al., 
2003) and yeast (Gojkovic et al., 2000). The proteins show high sequence homology 
with other zinc-dependent cyclic amidohydrolases like DHOT, hydantoinase and 
allantoinase, and a common ancestry has been proposed (Gojkovic et al., 2003; Kim 
and Kim, 1998). Structures of yeast (S. kluyveri) and slime mold (D. discoideum) 
DHP’s have been resolved recently (Lohkamp et al., 2006). They show the same 
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overall structure and active site architecture, as members of the amidohydrolase 
family (DHOT, hydantoinase). Since DHOT is a pyrimidine biosynthetic enzyme, the 
previosly found sequence homology and now the finding of almost identical structural 
fold, strongly suggest a common origin of catabolic (DHP) and anabolic (DHOT) 
enzymes in pyrimidine metabolism.  
In vertebrates, a group of DHP homologous proteins (DRP), is involved in both 
central nervous system and enteric nervous system (Horiuchi et al., 2000; Inagaki et 
al., 2000). It seems as if DRP’s are required in most cell tissues (especially the brain, 
heart and skeletal muscle), while DHP is confined to the liver and kidney (Hamajima 
et al., 1996). 
 
beta-Ureidopropionase 
The final catabolic enzyme, UP, has been purified to homogeneity from rat and calf 
liver (Tamaki et al., 1987c; Waldmann et al., 2005), and partly purified from maize 
(Walsh et al., 2001), mouse liver (Sanno et al., 1970), Clostridium uracilium 
(Campbell, 1960). Genes have been cloned from rat (Kvalnes-Krick and Traut, 1993), 
human (Vreken et al., 1999), A. thaliana (Walsh et al., 2001) and S. kluyveri 
(Gojkovic et al., 2001). Also putative UP encoding genes from D. melanogaster and 
D. discoideum, have been identified by heterologues expression in a UP (pyd3) 
deficient S. kluyveri strain (Gojkovic et al., 2001). Phylogenetic analysis of different 
UP’s divides them into two groups, one having S. kluyveri UP grouped with bacterial 
N-carbamoyl-L-amino acid amidohydrolases, and another with all other UP’s 
(Gojkovic et al., 2001). Bacterial N-carbamoyl-D-amino acid amidohydrolases were 
placed somewhere between the two UP groups, indicating that the yeast UP evolved 
independently from the UP from higher eukaryotes. The recently determined structure 
suggests that the yeast UP shares the origin with some proteases (Lundgren et al., 
2003). 
OXIDATIVE CATABOLISM OF PYRIMIDINES 
The presence of the oxidative pathway was originally found in soil-bacteria belonging 
to the Mycobacterium, Corynebacterium and Norcadia genera (Hayaishi and 
Kornberg, 1952; Lara, 1952a; Lara, 1952b; Wang and Lampen, 1952). It was first 
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believed to be a 2-step pathway with uracil dehydrogenase (UDH, EC 1.1.99.19) 
converting uracil/thymine into barbiturate/5-methylbarbiturate. Then the barbiturates 
were hydrolyzed by barbiturase (BAA, EC 3.5.2.1) into urea and 
malonate/methylmalonate. It was first 50 years later when BAA was characterized 
from Rhodococcus erythropolis, it was clear that another enzyme was needed in order 
to change barbiturate into urea and malonate (Soong et al., 2001). The third enzyme 
was ureidomalonase (UM), which hydrolyzes ureidomalonate (product of the BAA 
reaction) to urea and malonate (Soong et al., 2002).  
The UDH gene has not been found yet, but the enzyme was partly purified and it was 
found to be dependent on methylene blue as electron acceptor (Hayaishi and 
Kornberg, 1952). 
BAA is a tetramer, with a theoretical monomer size of 39 kDa. It has the classical 
zinc-binding motif (D-X-H-X-H) known from the zinc-containing amidohydrolase 
superfamily, but where other members have the motif in the N-terminal part, 
barbiturase has it in the C-terminal part. Its closest relative is cyanuric 
amidohydrolase (CAA), which is involved in degradation of s-triazine herbicides 
(Karns, 1999). A noteable thing is that CAA does not contain the two crucial 
histidines in the zinc-binding motif. It is speculated that the enzyme evolved from 
BAA, because of the unatural substrate and its locations on a transposable element 
(Eaton and Karns, 1991).  
METABOLISM OF BETA-ALANINE AND D-
AMINOISOBUTYRATE 
In microorganisms, a major function of BAL is as a constituent of pantothenate 
biosynthetic pathway (Webb et al., 2004). Pantothenate is formed by condensation of 
(R)-pantoate, derived from valine biosynthesis, and BAL (Figure 4).  
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Since pantothenate (vitamin B5) is an essential constituent in animal nutrition, BALs 
must have a different function, than pantothenate precursor, in animals. BAL is found 
in the rat central nervous system (CNS) along with known neurotransmitter gamma-
aminobutyrate (GABA) (DeFeudis and Martin, 1977). BAL has been shown to 
activate both glycine and GABAA receptors, and it works as a potent inhibitor of 
GABA uptake system in glial cells (Mabjeesh et al., 1992; Wu et al., 1993). Uptake 
systems in mouse brain and rat astrocytes have been demonstrated (Holopainen and 
Kontro, 1986; Kontro, 1983). The transport across the blood-brain barrier is mediated 
by a Na+/Cl- dependent mechnanism (Komura et al., 1996). This indicates a role of 
BAL in the vertebrate CNS, and some of the neurological symptoms seen in patients 
with defects in uracil degradation has been attributed to a decline in BAL 
concentrations (van Kuilenburg et al., 1999a). Recently this view has been weakened 
by the finding of normal levels of BAL in cerebrospinal fluid (CSF) and only weakly 
lowered levels in urine and plasma of patients with DHPDH deficiency (first step in 
pyrimidine degradation) (Fiumara et al., 2003; van Kuilenburg et al., 2004). How the 
BAL homeostasis is kept in these patients is not known, but metabolism of BAL 
containing dipeptides like carnosine (beta-alanyl-histidine) and anserine (beta-alanyl-
1-methyl-histidine) might play a role. In Drosophila melanogaster, BAL is involved 
in pigmentation, by condensation with dopamine to form N-beta-alanyl-dopamine, 
which in turn gets oxidized yielding a tan pigment. A mutation leading to a black 
 
Figure 4: (R)-pantothenate is synthesized by condensation 
of (R)-pantoate and BAL. 
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pigmentation (black, b), was shown to be caused by hyperactivity of BAL 
catabolizing enzyme, and a suppresor mutation (su(b)) was found to have decreased 
activity (Weber et al., 1992). BAL has also been shown as a neurotransmitter in 
insects (Sandberg and Jacobson, 1981). 
The function of DBAIB, the corresponding product originating from thymine 
degradation, is largely unknown, but also this molecule is thought to have a function 
in the CNS. Patients having DHPDH deficiency, show, contrary to BAL, a decrease in 
DBAIB level in CSF, and this might explain the neurological abnormalities seen in 
these patients (van Kuilenburg et al., 2004). 
 
Biosynthesis 
There are two major pathways for BAL synthesis besides uracil degradation, which 
were presented in the previous parts. These are L-aspartate decarboxylation and 
polyamine breakdown, but also other pathways have been proposed (Figure 5). In E. 
coli, direct decarboxylation of L-aspartate by the panD gene product, aspartate 
decarboxylase (ASPDC, EC 4.1.1.15) gives BAL and CO2 (Cronan, Jr., 1980). The  
panD gene along with the three other pan genes, panB (ketopantoate 
hydroxymethyltransferase, EC 2.1.2.11), panC (pantoate-BAL ligase, EC 6.3.2.1), 
and panE (2-dehydropantoate 2-reductase, EC 1.1.1.169) constitutes the pantothenate 
 
Figure 5: Different ways of BAL synthesis. The major routes are the prokaryotic decarboxylation of L-aspartate, the 
yeast breakdown of putrescine, spermine and spermidine, and the more widely distibuted reductive degradation of 
uracil found in bacteria, yeast, insects and mammals. The minor routes are hydrolysis of the dipeptides carnosine 
and anserine, and the multi-step conversion of propionate to BAL with malonic semialdehyde being the immidiate 
precursor.  
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biosynthetic pathway. In S. cerevisiae, the ECM31 and PAN6 (YIL145c) genes are 
homologous to panB and panC, respectively, and are required for pantothenate 
biosynthesis (White et al., 2001). PAN5 (YHR063c) is a structural homolog of panE, 
and is therefore thought to be involved in (R)-pantoate synthesis. Instead of using 
aspartate as a BAL source, S. cerevisiae uses two specialized aldehyde 
dehydrogenases (ALD2 and ALD3) to convert 3-aminopropanal to BAL (White et al., 
2003). The 3-aminopropanal is synthesized by polyamine degradation (from three 
SPE genes) and the amine oxidase encoded by FMS1 (White et al., 2001). In some 
yeast, like A. nidulans and S. pombe, BAL (for pantothenate synthesis) is derived 
from uracil degradation and not polyamine breakdown or aspartate decarboxylation 
(Arst, Jr., 1978; Stolz et al., 2004). Uracil and beta-ureidopropionate (BUP), but not 
dihydrouracil (DHU) could serve as a BAL source in S. pombe. It was proposed that 
uracil is converted to BAL in an alternative way, bypassing DHU and maybe also 
BUP (Stolz et al., 2004). The pantoC-3 mutant of A. nidulans could use BUP, but not 
uracil or DHU as BAL source and was believed to be blocked in DHP (second step of 
uracil degradation) (Arst, Jr., 1978). It was also found that 10 mM DL-beta-
aminoisobutyrate ([DL]BAIB) could be used as a BAL source in the pantoC-3 strain, 
but not by a pantoC-3 gatA-2 (gamma-aminobutyrate aminotransferase, GABA-AT). 
This led to the conclusion, that a GABA-AT catalyzed conversion of malonic 
semialdehyde could serve as a BAL source. 
 
Catabolism 
BAL and DBAIB are further transported into the mitochondria where they are 
catabolized to malonic semialdehyde (MSA) and methylmalonic semialdehyde 
(MMSA), respectively (Mizota et al., 1988; Tamaki et al., 1987b). In mammals this is 
done by BAL aminotransferase (BAL-AT, EC 2.6.1.19) and DBAIB aminotransferase 
(DBAIB-AT, EC 2.6.1.40), respectively (Tamaki et al., 1982; Ueno et al., 1990). 
There is an enormous substrate overlap within this group of enzymes (Table 2), which 
has resulted in some enzymes were given multiple names.  
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For example the enzyme L-beta-aminoisobutyrate aminotransferase (LBAIB-AT, EC 
2.6.1.22), which is involved in valine metabolism, and GABA aminotransferase 
(GABA-AT, EC 2.6.1.19) are identical to BAL-AT (Kontani et al., 1999; Tamaki et 
al., 1987a), and alanine-glyoxylate aminotransferase 2 (AGT 2, EC 3.6.1.44), is 
identical to DBAIB-AT (Kontani et al., 1993). Because both BAL-AT and DBAIB-
AT can use BAL as donor, they are sometimes termed BAL-AT I and BAL-AT II, 
respectively, where the real difference is that BAL-AT I specifically uses aKG as 
acceptor (EC 2.6.1.19) and BAL-AT II uses pyruvate (EC 2.6.1.18). It was found that 
in rats, BAL-AT I was the sole activity present in the brain, and in the liver and 
kidney it was seven times higher than BAL-AT II (Kontani et al., 1999). This 
identifies BAL-AT I as the major BAL catabolizing enzyme in mammalian systems, 
and BAL-AT II should be called DBAIB-AT. Since some bacterial BAL-AT 
enzymes, which use pyruvate as acceptor, cannot use [DL]BAIB as donor, these are 
indeed true BAL-AT II enzymes. To reduce confusion a list of the names with 
indication of the difference between them based on their activities is shown in Table 
3. The names listed in this table will be used throughout the text. Both brain and liver 
BAL-AT I are localized in the mitochondrial matrix (Schousboe et al., 1977; Tamaki 
et al., 1987b).  
 
Table 2: Relative activities of purified BAL-AT and DBAIB-AT. Numbers are as percentage of the enzyme activity. 
The highest AMINO DONOR and AMINO ACCEPTOR activity for each enzyme is set to 100. N.D. = not determined.  
 BAL-AT 
(Rabbit)a 
BAL-AT 
(Rat)b 
DBAIB-AT 
(Rat)c 
DBAIB-AT 
(Rat)d 
BAL-AT 
(B.cereus)e 
GABA-AT 
(B.cereus)e 
AMINO DONOR       
β-Alanine 76 100 60 100 100 3 
γ-Aminobutyrate 100 100 1 1 43 100 
δ-Aminovalerate 92 95 0 5 0 80 
DL-Aminoisobutyrate 39 48 78 48 0 0 
D-Aminoisobutyrate N.D. 1 100 100 N.D. N.D. 
L-Aminoisobutyrate N.D. 65 0 14 N.D. N.D. 
AMINO ACCEPTOR       
α-Ketoglutarate 100 100 3 0 27 100 
Pyruvate 6 2 100 92 87 6 
Glyoxylate 7 7 89 100 0 33 
Oxaloacetate 0 1 63 89 100 5 
a
 (Tamaki et al., 1982), b (Fujimoto et al., 1986), c (Tamaki et al., 1990), d (Ueno et al., 1990), e (Yonaha et al., 1985) 
Introduction 
23 
The rat brain and liver type BAL-AT I differ in the N-terminal amino acid sequence, 
both to each other, but also to the predicted sequence from rat cDNA, but the activity 
of the two enzymes were practically the same, only a little difference in KM for BAL 
was seen (Kontani et al., 1999). The difference in the N-terminal is due to the 
proteolytic activities of the two mitochondrial endopeptidases, which produces either 
the mature brain BAL-AT I or the mature liver BAL-AT I. The processing protease 
from the rat liver was identified as the 418-1305 peptide of carbamoylphosphate 
synthetase I (Ohyama et al., 2004). The human BAL-AT I gene is highly expressed in 
brain, liver, kidney and pancreas (Jeon et al., 2000). 
The products of the BAL-AT I and DBAIB-AT reactions are, as mentioned before, 
MSA and MMSA. These compounds are further metabolized to acetyl-CoA and 
propionyl-CoA by MMSA dehydrogenase (MMSADH) (Goodwin et al., 1989). In 
rats the enzyme is found in kidney and liver tissue, while neither mRNA or protein 
can be detected in the brain (Kedishvili et al., 1992). This distribution is much 
different from the BAL-AT I (liver, kidney and brain), but the same as DBAIB-AT 
(liver and kidney), as mentioned in previous section. This raises a question on how the 
rat catabolizes BAL in the brain, and if that does not happen, why is there BAL-AT I 
activity in the brain?. Either there is a specific brain type MMSADH or GABA is 
totally dominating the enzyme, hereby preventing BAL/DBAIB degradation. Because 
of MMSADH involvement in valine degradation, this enzyme has also been 
characterized and even crystallized from bacteria (Dubourg et al., 2004; Zhang et al., 
1996).  
Most yeast have the ability to utilize BAL as a sole nitrogen source (LaRue and 
Spencer, 1968). Usually yeast have a BAL-AT II and a GABA-AT (Yonaha et al., 
1983). In S. cerevisiae only the GABA-AT is present, and BAL cannot be degraded in 
this organism. In A. nidulans and U. maydis mutation in the gatA and ugatA loci 
respectively, decrease the ability to utilize BAL as sole nitrogen source, indicating 
Table 3: Terminology used for BAL degrading enzymes.  
Key: + = primary activity (>50% of best substrate), - = not substrate (<30% of best), +/- = indifferent 
 AMINO DONOR AMINO ACCEPTOR 
Name BAL DBAIB GABA aKG pyruvate 
BAL-AT I + - +/- + - 
BAL-AT II + - +/- - + 
DBAIB-AT + + +/- - + 
GABA-AT - +/- + + - 
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that these loci might encode BAL-AT I enzymes. The fact that they still grow to some 
degree, despite the presence of a mutation, shows that there is a substrate overlap with 
other aminotransferases in the cell. Nothing is known on MSA or MMSA metabolism 
in yeast. 
CLINICAL ASPECTS OF DEFECTS IN PYRIMIDINE 
DEGRADATION IN MAN 
Genetic deficiencies 
Inborn errors in the all three enzymes of the pyrimidine catabolic pathway have been 
identified (Berger et al., 1984; Duran et al., 1991; Moolenaar et al., 2001). The most 
commonly encountered is the DHPDH deficiency (more than 50 cases), while both 
the DHP deficiency and the UP deficiency has been described in around 5-10 patients 
each. The most common genotype leading to DHPDH deficiency is the IVS14+1G>A 
(> 50% of patients), which leads to a deletion of a 165-bp fragment (van Kuilenburg 
et al., 1999a). Usually, patients have first been diagnosed for having motor retardation 
and mental retardation for some time (Christensen et al., 1998; van Kuilenburg et al., 
1999b; Vreken et al., 1998). Urinary, plasma and CSF levels of thymine and uracil are 
elevated in DHPDH patients. Neurological abnormalities in patients suffering from 
DHPDH, DHP and UP deficiency have been explained by lowered BAL 
concentrations caused by the block in pyrimidine degradation. A study of the BAL 
and DBAIB concentrations in DHPDH patients, showed that BAL homoestasis was 
intact, indicating an alternative route for BAL synthesis (van Kuilenburg et al., 2004). 
DBAIB was significantly lower in DHPDH patients compared to controls, which 
might suggest that some of the abnormalities seen in patients, could originate from 
altered DBAIB instead. Nothing is known on the BAL and DBAIB homoestasis in 
patients with DHP and UP deficiency, since patients have not been tested for 
compounds or enzyme activities after the identified block. In patients with UP 
deficiency (UP activity is absent), a large increase in urinary BUP and DBUIB is 
detected (van Kuilenburg et al., 2001). Pyrimidine and dihydropyrimidine 
concentrations are slightly increased. A possible role of BUP in the neuropathology of 
patients with UP deficiency and patients with severe propionic aciduria has been 
proposed (Kolker et al., 2001). Deficiency in BAL-AT I is also very rare. The patients 
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have seizures, brain abnormalities and a high-pitched cry, an index of severe CNS 
disease (Medina-Kauwe et al., 1999). A large increase in GABA, homo-carnosine and 
BAL concentrations in both plasma and CSF was seen. The severity of the BAL-AT I 
disease, must be ascribed to the abnormal GABA metabolism, rather than the BAL 
metabolism. The first case of MMSADH deficiency was found in 1981 (Congdon et 
al., 1981). A characteristic over-excretion of BAL, [DL]BAIB and [DL]-beta-
hydroxyisobutyrate, along with an impairment in oxidation of 2-C of valine and 1-C 
of BAL (Gray et al., 1987; Pollitt et al., 1985). In another case normal BAL and beta-
hydroxypropionate excretions was seen, but valine and thymine metabolism showed 
clearly a deficiency in MMSADH (Roe et al., 1998). While the former patient was 
perfectly healthy, the latter showed signs of developmental delay, but still because of 
the mild phenotype, patients are rarely found. 
 
Pharmacological influence 
A lot of cancer types like colorectal, breast and head and neck are treated with the 
chemoterapeutic agent 5-fluorouracil (5-FU) (van Kuilenburg, 2004). The 5-FU needs 
to anabolised to the nucletide level in the cell in order to exert its cytotoxicity. It gets 
incorporated into RNA as 5-fluorouridine 5’-triphosphate (5-FUTP) and into DNA as 
5-fluoro-2’-deoxyuridine 5’-triphosphate (5-FdUTP) leading to destabilization of 
both. While these effects on the nucleic acid stability should be devastating for the 
cells, it is believed that the most profound anti-tumour effect exerted by 5-FU arises 
when it has been anabolised to the 5-fluoro-2’deoxyuridine 5’-monophosphate (5-
FdUMP) level. 5-FdUMP is a potent inhibitor the enzyme thymidylate synthase (TS), 
which is responsible for the methylation of dUMP. The dosage and administration 
schedule of the drug needs to be carefully planned in order to minimize the side 
effects from the treatment. DHPDH is believed to be a key determinant in the toxicity 
of 5-FU, while heterozygotes in DHP and UP do not seem to be affected. The 
reductive degradation of 5-FU leads to alpha-fluoro-beta-alanine (FBAL) and it’s the 
major (> 95 %) of urinary catabolites (Diasio and Harris, 1989). It has been found that 
defluorination of FBAL is caused be BAL-AT II in rat liver homogenates (Porter et 
al., 1995). The natural substrates of DHP is six-membered pyrimidine rings (eg. DHU 
and DHT), but it can also hydrolyze drugs based on the five-membered rings 
hydantoin and succinimide (Dudley et al., 1974). 
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INTRODUCTION TO YEAST 
Yeast have been used for millenia as “producers” of beer, wine and bread (Piskur et 
al., 2006), and recently also as producers bio-ethanol, vitamins and pharmaceutical 
products like hormones and protein drugs, through heterologues expression. Despite 
these ”good” purposes several yeast species are pathogenic to e.g. humans and plants. 
The most well-known yeast is Saccharomyces cerevisiae, which offers unique 
opportunities to study eukaroytic gene regulation and evolution, cell cycle, metabolic 
pathways and other molecular genetics and cell biology related subjects. The many 
years of focus on S. cerevisiae has left its genome thoroughly annotated, and even a 
functional profiling of the genome has been made (Giaever et al., 2002). Because of 
these effort’s in making S. cerevisiae the top yeast model organism, it is often used as 
a reference for annotations of genes from other organisms. In the recent years a 
number of genomic sequencing projects has been undertaken and now at least 16 
annotated fungal genomes are collectively available in NCBI databases. The power of 
having more genomes sequenched, is e.g. the annotation of ORF’s can be done more 
easily, if other homologs can be found. Start and stop codons are better determined, if 
the size of homologous proteins in other organisms is known. Comparative genomic 
analysis has greatly redefined the S. cerevisiae proteome, since comparisons of 
closely related species, reveal wrongly annotated genes. It is estimated that approx. 
500 of approx. 6000 annotated genes should be eliminated, approx. 300 start or stop 
codons should be changed (Kellis et al., 2003). Especially the non-coding regions of 
the genome are getting a lot of attention, since intergenic functional elements are 
difficult to find from a single genome sequence of poorly studied yeasts (Cliften et al., 
2001; Kellis et al., 2003). 
 
Phylogeny 
For a long time classification of yeast species in genera and families were based on 
morphology, sexual states and physiology. With the bioinformatical approach, based 
on sequences from slowly evolving genes like ribosomal DNA, the former 
classification has been redefined a number of times. Recently Kurtzman et al. divided 
the ”Saccharomyces complex” (Saccharomyces related species) into 14 clades 
(Kurtzman and Robnett, 2003). The resulting tree clearly showed that the previous 
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division of the species into taxa, based on behavior and abilities (phenotype), were not 
supported by their DNA sequence relationship (genotype). A simplified phylogenetic 
tree of the ”Saccharomyces complex” is presented in Figure 6. Especially two genera 
are split, as mentioned in the figure caption. Strains from the Saccharomyces genus 
has been divided into three groups; sensu stricto, sensu lato and an outgroup 
composed by S. kluyveri (Barnett, 1992). This would translate into groups, where 
sensu stricto species belong to clade 1, sensu lato species belong to clade 2 and 3, 
while S. kluyveri as an outgroup belong to clade 10. 
 
Nitrogen metabolism and regulation 
The flow of nitrogen is a central metabolic entity in microorganisms. Different yeast 
can utilize a variety of different compounds as sole nitrogen sources, indicating the 
presence of different specific catabolic pathways (Large, 1986). In general 
nitrogenous compounds like amino acids are easily utilized through transaminase 
reactions leading to glutamate, which is the predominant amino donor in many 
biosynthetic reactions. If a compound can serve as a nitrogen source, then usually all 
 
Figure 6: Simplified phylogenetic tree adapted from Kurtzman and Robnett, 
2003. Species from each of the 14 clades (branch points) are presented with 
S. cerevisiae being clade 1. It is seen that the genera Kluyveromyces 
(underlined) are found in two groups one close to S. cerevisiae (Clade 2, 4, 
5, 6) and one distant (Clade 10, 11). In Clade 10 is also found a 
Saccharomyces yeast, namely S. kluyveri (bold). 
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intermediates in the conversion from the compound to nitrogen (ammonia or 
glutamate) can be used. This is of course dependent on effective transport systems for 
the intermediates. An example of this is the S. cerevisiae allantoin degradation 
pathway. Allantoin is a degradation product from purine degradation, and its further 
degradation goes through five steps, before all four nitrogen atoms are liberated as 
ammonia (Figure 7). The first three steps are dependent on the DAL1-3 genes, 
encoding allantoinase (EC 3.5.2.5), allantoicase and ureidoglycolate hydrolase, 
respectively (Buckholz and Cooper, 1991; Yoo et al., 1985). This results in 
production of two urea molecules. S. cerevisiae does not have the normal urease (EC 
3.5.1.5.), but instead urea is degraded by the DUR1,2 gene product, a multifunctional 
urea amidolyase and allophanate hydrolase (Cooper et al., 1980).  
 
The genes in allantoin pathway are induced by the end-product allophanate or a non-
metabolizable analog oxalurate (Cooper and Lawther, 1973; Sumrada and Cooper, 
1974). Another pathway is the gamma-aminobutyrate (GABA) pathway (Ramos et al., 
1985). The catabolism of GABA is performed by UGA1 and UGA2, encoding GABA-
AT and succinic semialdehyde dehydrogenase (SSADH, EC 1.2.1.16). This pathway 
 
Figure 7: Allantoin degradation. Dal1p = allantoinase, Dal2p 
= allantoicase, Dal3p = ureidoglycolate hydrolase, Dur1p = 
urea carboxylase, Dur2p = allophanate hydrolase. 
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is induced by GABA, and regulated by the UGA3 gene product (Andre and Jauniaux, 
1990). 
The nitrogen metabolism are controlled on two levels; global (via nitrogen catabolite 
repression, NCR) and pathway (via specific inducers). Two GATA-family 
transcription factors Gat1p and Gln3p, function as global activators of for example the 
DUR, DAL and UGA, when a poor nitrogen source (proline) is present. When a good 
nitrogen source (glutamine, asparagine or ammonia) becomes available, Gat1p and 
Gln3p gets phosphorylated, excluded from the nucleus and prevented from reentering 
by the Ure2 protein (Cox et al., 2000; Cunningham et al., 2000a). Two other GATA-
family transcription factors Dal80p and Deh1p function as global repressors by 
competing with Gat1p and Gln3p (Coffman et al., 1997; Cunningham et al., 2000b; 
Svetlov and Cooper, 1998). Two non-global activators, Dal81p and Dal82p are 
involved in inducer specific activation of different pathways (Bricmont et al., 1991; 
ElBerry et al., 1993). The pathway specific inducer Uga3p, has only been found to 
induce UGA genes (Andre, 1990). 
 
Pyrimidine degradation in yeast/fungi 
It was Di Carlo et al that in 1952 made the first real study of pyrimidine degradation 
in yeast (Di Carlo et al., 1952). The reference was primarely work done on dogs by 
Cerecedo, Emerson and Stekol in the period from 1927-33 (Cerecedo, 1927; 
Cerecedo, 1930; Cerecedo, 1931; Emerson and Cerecedo, 1930; Stekol and Cerecedo, 
1931; Stekol and Cerecedo, 1933). Cerecedo and co-workers had come to the 
conclusion that the sequence of pyrimidine breakdown in dogs, was uracil -> 
isobarbiturate -> isodialurate -> urea + oxalic acid. Di Carlo and co-workers analyzed 
S. cerevisiae and Torula utilis (Pichia jadinii) for ability to grow on 64 different 
compounds. While the nitrogen from 14 compounds were fully assimilated by T. utilis 
only 4 (asparagine, aspartate, DHO and oxalurate) were assimilated in S. cerevisiae. A 
route leading from uracil -> DHU -> DHO -> urea was finally suggested. Two 
important observations were made; thymine and barbiturate did not support the 
growth of either species, and among the assimilated compounds by T. utilis uracil, 
DHU, BUP and BAL were found. Shortly after, the reductive degradation of both 
thymine and uracil was showed in rats, and the reversibility of the first and second 
step, but not the third was demonstrated (Fink et al., 1952; Fink et al., 1953; Fink et 
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al., 1956). In the filamentous fungus Neurospora crassa appearence of DHU and BUP 
was reported in media from cells grown with excess uridine, and both uracil, DHU 
and BUP, but not BAL was shown to complement a pyrimidine requiring mutant 
(Woodward et al., 1957). Now, it looked as if the pyrimidine catabolic pathway of 
mammals and fungi, were at least very similar if not identical. This hypothesis was 
strengthened by new experiments on Torulopsis utilis (P. jadinii) demonstrating in-
vitro DHP activity in uracil grown cells, and the observation that cells adapted fast to 
a change in media from uracil to DHU or BUP (Piret et al., 1964). But it did not take 
long before urea was again postulated as the end-product of uracil degradation in two 
basidiomycetes, Agaricus bisporus and Lycoperdon pyriforme (Reinbothe, 1964). 
This time without the involvement of DHU, but rather via an oxidative pathway not 
including barbiturate or a reductive pathway implying ribotide derivatives of 
pyrimidines. 
Finally in 1968 a systematic (and ambitious) study on utilization of pyrimidines by 
127 species of yeast was published (LaRue and Spencer, 1968). Cytosine, uracil, 
thymine, DHU, DHT, BAL and [DL]BAIB were tested as sole nitrogen sources, and 
the result was complex. The uracil pathway was the most abundant with 69, 53, 69 
strains growing on uracil, DHU and BAL respectively. In the thymine pathway 13, 28, 
79 strains grew on thymine, DHT and [DL]BAIB respectively. Of the 69 strains 
growing on uracil 48 grew on DHU, and of the 13 strains growing on thymine four 
grew on DHT. All in all, there was no clear evidence for a widespread intact reductive 
pathway within the yeast, but practically all non-cerevisiae like Saccharomyces 
strains tested, could grow on the tested compounds except thymine. However, the 
main deficiency of these studies was the phylogenetic relationship among the tested 
yeasts was not clear.  
It was not until 1998, that the study of the yeast pathway, was taken up again, 
focusing on S. kluyveri, which contrary to indications from the name, is a not a close 
relative of S. cerevisiae. (Gojkovic et al., 1998). Here random whole genome 
mutagenesis was used combined with mutant screening on media containing uracil or 
BAL as sole nitrogen sources. Four classes of mutants were produced, designated 
pyd1, pyd2, pyd3 and bac (PYrimidine Degradation and Beta-Alanine Catabolism) 
based on their lack of ability to use uracil, DHU, BUP or BAL as sole nitrogen 
sources. The reductive pathway has now been described in much detail in the yeast, S. 
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kluyveri, Two of the three genes involved (PYD2 and PYD3) have been identified by 
functional complementation of pyd2 and pyd3 mutants respectively (Gojkovic et al., 
2000; Gojkovic et al., 2001). The two geneproducts have been crystalized (Dobritzsch 
et al., 2003; Dobritzsch et al., 2005) and the structure have been determined 
(Lohkamp et al., 2006; Lundgren et al., 2003). Even though these findings represent a 
strong evidence for the presence of a functional reductive pyrimidine catabolic 
pathway in yeast, the first gene (PYD1) has not been identified yet. The Pyd1p 
enzymatic activity (DHPDH), has never been proven in-vitro, but indirect in-vivo 
evidence of the activity was demonstrated when 120 times higher amount of BUP was 
excreted by pyd3 cells compared to wild type cells when grown in proline + uracil 
media (both 0.1 %) (Gojkovic et al., 2001). 
 
Saccharomyces kluyveri 
It was first isolated from Drosophila pinicola in California (Phaff et al., 1956). It was 
found to be heterothallic, requiring two different mating types to sporulate 
(Wickerham, 1958). Sporulation results in 4 spherical spores per ascus, but the asci do 
not rupture upon maturity, which sometimes presents a problem in the laboratory. The 
first auxotrophic mutants described were ura3 selected on 5-fluoroorotate (Fujimura, 
1991). It was also shown that S. kluyveri ura3 could be complemented, when 
transformed with a centromere-based plasmid carrying the URA3 gene from S. 
cerevisiae. So both the stable replication of the centromere-based plasmid and the 
expression of a foreign gene was demonstrated. The HIS3 gene of S. kluyveri was 
partially removed in a ura3 background, showing the posibility to use homologous 
recombination as a molecular technique (Weinstock and Strathern, 1993). The 
Saccharomyces genus has been divided into petite-positive and petite-negative 
species, where the latter consists of only one, namely S. kluyveri. S. kluyveri can grow 
anaerobically, like all other Saccharomyces species, but it is not able to produce 
petites (Moller et al., 2001a). The ability to grow without oxygen, seems to be related 
to the de novo pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase 
(DHODH) (Gojkovic et al., 2004). The anaerobic S. cerevisiae has a cytosolic oxygen 
independent DHODH (ctDHODH), while the aerobic, Schizosaccharomyces pombe 
has a mitochondrial oxygen dependent DHODH (mtDHODH). S. kluyveri seems to be 
in between in that it has both the ctDHODH and the mtDHODH, and therefore has its 
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pyrimidine biosynthesis uncoupled from the respiratory chain. Since it’s not enough 
to have this ctDHODH for S. kluyveri to produce respiratory petites, other factors 
most be involved. The use of S. kluyveri as a heterologues protein producer showed a 
3.6 fold higher yield than a S. cerevisiae reference strain, when producing proteinase 
A (Moller et al., 2001b). What really makes S. kluyveri unique in the Saccharomyces 
genus is its ability to degrade a wide variety of nucleobases (Gojkovic et al., 1998; 
LaRue and Spencer, 1968). Especially the pyrimidine degradation pathway has been 
studied, and it has been shown that S. kluyveri degrades pyrimidines via the reductive 
pathway (described in more detail previosly). The S. kluyveri PYD2 gene encoding 
DHP, was the first gene found to be involved in pyrimidine degradation in unicellular 
eukaryotes (Gojkovic et al., 2000). Because of its evolutionary placement between 
primitive oxygen dependent and modern oxygen independent yeast, further studies 
into this organism might give more detailed information on the mechanism that drive 
evolution in the yeast genera. 
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ABSTRACT 
The pyrimidine catabolic pathway is of crucial importance in cancer patients, because 
it is involved in degradation of several chemotherapeutic drugs, as 5-fluorouracil, but 
it is also important in plants, unicellular eukaryotes and bacteria for the degradation of 
pyrimidine-based biocides/antibiotics. During the last decade we have developed a 
yeast species, Saccharomyces kluyveri, as a model and tool to study the genes and 
enzymes of the pyrimidine catabolic pathway. In this report we studied degradation of 
uracil and its putative degradation products in thirty-eight yeasts and showed that this 
pathway was present in the ancient yeasts but was lost app. 100 million years ago in 
the S. cerevisiae lineage. 
 
Keywords: uracil degradation, pyrimidines, yeast, evolution, cancer. 
INTRODUCTION 
Pyrimidine bases, among them several anti-cancer drugs, are degraded via a reductive 
or an oxidative pathway (Vogels and van der Drift, 1976). The reductive pathway is 
better studied, primarily because it is important in humans. The enzymes involved in 
the reductive degradation have been purified from a variety of organisms, like 
mammals, insects, molds, yeast and bacteria (Gojkovic et al., 2003; Schmitt et al., 
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1996; Yokota et al., 1994). The crystal structures of pig dihydropyrimidine 
dehydrogenase (DHPDH, EC 1.3.1.2), catalyzing the conversion of uracil to 
dihydrouracil (DHU) (Dobritzsch et al., 2001), and Saccharomyces kluyveri beta-
ureidopropionase (UP, EC 3.5.1.6), catalyzing the conversion of beta-
ureidopropionate (BUP) to beta-alanine (BAL) (Lundgren et al., 2003), have been 
solved. S. kluyveri dihydropyrimidinase (DHP, EC 3.5.2.2), which opens the DHU 
ring resulting in BUP has recently been crystallized (Dobritzsch et al., 2005). In 
addition, two S. kluyveri catabolic genes, PYD2 and PYD3, encoding DHP and UP, 
and their expression have been characterized in detail (Gojkovic et al., 2000; 
Gojkovic et al., 2001). Thereby, S. kluyveri, is becoming a useful model to understand 
the degradation of pyrimidines. However, the fate of uracil in yeast and the involved 
genes and enzymes are still largely unknown. In this paper, we would like to address 
the origin of the present situation regarding the pyrimidine catabolism in yeast. 
Thirty-eight yeast species belonging to the genera Saccharomyces, Arxiozyma, 
Kluyveromyces, Candida, Zygosaccharomyces, Torulaspora and Hanseniaspora were 
analyzed for their growth on uracil, DHU, BUP and BAL as the sole nitrogen source. 
One should keep in mind that the ability to utilize uracil as the sole nitrogen source is 
a complex of several biochemical pathways and the corresponding regulatory 
mechanisms. 
MATERIALS AND METHODS 
Strains 
The strains used in growth experiments and their accession numbers are listed in 
Table 1. All strains are maintained in the ARS Culture Collection (NRRL), National 
Center for Agricultural Utilization Research (Peoria, Illinois USA), except 
Zygosaccharomyces bailii (ISA 1307) from Culture Collection of the Instituto 
Superior de Agronomia (Lisbon, Portugal), Zygosaccharomyces bailii (ATCC 36947) 
and Zygosaccharomyces bailii (ATCC 60483) from American Type Culture 
Collection (Manassas, Virginia USA) and Kluyveromyces lactis (CBS 2359) from 
Centraalbureau voor Schimmelcultures (Utrecht, The Netherlands).  
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Growth test 
Uracil, DHU, BUP and BAL were purchased from Sigma. Yeast Nitrogen Base w/o 
amino acids and ammonium sulphate was purchased from Difco. The growth test was 
done by spotting 5 µL of culture on synthetic defined (SD) plates (1 % succinic acid, 
0.6 % sodium hydroxide, 2 % glucose, 0.17 % yeast nitrogen base w/o amino acids 
and ammonium sulfate, 2 % agar) supplemented with 0.5 % ammonium sulfate 
(control) or 0.1 % uracil, DHU, BUP and BAL respectively. Growth was determined 
after 7 days at 30°C. All given percentages are in w/v. 
RESULTS 
Utilization of uracil, DHU, BUP and BAL 
The ability of different strains to grow on uracil, DHU, BUP or BAL, as the sole 
nitrogen source, is shown in Table 1. The different species analyzed are listed 
according to their phylogenetic relationship, as reported by Kurtzman and Robnett 
(Kurtzman and Robnett, 2003). Note that the present yeast nomenclature does not 
reflect their phylogenetic relationship. For example, S. kluyveri is not very closely 
related to other Saccharomyces yeasts. In other words, higher a species is listed in this 
table, more closely it is related to S. cerevisiae. The growth was classified as no 
growth (-), some growth (+) and full growth (++), compared to the control plates 
(with ammonium sulfate as the sole nitrogen source). It is interesting to point out that 
the growth on uracil, DHU or BUP is in general linked in all species, but K. lodderae 
and H. valbyensis (Table 1).  
 
Loss of pyrimidine catabolic pathway 
Figure 1 shows a simplified tree of the Saccharomyces complex based on data from 
Kurtzmann and Robnett (2003) and summarizes the loss of the ability to grow on 
uracil, DHU, BUP and BAL. In general, the presence or absence of the tested abilities 
can be well explained as a function of the gene-loss events at various time-points in 
the evolutionary history. Uracil, DHU and BUP phenotypes are linked, and the ability 
to grow on these three compounds was “lost” independently and before the loss of the 
BAL phenotype (Figure 1). A few minor discrepancies are found within the ability to 
degrade BAL. The ability to utilize BAL was lost in the S. cerevisiae – S. rosinii 
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lineage (Table 1). Surprisingly, it is still found in S. unisporus, which is a very close 
relative of S. servazzii. S. unisporus has kept the ability even though it was lost in A. 
telluris, S. spencerorum and S. rosinii. Apparently, this ability has also, 
independently, been lost in the K. delphensis lineage (a close relative of C. glabrata) 
and C. castellii. K. delphensis and C. castellii has in fact lost this ability, even though 
all closely related species still posses it. 
 
 
Figure 1: The presence of pyrimidine degradation pathway. A simplified phylogenetic tree of five prominent yeast 
species is shown and the occurrence of the whole-genome duplication (WGD), which took place approximately 100 
mill. years ago, is indicated. The ability to utilize uracil, DHU, BUP and BAL is shown next to the species. 
DISCUSSION 
The yeast S. kluyveri can grow on uracil, DHU, BUP and BAL, which all are 
components of the reductive pyrimidine pathway known from humans, while S. 
cerevisiae cannot. The growth tests of thirty-eight strains from the Saccharomyces 
complex on uracil and the intermediates of the reductive pathway was done in order to 
understand the diversity and evolution of the ability to degrade pyrimidines. It seems 
that the ability to utilize uracil, DHU and BUP as sole nitrogen source was lost at 
approximately the same time, when the yeast genome was duplicated11, while the 
ability to use BAL was lost much later, and perhaps independently in a few lineages. 
Apparently, the major metabolic changes which followed the yeast genome 
duplication, made the possibility to regulate pyrimidine pools via degradation and to  
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produce BAL from BUP (for pantothenate synthesis) obsolete. The extensive 
sequencing of the yeast genomes (Piskur and Langkjaer, 2004) now provides a tool to 
find the genetic background for many phenotypes and to deduce their evolutionary 
history. However, one should keep in mind that we still do not understand the genetic 
Table 1: Utilisation of different nitrogen sources: growth on uracil, DHU, BUP and BAL was tested on minimum 
medium plates. The yeast strains are listed according to the phylogenetic relationship presented by Kurtzman and 
Robnett, 2003.  
Strain (Accesion number) Uracil DHU BUP BAL 
Saccharomyces cerevisiae (CEN.PK 113-7D) - - - - 
Saccharomyces paradoxus (Y-17217) - - - - 
Saccharomyces pastorianus (Y-27171) - - - - 
Saccharomyces bayanus (Y-12624) - - - - 
Saccharomyces servazzii (Y-12661) - - - - 
Saccharomyces unisporus (Y-1556) - - - ++ 
Arxiozyma telluris (YB-4302) - - - - 
Saccharomyces spencerorum (Y-17920) - - - - 
Saccharomyces rosinii (Y-17919) - - - - 
Kluyveromyces lodderae (Y-8280) - - + ++ 
Saccharomyces exiguus (Y-12640) - - - ++ 
Saccharomyces barnettii (Y-27223) - - - ++ 
Candida humilis (Y-17074) - - - + 
Saccharomyces castellii (Y-12630) - - - ++ 
Candida glabrata (Y-65) - - - ++ 
Kluyveromyces delphensis (Y-2379) - - - - 
Kluyveromyces bacillisporus (Y-17846) - - - ++ 
Candida castellii (Y-17070) - - - - 
Kluyveromyces blattae (Y-10934) - - - ++ 
Kluyveromyces phaffii (Y-8282) - - - + 
Zygosaccharomyces rouxii (Y-229) ++ ++ ++ ++ 
Zygosaccharomyces bailii (ISA 1307) ++ ++ ++ ++ 
Zygosaccharomyces bailii (ATCC 36947) ++ ++ ++ ++ 
Zygosaccharomyces bailii (ATCC 60483) ++ ++ ++ ++ 
Zygosaccharomyces bisporus (Y-12626) ++ ++ ++ ++ 
Zygosaccharomyces florentinus (Y-1560) ++ ++ ++ ++ 
Torulaspora globosa (Y-12650) ++ + + ++ 
Torulaspora pretoriensis (Y-17251) + + + ++ 
Torulaspora delbrueckii (Y-866) + + ++ ++ 
Zygosaccharomyces microellipsoides (Y-1549) ++ ++ ++ ++ 
Zygosaccharomyces fermentati (Y-7434) ++ ++ ++ ++ 
Kluyveromyces thermotolerans (Y-8284) ++ + ++ ++ 
Saccharomyces kluyveri (Y-12651) ++ ++ ++ ++ 
Kluyveromyces wickerhamii (Y-8286) ++ ++ ++ ++ 
Kluyveromyces lactis (CBS 2359) ++ ++ ++ ++ 
Hanseniaspora valbyensis (Y-1626) ++ - - ++ 
Hanseniaspora vineae (Y-17529) ++ + + ++ 
Hanseniaspora occidentalis (Y-7946) - - - ++ 
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or biochemical background of uracil degradation in any yeast. In addition, the ability 
to utilize uracil, DHU, BUP and BAL is a complex process which requires the 
presence of the genes coding for the degradation enzymes, presence of the recipients 
of the nitrogen originating from “poor” N-sources, an efficient uptake system, and a 
complex regulatory net. When our knowledge on all these elements is improved in at 
least one yeast species, a comparative genome analysis will add an even additional 
insight on the evolution of the uracil, DHU, BUP and BAL degradation. 
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ABSTRACT 
Have all metabolic pathways already been described? In mammals pyrimidine 
degradation starts with reduction of uracil to dihydrouracil (DHU), while in some 
bacteria uracil is initially oxidized to barbiturate. Previosly, it has been shown that in 
the yeast Saccharomyces kluyveri, two loci, PYD2 and PYD3 are involved in 
degradation of DHU and beta-ureidopropionate (BUP). These two genes are a part of 
the reductive pathway of uracil degradation. However when the PYD2 and PYD3 
genes were disrupted, the corresponding strains could still grow on uracil, but not on 
DHU or BUP. This suggested that in S. kluyveri uracil is not degraded via the 
reductive pathway. A mutagenesis approach and subsequent characterization of 
mutants revealed several genes (PYD11,12,13,14,15,16), that are involved in uracil 
degradation. Homology searches showed that these genes are also present in other 
fungi as well as in some bacteria, and in bacteria some of them (PYD11,14,16) are 
often clustered together. A HPLC method for separation of the reaction intermediates 
of the novel uracil degradation pathway was developed, and urea was identified as 
one of the intermediates along with five unidentified compounds. Apparently, the S. 
kluyveri PYD1 enzyme complex catalyzes a novel biochemical pathway, in which 
ribosylated uracil species (i.e. UMP) and urea seem to be the central intermediates. 
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INTRODUCTION 
Previous litterature reports that pyrimidine bases are degraded via a reductive or an 
oxidative pathway (Vogels and van der Drift, 1976). The reductive pathway, found in 
both eukaryotes and prokaryotes, consists of three enzymatic steps; dihydrouracil 
dehydrogenase (DHPDH), dihydropyrimidinase (DHP) and beta-ureidopropionase 
(UP). This pathway is most well studied in mammals, where substantial advances in 
understanding of its involvement in human disease (van Gennip et al., 1997) and 
pharmacokinetics of pyrimidine based drugs, like 5-fluorouracil (Kubota, 2003) have 
been achieved. The oxidative pathway has been found in soil bacteria of the genera, 
Mycobacterium, Corynebacterium and Norcadia (Hayaishi and Kornberg, 1952; Lara, 
1952a; Lara, 1952b; Wang and Lampen, 1952), but in fact only one enzyme involved 
in oxidative degradation (barbiturase) has been purified so far (Soong et al., 2001). 
The corresponding gene has been sequenced and this enzyme has a very limited 
number of homologous proteins among the known sequences (Soong et al., 2002). 
Pyrimidine degradation has been examined in a variety of fungi, but no clear picture 
of the existing pathways has been found (Di Carlo et al., 1952; LaRue and Spencer, 
1968; Reinbothe, 1964; Woodward et al., 1957). In recent years, the studies have been 
focused on the yeast, Saccharomyces kluyveri, where a genetic approach, identified 
three genetic loci (PYD1, PYD2, PYD3) possibly involved in the degradation of uracil 
to beta-alanine (BAL) via dihydrouracil (DHU) and beta-uriedopropionate (BUP) 
(Gojkovic et al., 1998). The last two genes (PYD2, PYD3), have been characterized, 
and found to encode the yeast DHP (Pyd2p) and UP (Pyd3p) with low (28 %) or no 
identity to their human counterparts (Gojkovic et al., 2000; Gojkovic et al., 2001). 
Both S. kluyveri DHP (Lohkamp et al., 2006) and UP (Lundgren et al., 2003) have 
been studied in detail, and their structure recently elucidated. However, so far the 
DHPDH activity (Figure 1), has not been measured in S. kluyveri, and a homologous 
gene has not been identified within the S. kluyveri genome sequence (Cliften et al., 
2003).  
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In this paper six genetic loci, PYD11,12,13,14,15,16, involved in the uracil 
degradation pathway in S. kluyveri are presented. Homology searches indicate that the 
pathway is also found in other fungi and bacteria. In order to separate individual 
intermediates of the pathway, a HPLC method was developed, confirming that uracil 
degradation in S. kluyveri represents a novel pathway. Speculations on the 
involvement of uracil degradation in beta-alanine (BAL) and pantothenate metabolism 
are discussed. 
MATERIALS & METHODS 
Materials 
Uracil (U0570), DHU (D7628), BUP (94250) and BAL (05159) were purchased from 
Sigma. Yeast nitrogen base w/o amino acids and ammonium sulfate was purchased 
from Difco. [2-14C]-uracil (MC124), [6-14C]-uracil (MC159), [2-14C]-uridine 
(MC105), [14C]-urea (MC141), [2-14C]-DHU (MC314), [carbamoyl-14C]-BUP 
(MC2047), [3H]-BAL (MT1527) were purchased from Moravek Biochemicals. Oligos 
used were purchased from DNA Technology, Denmark, and are presented in Table 1. 
Sequencing was done by MWG Biotech, Germany. 
 
Strains and growth media 
The S. kluyveri strains used for the knock-out and mutagenesis studies, and the strains 
produced in these studies are presented in Table 2. The strains were grown in YPD 
medium (1 % yeast extract, 2 % Bactopeptone, 2 % glucose) or synthetic defined 
(SD)/N-minimal medium (1 % succinic acid, 0.6 % sodium hydroxide, 2 % glucose, 
0.67 % yeast nitrogen base w/o amino acids and ammonium sulfate) supplemented 
with different nitrogen sources (0.5 % ammonium sulfate (SD), 0.1 % for all other 
types (N-minimal)). For solid medium (plates) 2 % agar was added. All percentages 
are w/v. The Escherichia coli strain XL1-Blue (Stratagene) was used for plasmid 
 
Figure 1: DHPDH reaction. 
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amplification. Bacteria were grown at 37°C in Luria-Bertani medium supplemented 
with 100 mg/L of ampicillin for selection (Sambrook et al., 1989). G418 selection 
media consisted of YPD supplemented with 75 mg/L of G418 (SIGMA G5013). 
 
Mutagenesis 
Yeast mutants were generated from the strains Y156 and Y159 with ethyl 
methanesulfonate (EMS) as described by Gojkovic et al., 1998. Mutagenized cells 
Table 1: Oligos used for targetted disruptions. Underlined sequences are reverse complements of either KanMX3 5’ 
or KanMX3 3’. 
Name Sequence (5’ -> 3’) 
KanMX3 5’ AAGCTTGCCTCGTCCCCGCCGGGTC 
KanMX3 3’ GGGCGCAGAGCCGTGGCAGGGCTCG 
PYD2 1-5’ GCTATGAGTTCTAGCAGAAAAGGGT 
PYD2 1-3’ GACCCGGCGGGGACGAGGCAAGCTTGTTCAATGTGGTGCAGGAGAATAGA 
PYD2 2-5’ CGAGCCCTGCCACGGCTCTGCGCCCGACTATTTAACTTGACATGATACAC 
PYD2 2-3’ CAGTGGTAAGAAACATGGTGAACTG 
PYD3 1-5’ TACTATTACTACTGTTTCCGCCAGC 
PYD3 1-3’ GACCCGGCGGGGACGAGGCAAGCTTAAAACGTGCACCTTCTTCGTTAAAC 
PYD3 2-5’ CGAGCCCTGCCACGGCTCTGCGCCCGGTTTGTTCACCTGTGGTATTATTG 
PYD3 2-3’ TCAGTGCCCTCTAATCACTCTGTAG 
PYD11 1-5’ ATATATATCAGCTCAGTGGCGTATC 
PYD11 1-3’ GACCCGGCGGGGACGAGGCAAGCTTGGAGATAGTTTGTTTTGATGGATTG 
PYD11 2-5’ CGAGCCCTGCCACGGCTCTGCGCCCTTAATGTTTGGTATTGAAGAAGCTG 
PYD11 2-3’ TTAATGTTTGGTATTGAAGAAGCTG 
PYD12 1-5’ ACATCTTTGTTTCGTTGGACTTC 
PYD12 1-3’ GACCCGGCGGGGACGAGGCAAGCTTGTAAGTAGTGCTCTGGTAGCCAATG 
PYD12 2-5’ CGAGCCCTGCCACGGCTCTGCGCCCAGAGAACACAGAGTGTGGAAAATC 
PYD12 2-3’ ATCTTTGACCCAAAGTACTACAAGC 
PYD13,15 1-5’ ACTTGTTTCCTATTTGACAGACTCC 
PYD13,15 1-3’ GACCCGGCGGGGACGAGGCAAGCTTAAACTATCCACCAAGATTTGTTTTC 
PYD13,15 2-5’ CGAGCCCTGCCACGGCTCTGCGCCCTCCTAGGTTCAAAGTACAATCCTTC 
PYD13,15 2-3’ CGAGTATTCAGAGTAAACCATCTCA 
PYD14 1-5’ GTGGAAATCTTCAAGACCTTAGTTG 
PYD14 1-3’ GACCCGGCGGGGACGAGGCAAGCTTTAATACACCCATGCATTCTACTCAC 
PYD14 2-5’ CGAGCCCTGCCACGGCTCTGCGCCCAAGTTTTCATCGAAGCTACCTTAAC 
PYD14 2-3’ ATTCTTGTTTAGATTGCAATGATCC 
PYD16 1-5’ GTGAGACAAAGCCTAACTAAAATCC 
PYD16 1-3’ GACCCGGCGGGGACGAGGCAAGCTTTAATCCTTGTAAAACTTCCCATTTC 
PYD16 2-5’ CGAGCCCTGCCACGGCTCTGCGCCCTCTAAACTTTTCGTTCTTCAAATCC 
PYD16 2-3’ CAATATAGAAGAACATCCTGTGCTG 
URH1 1-5’ AATCTTGTTGTAATCACCACTTTTG 
URH1 1-3’ GACCCGGCGGGGACGAGGCAAGCTTTTGCCAAGATCAATAATCAGATAAC 
URH1 2-5’ CGAGCCCTGCCACGGCTCTGCGCCCCAGGTGTCCATAACTTCGTTATATG 
URH1 2-3’ CAGGGAAAACTTGATGGATAACTAC 
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were plated on YPD plates (100-200 colonies pr. plate) and grown for 2-3 days at 
25°C. The plates where replicated onto new SD or uracil N-minimal plates. After 5-7 
days at 25°C, colonies were chosen based on inability to grow on uracil N-minimal 
plates compaired to control plates. Strains were grouped based on interallelic 
complementation tests, which were carried out by crossing mutants on YPD plates 
and replica plating to uracil N-minimal plates (see Table 3). 
 
Complementation of pyd1 mutants with genomic library 
The S. kluyveri wild type genomic library prepared by F. Lacroute, was based on the 
shuttle vector pFL44S (Bonneaud et al., 1991). Mutants from each of the 
complementation groups were transformed with the library DNA using 
electroporation procedure (Gojkovic et al., 2000) and plated on uracil N-minimal 
plates for selection. A number of transformants from each mutant strain were tested 
for plasmid loss, before rescue of the plasmid into the E. coli strain. Sequencing of the 
inserts was done using the primers M13rev-29 and M13uni-21 from MWG Biotech, 
Germany. The obtained sequences were searched for ORFs and the complementing 
ORF was identified by further complementation if neccesary. The complementation 
groups and the rescued plasmids along with accesion no. for the complementing ORFs 
are presented in Table 4. 
 
 
 
Table 4: pyd1 mutants divided into their respective complementation groups and the complementing plasmids. 
Parental strains are $ = Y156, others = Y159 
Mutant locus Plasmid Accession no. Strains 
pyd11 p540 AY154654 Y786, Y804, Y842$, Y848$, Y853, Y855, Y954, Y957, Y958 (9) 
pyd12 p471 AY154653 Y787$, Y805, Y816$, Y817$, Y856, Y952 (6) 
pyd13 p637 DQ512718 Y806, Y808$, Y849, Y850, Y852, Y857, Y937$, Y950, Y951, Y953, Y959, Y961, Y963, Y964 (14) 
pyd14 p722 DQ512719 Y810$, Y813$, Y814, Y815, Y845$, Y846, Y847, Y935$, Y936$, Y948, Y962 (11) 
pyd15 p638 DQ512718 Y807$, Y843$, Y844$, Y960 (4) 
pyd16 p731 DQ512720 Y811$ (1) 
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Table 2: Strains used and/or constructed 
Designation Reference/origin Genotype Comments  Designation Reference/origin Genotype Comments 
Y057 NRRL Y-12651 Diploid, prototroph   Y950 Y159 MATa ura3 pyd13 EMS 
Y090 L. Marsch, MYA-2152 MATα thr   Y951 Y159 MATa ura3 pyd13 EMS 
Y091 L. Marsch, MYA-2153 MATa his aux   Y952 Y159 MATa ura3 pyd12 EMS 
Y156 J. Strathern, GRY1175 MATα ura3   Y953 Y159 MATa ura3 pyd13 EMS 
Y159 J. Strathern, GRY1183 MATa ura3   Y954 Y159 MATa ura3 pyd11 EMS 
Y786 Y159 MATa ura3 pyd11 EMS  Y955 Y159 MATa ura3 pyd17 EMS 
Y787 Y156 MATα ura3 pyd12 EMS  Y957 Y159 MATa ura3 pyd11 EMS 
Y804 Y159 MATa ura3 pyd11 EMS  Y958 Y159 MATa ura3 pyd11 EMS 
Y805 Y159 MATa ura3 pyd12 EMS  Y959 Y159 MATa ura3 pyd13 EMS 
Y806 Y159 MATa ura3 pyd13 EMS  Y960 Y156 MATα ura3 pyd15 EMS 
Y807 Y156 MATα ura3 pyd15 EMS  Y961 Y159 MATa ura3 pyd13 EMS 
Y808 Y156 MATα ura3 pyd13 EMS  Y962 Y159 MATa ura3 pyd14 EMS 
Y810 Y156 MATα ura3 pyd14 EMS  Y963 Y159 MATa ura3 pyd13 EMS 
Y811 Y156 MATα ura3 pyd16 EMS  Y964 Y159 MATa ura3 pyd13 EMS 
Y813 Y156 MATα ura3 pyd14 EMS  Y986 Y156 MATα ura3 pyd2::KanMX3 Deletion 
Y814 Y159 MATa ura3 pyd14 EMS  Y1046 Y156 MATα ura3 pyd3::KanMX3 Deletion 
Y815 Y159 MATa ura3 pyd14 EMS  Y1156 Y90 MATα thr pyd11::KanMX3 Deletion 
Y816 Y156 MATα ura3 pyd12 EMS  Y1157 Y90 MATα thr pyd11::KanMX3 Deletion 
Y817 Y156 MATα ura3 pyd12 EMS  Y1158 Y91 MATa his aux pyd11::KanMX3 Deletion 
Y842 Y156 MATα ura3 pyd11 EMS  Y1159 Y91 MATa his aux pyd12::KanMX3 Deletion 
Y843 Y156 MATα ura3 pyd15 EMS  Y1160 Y91 MATa his aux pyd12::KanMX3 Deletion 
Y844 Y159 MATa ura3 pyd15 EMS  Y1161 Y156 MATα ura3 pyd12::KanMX3 Deletion 
Y845 Y156 MATα ura3 pyd14 EMS  Y1162 Y156 MATα ura3 pyd12::KanMX3 Deletion 
Y846 Y159 MATa ura3 pyd14 EMS  Y1163 Y90 MATα thr pyd13,15::KanMX3 Deletion 
Y847 Y159 MATa ura3 pyd14 EMS  Y1164 Y90 MATα thr pyd13,15::KanMX3 Deletion 
Y848 Y156 MATα ura3 pyd11 EMS  Y1165 Y91 MATa his aux pyd13,15::KanMX3 Deletion 
Y849 Y159 MATa ura3 pyd13 EMS  Y1166 Y91 MATa his aux pyd13,15::KanMX3 Deletion 
Y850 Y159 MATa ura3 pyd13 EMS  Y1167 Y156 MATα ura3 pyd14::KanMX3 Deletion 
Y852 Y159 MATa ura3 pyd13 EMS  Y1168 Y90 MATα thr pyd16::KanMX3 Deletion 
Y853 Y159 MATa ura3 pyd11 EMS  Y1169 Y90 MATα thr pyd16::KanMX3 Deletion 
Y855 Y159 MATa ura3 pyd11 EMS  Y1170 Y91 MATα ura3 pyd16::KanMX3 Deletion 
Y856 Y156 MATα ura3 pyd12 EMS  Y1171 Y91 MATα ura3 pyd16::KanMX3 Deletion 
Y857 Y159 MATa ura3 pyd13 EMS  Y1172 Y90 MATα thr urh1::KanMX3 Deletion 
Y935 Y156 MATα ura3 pyd14 EMS  Y1173 Y90 MATα thr urh1::KanMX3 Deletion 
Y936 Y156 MATα ura3 pyd14 EMS  Y1174 Y91 MATa his aux urh1::KanMX3 Deletion 
Y937 Y156 MATα ura3 pyd12 EMS  Y1175 Y91 MATa his aux urh1::KanMX3 Deletion 
Y948 Y159 MATa ura3 pyd14 EMS      
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Table 3: Complementation test for putative pyd1 mutants. Diploid strains were replica plated from YPD to URA media, and checked for growth (complementation) or lack of growth (non-
complementation) after 2 days. On the basis of these results, six complementation groups were identified. 
Bold strain name = MATa, Italic strain name = MATα, (-) = same mating type, + = complementing mutants, - = non-complementing mutants. 
 
Y786 Y787 Y804 Y805 Y806 Y807 Y808 Y810 Y811 Y813 Y814 Y815 Y816 Y817 Y842 Y843 Y844 Y845 Y846 Y847 Y848 
Y786 (-)                     
Y787 + (-)                    
Y804 (-) + (-)                   
Y805 (-) - (-) (-)                  
Y806 (-) + (-) (-) (-)                 
Y807 + (-) + + + (-)                
Y808 + (-) + + - (-) (-)               
Y810 + (-) + + + (-) (-) (-)              
Y811 + (-) + + + (-) (-) (-) (-)             
Y813 + (-) + + + (-) (-) (-) (-) (-)            
Y814 (-) + (-) (-) (-) + + - + - (-)           
Y815 (-) + (-) (-) (-) + + - + - (-) (-)          
Y816 + (-) + - + (-) (-) (-) (-) (-) + + (-)         
Y817 + (-) + - + (-) (-) (-) (-) (-) + + (-) (-)        
Y842 - (-) - + + (-) (-) (-) (-) (-) + + (-) (-) (-)       
Y843 + (-) + + + (-) (-) (-) (-) (-) + + (-) (-) (-) (-)      
Y844 + (-) + + + (-) (-) (-) (-) (-) + + (-) (-) (-) (-) (-)     
Y845 + (-) + + + (-) (-) (-) (-) (-) - - (-) (-) (-) (-) (-) (-)    
Y846 (-) + (-) (-) (-) + + - + - (-) (-) + + + + + - (-)   
Y847 (-) + (-) (-) (-) + + - + - (-) (-) + + + + + - (-) (-)  
Y848 - (-) - + + (-) (-) (-) (-) (-) + + (-) (-) (-) (-) (-) (-) + + (-) 
Y849 
     
+ - + + + 
   
+ + + + + 
   
Y850 
     
+ - + + + 
   
+ + + + + 
   
Y852 
     
+ - + + + 
   
+ + + + + 
   
Y853 
     
+ + + + + 
   
+ - + + + 
   
Y855 
     
+ + + + + 
   
+ - + + + 
   
Y856 
     
+ + + + + 
   
- + + + + 
   
Y857 
     
+ - + + + 
   
+ + + + + 
   
Y935 +   + + (-) (-)  (-)  -  (-)  (-) (-) (-) (-)    
Y936 +   + + (-) (-)  (-)  -  (-)  (-) (-) (-) (-)    
Y937 +   + - (-) (-)  (-)  +  (-)  (-) (-) (-) (-)    
Y948 
 
+ (-) (-) (-) + +  + -   + + + + + -  (-) + 
Y950 
 
+ (-) (-) (-) + -  + +   + + + + + +  (-) + 
Y951 
 
+ (-) (-) (-) + -  + +   + + + + + +  (-) + 
Y952 
 
- (-) (-) (-) + +  + +   - - + + + +  (-) + 
Y953 
 
+ (-) (-) (-) + -  + +   + + + + + +  (-) + 
Y954 
 
+ (-) (-) (-) + +  + +   + + - + + +  (-) - 
Y955 
 
+ (-) (-) (-) + +  + +   + + + + + +  (-) + 
Y957 
 
+ (-) (-) (-) + +  + +   + + - + + +  (-) - 
Y958 
 
+ (-) (-) (-) + +  + +   + + - + + +  (-) - 
Y959 
 
+ (-) (-) (-) + -  + +   + + + + + +  (-) + 
Y960 
 
+ (-) (-) (-) - +  + +   + + + - - +  (-) + 
Y961 
 
+ (-) (-) (-) + -  + +   + + + + + +  (-) + 
Y962 
 
+ (-) (-) (-) + +  + -   + + + + + -  (-) + 
Y963 
 
+ (-) (-) (-) + -  + +   + + + + + +  (-) + 
Y964 
 
+ (-) (-) (-) + -  + +   + + + + + +  (-) + 
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DNA sequence analysis 
Nucleotide sequence analysis and protein alignments where done with WinSeqEZ ver. 
1.0 (F. G. Hansen unpuplished) and ClustalX ver. 1.8 (Thompson et al., 1997). 
Database searches were performed using the default setup at the BLAST network 
services at the National Center for Biotechnology Information 
(www.ncbi.nlm.nih.gov/BLAST/). 
 
Gene disruptions  
Replacement cassettes with very long flanking homology regions (approx. 500 bp) 
were used to disrupt the genes. The homology regions were designed so correct 
integration would result in removal of the start codon and at least 2/3 of the targeted 
ORF. The dominant cassette (kanMX3) from the plasmid pFA6-kanMX3, which 
confers geneticin (G418) resistance, was used (Wach et al., 1994). PCR amplification 
was performed with Pfu polymerase (Stratagene) from wild type genomic DNA with 
the oligos designed for amplification of two parts of the gene to be disrupted. All 
oligos used are presented in Table 1. For each gene two 500 bp DNA products 
corresponding to two (5’ and 3’) parts of the genes, were produced with 25-bp 
extensions (underlined in the oligos in Table 1) homologous to the kanMX3 cassette. 
A 1500 bp DNA product corresponding to the kanMX3 cassette was produced using 
pFA6-kanMX3 as template. In a second PCR amplification, the two 500 bp parts of 
the genes, where fused to the kanMX3 cassette using the outer primers. The resulting 
linear fragments of each 2500 bp were used to transform cells using electroporation as 
described in Gojkovic et al. (Gojkovic et al., 2000), and selected on G418 plates. 
Correct integration of these inserts was confirmed by PCR. 
 
Growth conditions for HPLC experiments 
Y159 was grown in uracil N-minimal media. All pyd mutants were grown in 
proline/uracil N-minimal media. Cells were harvested (1500 x g, 5 min) and washed 
with SD (-ammonium sulfate) media. Incubation with [2-14C] and [6-14C] labelled 
uracil was done in SD (-ammonium sulfate) media + 7 mM uracil (9:1), so final 
concentration of uracil was 700 µM. Incubation volume varied from 200 – 500 µl and 
the labelled uracil was added in 1:50 – 1:100 ratio either separately or both at the 
same time. It was found that > 1 x 108 cells / 250 µL was needed. If less was used, 
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none or very little radioactivity was detected in the cell fraction. Consequently, the 
nucleotide pools were almost undetectable on the HPLC. Incubation with labelled 
uracil was done for 30 – 60 min. 
 
Sample preparation 
Preparation was done at 4°C. After incubation, cells where harvested (14000 rpm, 1 
min). 500 µL 10% trichloroacetic acid was added to the pellet, then it was vortexed 
and put on a spinning wheel for incubation (15-30 min, spinning). The tube was 
vortexed (10-15 s) and then spun down (14000 rpm, 1 min). The supernatant was 
transferred to a tube containing 700 µL Freon/trioctylamine (1:0.28), vortexed (30 s) 
and spun down (14000 rpm, 1 min). The top fraction was transferred to a tube 
containing 500 µL Freon/trioctylamine, vortexed (30 s) and spun down (14000 rpm, 1 
min). The top fraction was transferred to a new tube. Samples were analyzed directly 
from fresh preparations. 
 
HPLC conditions 
Two columns were used. ZIC-HILIC (SeQuant, PEEK 150 x 4.6 mm, 200 Å, 5 µm), 
ZIC-pHILLIC (SeQuant, PEEK, 100 x 4.6 mm, 200 Å, 5 µm). Both columns were run 
isocratically with different buffers ranging between 80-90 % acetonitrile (ACN) and 
2-10 mM ammonium acetate (AmAc) (pH~8) or ammonium carbonate pH 9.6. 
Detection was done with a UV spectrophotometer (set at 260 nm) and a continuous 
liquid scintillation counter. For GC/TOFMS analysis, samples were derivatized by 
trimethylsilylation before electron impact spectrums were recorded. 
RESULTS 
Utilization of uracil as sole nitrogen source is independent of PYD2 and PYD3 
S. kluyveri was mutagenized to obtain strains, which cannot degrade uracil. Screening 
of >50000 colonies yielded a total of 45 mutants failing to utilize uracil as sole 
nitrogen source. When a phenotypic test of the mutants was done on different media, 
all mutants could grow on DHU as sole nitrogen source. This was surprising, since 
pyd2 and pyd3 mutants were also expected in the mutant pool, and these should not 
grow on DHU as nitrogen source, if the degradation pathway was the same as in 
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mammals (FINK 1952). Two knock-out strains, Y986 ∆pyd2 and Y1046 ∆pyd3, with 
directed gene disruption of the PYD2 and PYD3 loci, respectively, were constructed. 
When growth tests were made, a remarkable difference between the previously 
described pyd2 (Y1019) and pyd3 (Y1021) strains and the new ∆pyd2 and ∆pyd3 was 
observed (see Table 5). Both Y986 and Y1046 could grow on uracil as sole nitrogen 
source, while Y1019 and Y1021 could not. Apparantly, the previously described pyd2 
and pyd3 strains were double mutants (Gojkovic et al., 1998). 
 
Genetic loci involved in uracil utilization 
The 45 pyd mutants (Table 3) were analyzed by interallelic complementation tests. 
This test grouped them into six different complementation groups termed 
pyd11,12,13,14,15,16 with 9, 6, 14, 11, 4 and 1 number of mutants, respectively. Six 
plasmids were rescued from the genomic library, one from each complementation 
group. Each plasmid could complement one specific pyd mutant, except for the 
plasmid (P637) complementing pyd13 mutants, which could also complement pyd15. 
Apparently, PYD13 and PYD15 could belong to the same locus. 
The plasmid inserts were sequenced and examined for the presence of ORFs. If the 
insert contained more than one ORF, the “right” one was elucidated by further 
complementation experiments. Mutant strains carrying gene disruptions in each of the 
six putative PYD1X genes (elucidated on the basis of the insert analysis) were created 
(Table 2). The resulting ∆pyd1X strains all failed to utilize uracil as sole nitrogen 
source (Table 6) and therefore confirmed the previous results. 
 
Table 5: Growth of pyd2, and pyd3 mutant strains on uracil (URA), dihydrouracil (DHU), beta-uridopropionate (BUP) 
and beta-alanine (BAL) media. +++ = good growth, - = no growth. Y1019 and Y1021 are apparently double mutants. 
Mutant URA DHU BUP BAL 
Y986 ∆pyd2 
Y1019 pyd2* 
+++ 
- 
- 
- 
+++ 
+++ 
+++ 
+++ 
Y1046 ∆pyd3 
Y1021 pyd3** 
+++ 
- 
- 
- 
- 
- 
+++ 
+++ 
* (Gojkovic et al., 2000), ** (Gojkovic et al., 2001) 
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Pyd11p and Pyd14p are conserved proteins 
Plasmid P540 complements the pyd11 mutants. It contains an ORF termed PYD11 
encoding a protein which contains a putative GTP cyclohydrolase II motif (see 
Appendix). Pyd11p has low homology (28 % identical) to GTP cyclohydrolase II 
(YBL033Cp, RIB1p) from S. cerevisiae, but high identity to a group of putative 
cyclohydrolases found in fungi and bacteria. The residues conserved in both Pyd11p 
and GTP cyclohydrolase II proteins belong to the active site of the cyclohydrolase. 
Plasmid P722 complements the pyd14 mutants. It contains an ORF termed PYD14 
encoding a protein, which has no assigned function and no conserved domains (see 
Appendix). A BLAST homology search yielded homologous proteins in fungi and 
bacteria, and interestingly PYD11 and PYD14 genes are allways found together in the 
analyzed organisms. 
 
PYD13,15 is homologous to the DUR1,2 gene from S. cerevisiae 
Plasmid P637 was found to complement both the pyd13 and pyd15 mutants. It 
contains a large ORF encoding a protein of 1830 amino acids (see Appendix). The 
protein has a high identity (74 % identical) to the S. cerevisiae bi-functional urea 
amidolyase encoded by the DUR1,2 gene. Plasmid P638 complements the pyd15 
mutants, but not the pyd13. It contains an ORF encoding a protein of 1046 amino acid 
identical to a truncated version of Pyd13p (Figure 2). The genotype of both types of 
Table 6: Growth of the pyd mutants on different nitrogen sources.  
Key: - = no growth, +++ = good growth.  
Genotype uracil uridine urea allantoin 
pyd11 
∆pyd11 
- 
- 
- 
- 
+++ 
+++ 
+++ 
+++ 
pyd12 
∆pyd12 
- 
- 
- 
- 
+++ 
+++ 
+++ 
+++ 
pyd13 
∆pyd13 
- 
- 
- 
- 
- 
- 
- 
- 
pyd14 
∆pyd14 
- 
- 
- 
- 
+++ 
+++ 
+++ 
+++ 
pyd15 
∆pyd15 
- 
- 
- 
- 
- 
- 
- 
- 
pyd16 
∆pyd16 
- 
- 
+++ 
- 
+++ 
+++ 
+++ 
+++ 
Genetics of uracil degradation in yeast 
71 
mutants was confirmed by their inability to utilize urea or allantoin as sole nitrogen 
sources (Table 6). The Pyd13,15 protein consists of 5 domains, where the first domain 
is the allophanate hydrolase (Dur2 part) and the remaining four are responsible for 
binding of biotin and ATP and bicarbonate dependent urea carboxylase (Dur1 part). 
The ORF on P638 consists of the Dur2 part and the biotin motif from the Dur1 part. 
 
PYD12 encodes a putative Zn(2)Cys(6) type transcription factor/regulator 
Plasmid P471 complements the pyd12 mutants. It contains one ORF encoding a 
putative Zn(2)Cys(6) transcription factor (see Appendix). Its closest homolog in S. 
cerevisiae is the YDR520C gene product (52 % identical), but the S. kluyveri protein 
contains two putative introns (536-686 and 1561-1662) elucidated based on sequence 
homology. The S. cerevisiae gene has been connected to caffeine sensitivity (Akache 
et al., 2001), but otherwise does not have any known function. 
 
PYD16 is homolog to the FUR1 gene from S. cerevisiae  
Plasmid P731 complements the pyd16 mutant. It contains one ORF encoding a protein 
which is identical (87 %) with S. cerevisiae uracil phosphoribosyltransferase (see 
Appendix). This mutant is able to grow on uridine as sole nitrogen source, while the 
pyd11,12,13,14,15 cannot (Table 6). The ∆pyd16 strain on the other hand cannot use 
uridine as sole nitrogen source. 
 
Sequence analysis of homologues genes in other organisms 
Pyd11,12,14 proteins were checked against the reference protein database (refseq), 
and a number of hits were found. Accession numbers for the homologous sequences 
1 10078
P637 MAP
FTH1 GRX5
DUR1,2
P638 sequence
Ty1 transposon
 
Figure 2: Map of the genomic inserts in P637 and P638. The DUR1,2 loci 
is shown along with other genes and elements on the insert. 
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are presented in Table 7. A total of 20 species (10 fungi and 10 bacteria) were 
identified as having both Pyd11p and Pyd14p, and none contained only one of them. 
Only four other species (all fungi) were found to contain Pyd12p, and two of those (S. 
cerevisiae and C. glabrata) does not have the PYD11 and PYD14 loci.  
After identification of the 22 species having at least one of the PYD11, PYD12 or 
PYD14 genes, the corresponding genomes were analysed for the three last genes. In 
order to do so, the Pyd13,15 protein, because of its size and multidomain structure, 
was split into five domains (see Appendix), before doing the homology search. The 
AHS1 and AHS2 domains were used as positive indicators of Pyd13p, while the 
amidase domain was used for Pyd15p. Pyd16p (Fur1p) was found in all the 22 
organisms and usually in more than one copy. The multisubunit protein Pyd13,15 was 
found in six of the 12 fungi, while two species have a protein that lacks the Pyd15 part 
and did not have any other homologous proteins for the Pyd15 part. One bacterial 
species has two proteins with homology to the Pyd13 and the Pyd15 part, 
respectively, and these two proteins are located next to each other on the 
chromosome. Of the remaining nine bacteria only two (Bradyrhizobium species) have 
homologous genes for the Pyd15 part. These two strains also have four proteins with 
homology to each of the four domains of Pyd13, and these four proteins are located 
next to each other on the chromosome. 
 
Gene organization in fungi and bacteria 
An analysis of the genomic location of the PYD1 genes was done. In nine of the ten 
bacteria found to contain Pyd11p and Pyd14p encoding genes (Cyanobacteria 
bacterium Yellowstone B-Prime was the exception), these genes were either located 
next to each other or as overlapping loci (indicating a polycistronic mRNA). In all 
nine cases a putative UPP gene identified as the bacterial homolog of the yeast FUR1 
gene was found downstream of the PYD11 and PYD14 loci. B. bacteriovorus had a 
putative uridine kinase (UDK) loci overlapping the UPP gene, indicating coregulation 
of these genes. In eukaryotes it’s relatively rare to see genes in the same pathway 
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Table 7: Accession no. for Pyd1X-like proteins. The table only contains reference sequences (refseq database), and only organisms 
containing at least one of either Pyd11p, Pyd12p or Pyd14p are presented. Note that some organisms contain duplicated genes. Key: - = 
no homologous proteins, (-) = low homology  
Strain Pyd11p Pyd12p Pyd13p 
UCA 
Pyd14p Pyd15p 
AH 
Pyd16p 
UPRT 
S. cerevisiae (-) NP_010808 NP_009767 - NP_009767 NP_011996 
C. glabrata (-) XP_446872 XP_449587 - XP_449587 XP_447193 
K. lactis XP_453829 XP_452240 XP_454317 XP_456217 XP_454317 XP_454985 
E. gossypii NP_986521 NP_986270 NP_984147 NP_982988 NP_984147 NP_985599 
Y. lipolytica XP_502565 (-) XP_504801 
XP_503658 
XP_504196 XP_504801 
XP_503658 
XP_504195 
XP_506088 
G. zeae XP_387653 (-) XP_391089 XP_386037 
XP_383324 
XP_391089 XP_384331 
A. fumigatus XP_749258 (-) XP_752919 XP_753675 
XP_747484 
- XP_754084 
XP_755956 
A. nidulans XP_680929 (-) XP_658491 XP_682066 - XP_682138 
XP_659737 
XP_658078 
U. maydis XP_756533 (-) - XP_757846 - XP_756240 
XP_760020 
C. neoformans (JEC21) XP_568373 (-) - XP_569387 - XP_570864 
XP_570874 
S. pombe NP_593508 (-) - NP_593506 - NP_594785 
NP_593510 
NP_593505 
N. crassa XP_955971 (-) - XP_961606 - XP_962865 
XP_955968 
R. euthropha YP_298185 - YP_299075 YP_298186 YP_299074 YP_298187 
YP_296724 
B. sp. BTAi1 ZP_00858116 - ZP_00858415-8* ZP_00858115 ZP_00863103 ZP_00858114 
ZP_00859443 
B. japonicum NP_773877 - NP_770276-9* NP_773878 NP_767684 NP_773879 
NP_773428 
R. metallidurans ZP_00595820 - (-) ZP_00595819 - ZP_00595818 
ZP_00594819 
L. pneumophila Lens YP_127501 - - YP_127502 - YP_127503 
L. pneumophila Paris YP_124506 - - YP_124507 - YP_124508 
L. pneumophila Philadelphia YP_096253 - - YP_096254 - YP_096255 
C. bacterium YP_476491 - - YP_478780 - YP_478151 
YP_478589 
P. sp. JS666 ZP_00506558 - - ZP_00506559 - ZP_00506560 
B. bacteriovorus NP_968420 - - NP_968419 - NP_968418 
* The two Bradyrhizobium strains contains what looks like an operon composed of four individual cistrons encoding each of the domains 
from the S. kluyveri Pyd13,15p UCA part. 
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located next to each other, but in S. pombe the PYD11 and PYD14 genes were found 
close to each other. They were flanked on one side by a bacteria-like UPP gene and 
on the other side by three genes (a putative Zn(2)Cys(6) protein, a yeast FUR1 
homologous gene and a yeast FUR4 homologous gene). This clustering of genes was 
also found in e.g. N. crassa and Y. lipolytica, where PYD11 and UPP or PYD14 and 
UPP were clustered, respectively. These gene organizations are presented in Figure 3. 
 
URH1 gene product is not involved in uridine degradation 
The finding that pyd16 could grow on uridine but not uracil as sole nitrogen source, 
suggested uridine to be one of the first intermediates in uracil degradation. The only 
 
 
 
 
 
Figure 3: Organization of genes homologous to SkPYD11, SkPYD14 and SkPYD16/FUR1 in varios organisms. In 
bacteria and yeast, PYD11 and PYD14 are located either as closely spaced or overlapping loci. Next to them is a 
putative UPP (bacterial type uracil phosphoribosyltransferase) or PYD16/FUR1 (yeast type uracil 
phosphoribosyltransferase). A: B. japonicum (NC_004463 REGION: 7957090..7963265), B: B. bacteriovorus 
(NC_005363 REGION: Comp(1452015..1457248)), C: S. pombe (NC_003424 REGION: 1831000..1844000), D: N. 
crassa (NW_047266 REGION: Comp(68218..83644)), E: Y. lipolytica (CR382131 REGION: 2440600..2446600). In 
B. bacteriovorus (B) the flanking genes are identified as mmsA (methylamonic semialdehyde dehydrogenase) and 
udk (uridine kinase). In S. pombe (C), both a bacterial upp and a yeast pyd16/fur1 gene are located nearby. The 
pyd16/fur1 gene in S. pombe (C) is flanked by a fur4 (uracil transporter) homolog and a Zn(2)Cys(6) motif protein. 
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way to obtain uracil from uridine is through the enzyme uridine hydrolase (or uridine 
phosphorylase in higher eukaryoytes). To test if uridine needed to be metabolized to 
uracil, a putative uridine hydrolase encoding gene (SkURH1) was disrupted. The 
∆urh1 strains (Y1172-Y1175) could utilize uridine and uracil as sole nitrogen source. 
This strongly suggests that uracil is not the first substrate in the catabolism of uridine. 
 
Results from HPLC experiments 
Separation of the reference compounds uracil, BUP and BAL was achieved on the 
ZIC-HILIC column. When a running buffer consisting of 80 % ACN and 10 mM 
AmAc pH 8 was used at 1 mL/min, the retention times were 2.8, 8.0, and 17.2 min, 
respectively. DHU had the same retention time as uracil in all tested buffer/column 
systems. 
The best separation of uracil, urea and uridine was found on the ZIC-pHILIC column 
using a running buffer consisting of 90 % ACN and 2 mM ammonium carbonate pH 
9.6 at 1 mL/min. The retention times were 4.5, 6.3 and 6.8. The buffer was relatively 
unstable, and after 5-10 runs (3-5 hours), there was a shift in retention times and urea 
and uridine were coeluting. 
Y159 and the four pyd1X mutants, Y954 (pyd11), Y852 (pyd13), Y814 (pyd14) and 
Y960 (pyd15), were grown in uracil-containing media and incubated with uracil 
labeled at either 2-C or 6-C (see Materials and Methods). A total of seven different 
peaks were identified (designated A – G). Figure 4 shows an example of elution 
profiles from the pHILIC column of sample and media fractions. Compound A was 
identified as urea based on retention time, coelution with urea as internal standard, 
and supported by the fact that A was only labelled at 2-C and only found in the 
pyd13,15 mutants, which are unable to degrade urea (see Table 6). Samples 
containing A were subjected to GC-MS and urea was positively identified. B was the 
only compound showing UV absorbance at 260 nm, and was identified as uridine, 
based on coelution with uridine as internal standard. 
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Figure 4: Elution profiles of Y814 (pyd14) cellular (SAMPLE) and media (S.N.) fractions. The running and buffer 
conditions were: 1 mL/min, 90 % ACN, 2 mM ammonium carbonate pH 9.6. The numbers (with the arrow) are in 
minutes. The peak eluting at approx. 4 minutes is uracil and it was usually not seen in the cellular fraction (though 
here it is present). The labelled peaks (B-G) are described in the text.  
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The buffer instability mentioned before made it difficult to identify peaks between 
samples, because they slowly changed position. Discrimination between compounds 
D and E was particularly difficult. Each strains had their unique pattern of compounds 
(see Table 8 and 9). Compounds A, B, D and E were found both in the cellular and in 
the media fractions, while C and F/G was strictly present in either the media or the 
cellular fraction, respectively. C, D and E were labelled only from the 6-C carbon. F 
was labelled at 2-C, but from the chosen experiments it was not possible to determine 
if it was also labelled at 6-C. The labelling of G could not be determined. The pyd11 
mutant (Y954) only showed B, besides a small amount of C. This mutant may 
therefore have a defect in the early steps of the pathway. The pyd14 mutant on the 
other hand showed all compounds except A, and as pyd11 it showed B in the media 
fraction. It could be that Pyd14p is involved in the downstream steps. 
It is important to stress, that uracil was usually not detected in the cells. Apparently, 
the imported uracil gets metabolised rapidly, and the intercellular pool of uracil is 
therefore primarily in the ribosylated state (uridine, UMP, UDP and UTP) which all 
could be detected in another separation system. 
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Table 8: Presence of various compounds in the cell fraction. Identified compounds are A = urea, B = uridine. The rest are 
unidentified. (+) = small peak detected in the experiment. 
   A B C D E F G 
STRAIN pyd LABEL 6.2-6.4 7.0-7.2 9.5-11 13-13.4 13.5-16.5 17 19.5 min (retention time) 
Y954 11 C-2   (+)           
Y954 11 C-2, C-6  +       
Y954 11 C-6   (+)           
Y852 13 C-2 +         +   
Y852 13 C-2, C-6 (+)   +     
Y852 13 C-6       +       
Y814 14 C-2, C-6  +  +  + (+) 
Y960 15 C-2 +             
Y960 15 C-6         +     
Y159 wt C-2   (+)           
Y159 wt C-2, C-6  (+)  + +    
Y159 wt C-6   +   + +     
Localization IN/OUT IN/OUT OUT IN/OUT IN/OUT IN IN 
Label 2-C 2-C 6-C 6-C 6-C 6-C 2-C 6-C? 2-C? 6-C? 
Table 9: Presence of variuous compounds in the media fraction. Identified compounds are A = urea, B = uridine. The rest 
are unidentified. (+) = small peak detected in the experiment. 
   A B C D E F G 
STRAIN pyd LABEL 6.2-6.4 7.0-7.2 9.5-11 13-13.4 13.5-16.5 17 19.5 min (retention time) 
Y954 11 C-2               
Y954 11 C-2, C-6  + (+)      
Y954 11 C-6  (+)       
Y852 13 C-2 +             
Y852 13 C-2, C-6 +  + + +    
Y852 13 C-6     + + +     
Y814 14 C-2, C-6  + + + +    
Y960 15 C-2 +             
Y960 15 C-6     + + +     
Y159 wt C-2               
Y159 wt C-2, C-6   + + +    
Y159 wt C-6   + + +    
Localization IN/OUT IN/OUT OUT IN/OUT IN/OUT IN IN 
Label  2-C 2-C 6-C 6-C 6-C 6-C 2-C 6-C? 2-C? 6-C? 
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DISCUSSION 
A “novel” pathway 
S. kluyveri can use uracil and all products of the reductive pyrimidine catabolic 
pathway as sole nitrogen sources (LaRue and Spencer, 1968). Previous studies on the 
S. kluyveri uracil degradation pathway resulted in the characterization of two genes 
(PYD2 and PYD3), which encode DHP and BS, respectively (Gojkovic et al., 2000; 
Gojkovic et al., 2001). These data strongly suggested the presence of the reductive 
pyrimidine catabolic pathway in this organism. In order to identify and characterize 
the first enzyme encoded by PYD1, random mutagenesis followed by screening for 
mutants, which were unable to utilize uracil as sole nitrogen source, was performed. 
The resulting 45 mutants were analysed for growth defects on DHU, and surprisingly 
all were found to grow normally, indicating that none of the mutants were pyd2 or 
pyd3. When the PYD2 and PYD3 loci were knocked-out, the resulting ∆pyd2 and 
∆pyd3 strains were still able to grow on uracil as sole nitrogen source. This proves 
that S. kluyveri degrades DHU via the two enzymes, PYD2 and PYD3, while uracil is 
degraded via the Pyd1 enzyme(s). This new pathway explains why no DHPDH 
activity could be measured in the cell free extracts (data not shown) and supports the 
previous observation that no DHPDH is not present in the S. kluyveri genome. It also 
explains why the Pyd2p activity is low in uracil-grown cells and high in DHU- and 
BUP-grown cells consitent with the observation that the PYD2 mRNA is induced by 
DHU and to some degree BUP, but not by uracil (Gojkovic et al., 2000). 
 
Five genes are involved in the “novel” pathway 
Mutants strains unable to use uracil as sole nitrogen source belonged to six different 
loci. Two of loci (PYD13 and PYD15) were found to be located within the same ORF, 
termed PYD13,15. A plasmid (P638) containing only the PYD15 part of the PYD13,15 
gene could complement pyd15, but not pyd13. This proves that the two loci work 
independently, or at least that the Pyd15 part is active without the Pyd13 part. In 
strains with gene disruptions (∆pyd1X), the same uracil phenotype was observed as 
for pyd1X mutants confirming the identity of the genes.  
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PYD11 and PYD14: Conserved elements found in fungi and bacteria 
Homologs of the two PYD11 and PYD14 loci, were found in 10 fungi and 10 bacterial 
species, and in nine of the ten bacteria they were located next to each other. The 
genetic structure with overlapping loci, indicated that the genes were part of a 
polycistron, which suggests coregulation at the transcription level. The fact that out of 
the six loci identified only PYD11 and PYD14 lack homologs in S. cerevisiae, 
suggests that these two loci are the core components and highly specific for this 
“new” uracil degradation pathway. The Pyd11 protein has a GTP cyclohydrolase II 
motif, with many of the functional residues conserved, while the Pyd14 protein 
sequence reveals no known structural/functional motifs. The striking resemblence of 
Pyd11p and GTP cyclohydrolase II indicates that the substrate may be a 
phosphoribosylated species. 
 
PYD16: Further indications of phosphoribosylated species as intermediate 
product 
PYD16 was highly identical to S. cerevisiae FUR1 gene. This was quite puzzling, 
since the background strain Y156 was ura3, and therefore totally dependent on FUR1 
salvage of pyrimidines. When assayed for UPRT activity, Y811 had the activity, but 
at 50-75 % of the level of Y156 (unpublished). The finding of this salvage enzyme as 
a part of the uracil degradation, indicates that uracil needs to be ribosylated, before a 
breakdown of the pyrimidine ring occurs, or that uracil transport in general is 
connected to the FUR1 gene. In S. cerevisiae, it has been shown that the regulation of 
the uracil transporter (Fur4p) by uracil is independent of the FUR1 locus (Seron et al., 
1999). This was interpreted as normal transporter-mediated uracil entry into the ∆fur1 
cells, even though an actual uracil flux measurement was not done. It seems that the 
function of PYD16/FUR1 would be to produce UMP. That uracil is transferred to 
UMP and not remaining at the nucleobase level (free uracil) is supported by pyd16 
and ∆urh1 ability to utilize uridine as nitrogen source, and from the lack of any 
measurable uracil pool in cell fraction from wild type or pyd1 mutants. The ∆pyd16 
strain could not utilize either uracil or uridine. This indicates an influence of uracil 
salvage on uridine salvage. A similar finding was observed when two recessive FUR1 
mutations (fur1-1, fur1-6) in S. cerevisiae were isolated (Jund and Lacroute, 1970). 
Both mutants were 5-fluorouracil (5-FU) resistent, but the fur1-1 mutant was as 5-
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fluorouridine (5-Furi) resistent as a fui1 mutant (uridine transport mutant), while the 
fur1-6 mutant was sensitive as wild type cells. This indicates that the fur1-1 mutation 
abolished uridine salvage, while the fur1-6 mutation did not. The fact that S. 
cerevisiae ura3 ∆fur1 is still able to grow on rich media (Seron et al., 1999), indicates 
a functional cytidine salvage (through the action of cytidine deaminase and uridine 
kinase encoded by CDD1 and URK1, respectively).  
 
PYD13 and PYD15: Urea as the terminal degradation product 
PYD13 and PYD15 were found to be highly identical to the S. cerevisiae DUR1,2 
locus. Growth test on urea and allantoin confirmed this (Table 6). The involvement of 
urea degrading enzymes in uracil degradation could indicate an oxidative degradation 
pathway. Since none of the identified pyd1X loci share any homology to the only 
identified gene in the oxidative pathway (encoding barbiturase), and the fact that S. 
kluyveri cannot utilize barbiturate as sole nitrogen source strongly indicates another 
reaction mechanism than oxidation of the 6-C atom of uracil. Evolution of the 
bifunctional enzyme urea amidolyase, can be seen by the finding that the two 
functional parts are separated in bacteria (but fused in eukaryotes). Apparently, 
evolution resulted in an enzyme (Pyd13,15/Dur1,2) from five different subunits as 
seen in for example B. japonicum. Firstly a urea carboxylase (UCA) was fused from 
four of the subunits as seen in R. metallidurans, and finally, fusion of the allophanate 
hydrolase (AH) with UCA, to generate the yeast type urea amidolyase (UAL). Why 
modern yeast have evolved a urea amidolyase instead of the normal urease is not 
known. Because the whole allantoin pathway is induced by allophanate, which can be 
made by UCA and not urease, that compound seems to be central and important for 
yeast.  
 
PYD12: Putative Zn(2)Cys(6) type transcription regulator 
A putative DNA binding motif is found in Pyd12p, suggesting that Pyd12p can 
function as a transcription factor. These types of transcription factors are known to be 
the key components of carbon and nitrogen metabolism in yeast. Some are involved in 
nitrogen catabolite repression (NCR) and others in induction of specific catabolic 
pathways. In S. cerevisiae, the DAL genes provide examples of inducible NCR genes. 
They are induced by either the end-product of the allantoin degradation pathway, 
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allophanate or by the non-metabolizable structural analog, oxalurate (Cooper and 
Lawther, 1973; Sumrada and Cooper, 1974). The induction is dependent on the 
specific gene regulator proteins Dal81 and Dal82, and the global activator Gln3p, 
while the NCR is controlled by the global repressor Dal80 protein (ter Schure et al., 
2000). Pyd12p might have a similar function as Dal81p/Dal82p, upregulating the 
PYD1X genes transcription in an inducer-specific manner. Since the PYD12 gene is 
also present in S. cerevsiae, which does not contain the PYD11 and PYD14 genes, and 
cannot utilize uracil, it may have a common regulatory role (connected to nitrogen 
metabolism) in both S. kluyveri and S. cerevisiae. It could be that uracil acts as an 
inducer of its own salvage. A 5-FU resistant phenotype would be expected from this 
scenario, which could lead to gene isolation previosly. Some inducer regulated genes 
are known to have a Gln3p induced basal transcription level even when inducer or the 
corresponding transcription factor are absent. This basal level of transcription might 
render pyd12 cells 5-FU sensitive, but could be insufficient for assimilation of uracil 
to support growth with uracil as sole nitrogen source. 
 
Intermediates in the novel uracil degradation pathway 
The finding of no or extremely low intracellular concentrations of uracil in all strains 
tested, and the accumulation of uridine even in mutant strains grown with proline as 
nitrogen source, strongly indicate that uracil as a free nucleobase is not the central 
intermediate. It is more likely that a ribosylated species (uridine, UMP, UDP or UTP), 
serves as a substrate for the first catabolic enzyme. At the same time it seems that 
uracil uptake and the following phosphoribosylation are tightly coupled to the 
degradation pathway. Besides urea and uridine five other radioactive compounds were 
found, and they were neither DHU, BUP or BAL. 
 
Proposed novel uracil degradation pathway 
Based on the six genetic loci identified and the HPLC experiments, the following 
hypothetical pathway is proposed (see Figure 5). The uracil uptake is immediately 
followed by and coupled to the phosphoribosylation into UMP by Pyd16p/Fur1p. The  
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first “real” catabolic enzyme is Pyd11p, which hydrolyses the uracil ring on one of the 
ribosylated uracil species (UriX), uridine, UMP, UDP or UTP, thereby producing an 
ureidomalonic semialdehyde-ribose(X) (UMSA-RX) (2-C and 6-C labelled). The 
reason for Pyd11p to be the pyrimidine ring attacking enzyme could be the GTP 
cyclohydrolase II motif, which indicates direct hydrolysis of a nucleobase connected 
to a ribose. In addition, the pyd11 mutant is the only mutant that only accumulates 
uridine. The conversion of UMSA-RX to ureidomalonic semialdehyde (UMSA) could 
be spontanuos hydrolysis because of the product instability or it could be catalyzed by 
an enzyme involved in a general breakdown of N-glucosidic bonds. The next enzyme 
is Pyd14p which converts UMSA to urea (2-C labelled) and malonic semialdehyde 
 
Figure 5: Proposal for a novel uracil degradation pathway. First uracil enter the cell and gets 
phosphoribosylated to UMP by Pyd16p. Normal cell metabolism converts UMP to uridine, UMP, UDP 
or UTP (UriX). The Pyd11p reaction is a hydrolysis of the N-1 C-6 bond yeilding ureidomalonic 
semialdehyde (UMSA)–ribose–X (UMSA-RX). Unspecific or enzymatic hydrolysis splits the N-
glucosidic bond of UMSA-RX to UMSA and Rib-X. Pyd14p hydrolyze UMSA to urea and malonic 
semialdehyde (MSA). Urea gets degraded to ammonia and carbondioxide in a two step reaction by 
the enzymes Pyd13p and Pyd15p. The further fate of MSA is not known, but conversion to BAL is a 
possibility. Other reactions could involve coupling to CoA (MSA dehydrogenase), oxidation (malonate 
dehydrogenase) or decarboxylating and reduction (MSA decarboxylase and alcohol dehydrogenase)  
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(MSA) (6-C labelled). The terminal enzyme is the Pyp13,15p complex converting 
urea into CO2 and ammonia via allophanate. Malonic semialdehyde would also be 
expected to be further metabolized, but none of the PYD1 genes would be involved, 
since they are focused on the nitrogen containing compounds. This might involve a 
mitochondrial dehydrogenase similar to mammalian methylmalonic semialdehyde 
dehydrogenase converting MSA to acetyl-CoA and CO2 or a reverse aminotransferase 
reaction converting MSA to beta-alanine (BAL). Oxidation or decarboxylation could 
also be a possibility. However, it is possible that no further metabolism of MSA takes 
place if it can be actively excreted. Pyd12p is not directly involved in the reactions, 
but serves as a positive regulator of one or several PYD1X genes. 
In conclusion, based on genetic and HPLC data, the flow of intermediates is proposed 
to be uracil -> UMP -> UriX -> UMSA-RX [F or G] -> UMSA [F or G] -> urea [A] + 
MSA and metabolites [C,D,E]. 
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Saccharomyces kluyveri PYD11 gene 
   1        .         .         .         .         .         .         .         .         . 
   ATGTCCCCTATTGCTGTTACCTCTCAAACTCCTGCTACTGAGGTGCCTTCCGTGAAAGAAATTCCACAAGTTATCACTAAATCTTCCCCA 
    M  S  P  I  A  V  T  S  Q  T  P  A  T  E  V  P  S  V  K  E  I  P  Q  V  I  T  K  S  S  P      
  91        .         .         .         .         .         .         .         .         . 
   GTGGAGAATTTAATTTTAACCACGTATCCAGAAGACTCTTCCCCAATCCCTTTGCAATGGGGTGCTCCTTCCACTGATTCTAGAGGACCA 
    V  E  N  L  I  L  T  T  Y  P  E  D  S  S  P  I  P  L  Q  W  G  A  P  S  T  D  S  R  G  P      
 181        .         .         .         .         .         .         .         .         . 
   ATCATTGCCACAAGATACAAAGAAGGATTGGCCAAACATAACGCTATTGGTGCTCACTCCGGCTCTTACTGTGTCTACCATGCTTTAGCA 
    I  I  A  T  R  Y  K  E  G  L  A  K  H  N  A  I  G  A  H  S  G  S  Y  C  V  Y  H  A  L  A      
 271        .         .         .         .         .         .         .         .         . 
   GTGGGCACGAAGCAGTTGGATCCTGAACACGTTGCCGACTATACCAACTCTCAACCAGCTTTTGCAGTTCCAGAACAAAAAACCTGGTAC 
    V  G  T  K  Q  L  D  P  E  H  V  A  D  Y  T  N  S  Q  P  A  F  A  V  P  E  Q  K  T  W  Y      
 361        .         .         .         .         .         .         .         .         . 
   AACGATGAAGATATCGTTGCTATGGATCCATTTGGTCACTTGACTCCATATTTATTTGATGAAGTTTCTACTAAAGAAAACGTTGAAATT 
    N  D  E  D  I  V  A  M  D  P  F  G  H  L  T  P  Y  L  F  D  E  V  S  T  K  E  N  V  E  I      
 451        .         .         .         .         .         .         .         .         . 
   AGACCAACTATCGCTGTCACTAAGGCTACTATGCAACTGTTTGAAATGAAAGATGCTGTCGAAAAAGGTAGATTAGAAGTCGATGGTGAA 
    R  P  T  I  A  V  T  K  A  T  M  Q  L  F  E  M  K  D  A  V  E  K  G  R  L  E  V  D  G  E      
 541        .         .         .         .         .         .         .         .         . 
   GTTGTCATCAATAAAAATGGTGACTTGAATGTTTCTAAAGTTGCCGTTGAACCAGTTTGGTACTTGCCAGGTGTTGCCAAGAGGTTTGGT 
    V  V  I  N  K  N  G  D  L  N  V  S  K  V  A  V  E  P  V  W  Y  L  P  G  V  A  K  R  F  G      
 631        .         .         .         .         .         .         .         .         . 
   GTCACCGAAGAGGAGTTAAGAAAAGCTCTGTTTGAAGATACCAATGGTATGTACCCCGAATTGGTCACCAGACCTGATATTAAGGTCTTC 
    V  T  E  E  E  L  R  K  A  L  F  E  D  T  N  G  M  Y  P  E  L  V  T  R  P  D  I  K  V  F      
 721        .         .         .         .         .         .         .         .         . 
   TTACCACCAATTGGTGGTCTTACCGTCTACATCTTTGGCAACCCAGACTTCGTCTCCGACCCTTCGAAAAAACTAGCTTTGAGAGTCCAC 
    L  P  P  I  G  G  L  T  V  Y  I  F  G  N  P  D  F  V  S  D  P  S  K  K  L  A  L  R  V  H      
 811        .         .         .         .         .         .         .         .         . 
   GATGAGTGTAATGGGTCCGATGTTTTTGGGTCTGATATTTGTACCTGTCGTCCATACTTAATGTTTGGTATTGAAGAAGCTGTCAAGGAA 
    D  E  C  N  G  S  D  V  F  G  S  D  I  C  T  C  R  P  Y  L  M  F  G  I  E  E  A  V  K  E      
 901        .         .         .         .         .         .         .         .         . 
   GCTCAAAACGGCGGCTCTGGTGTTGTTGTTTACTTTAGAAAGGAAGGCCGTGCATTGGGTGAAGTCACCAAGTACTTAGTTTACAATGCT 
    A  Q  N  G  G  S  G  V  V  V  Y  F  R  K  E  G  R  A  L  G  E  V  T  K  Y  L  V  Y  N  A      
 991        .         .         .         .         .         .         .         .         . 
   CGTAAGAGAGGCGGTGACACCGCCGACGAATACTTCCACAGAACTGAATGTATTGCAGGTGTTAGAGACATGAGATTCCAACAATTGATG 
    R  K  R  G  G  D  T  A  D  E  Y  F  H  R  T  E  C  I  A  G  V  R  D  M  R  F  Q  Q  L  M      
1081        .         .         .         .         .         .         .         .         . 
   CCGGATGTTTTGAAGTGGTTGGGTATCTCAAAAATTGACAGAATGCTATCTATGTCCAATATGAAGCATGATGCTATTGTCGATCAGGGT 
    P  D  V  L  K  W  L  G  I  S  K  I  D  R  M  L  S  M  S  N  M  K  H  D  A  I  V  D  Q  G      
1171        .         .         .         .         .         .         .         .         . 
   ATTCCAATTATTGAGAGAATCCCAATCCCAGATGAATTGGTTCCACCTGACTCCAGAGTTGAAATTGATGCAAAGATTAACTCTGGTTAC 
    I  P  I  I  E  R  I  P  I  P  D  E  L  V  P  P  D  S  R  V  E  I  D  A  K  I  N  S  G  Y      
1261        .         .         .         .         .         .         .        
   TTCACTAATGGTAAAGTGATGGACAAAAATGAATTGAAATCTGTTCAAGGTAGAACGTGGAATGACGTCAAATAA 
    F  T  N  G  K  V  M  D  K  N  E  L  K  S  V  Q  G  R  T  W  N  D  V  K         
Saccharomyces kluyveri Pyd11p sequence 
  1 MSPIAVTSQT PATEVPSVKE IPQVITKSSP VENLILTTYP EDSSPIPLQW GAPSTDSRGP 
 61 IIATRYKEGL AKHNAIGAHS GSYCVYHALA VGTKQLDPEH VADYTNSQPA FAVPEQKTWY 
121 NDEDIVAMDP FGHLTPYLFD EVSTKENVEI RPTIAVTKAT MQLFEMKDAV EKGRLEVDGE 
181 VVINKNGDLN VSKVAVEPVW YLPGVAKRFG VTEEELRKAL FEDTNGMYPE LVTRPDIKVF 
241 LPPIGGLTVY IFGNPDFVSD PSKKLALRVH DECNGSDVFG SDICTCRPYL MFGIEEAVKE 
301 AQNGGSGVVV YFRKEGRALG EVTKYLVYNA RKRGGDTADE YFHRTECIAG VRDMRFQQLM 
361 PDVLKWLGIS KIDRMLSMSN MKHDAIVDQG IPIIERIPIP DELVPPDSRV EIDAKINSGY 
421 FTNGKVMDKN ELKSVQGRTW NDVK 
Number of amino acids: 444 
Molecular weight: 49332.1 
Conserved Domain Search (Marchler-Bauer A, Bryant SH (2004), "CD-Search: 
protein domain annotations on the fly.", Nucleic Acids Res. 32:W327-331): 
Area: 251 – 421 
CDD: COG0807, RibA, GTP cyclohydrolase II 
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Saccharomyces kluyveri PYD12 gene 
   1        .         .         .         .         .         .         .         .         . 
   ATGGCCTCCGACAACAGCCAGACCCAAACACGCACGAAAAAGCCTCGCAAAAAGAGAAAGACATACAGCTGTGGGGTTTGCCGCAAGTTC 
  91        .         .         .         .         .         .         .         .         . 
   AAGACCCGGTGCGACTTTGAGCCGCTGGTTGGCAAGTGCCACCGTTGTAACGTGCTGAGGTTGGAGTGCTCTTTGACCAAGGAGCGGGAA 
 181        .         .         .         .         .         .         .         .         . 
   GAGGAAATACTTGCCGCCGTCGAAAGCACATCAAAGTCAACCCTAGCGCCCGCTTCTCTAGTCTCTGGCCAGTTACCTGCTTTGGCTGCT 
 271        .         .         .         .         .         .         .         .         . 
   GCCAACCCCGTGGTGGCAAACGACGCTGTCGTGGTTGCTCCCGTGGCAGCGACCCTGAGCAGCCGGTTGAACAAGTTGGAGTCTTCTGTG 
 361        .         .         .         .         .         .         .         .         . 
   GGCAGTTTGAATAGCAAGCTGGATCTGGCGCTGATGCTTTTGCAGGGCTCCAACTCTGCCATCAGCAATTTGAAAAACCTGACCTCGAGC 
 451        .         .         .         .         .         .         .         .         . 
   AAGGCGGGCATGGGCGACCGCAACGCTACCTACGACGACGATGACGACGGCGACGACGACGGCCATGACCACAGCGATAGTGACAGTGCC 
 541        .         .         .         .         .         .         .         .         . 
   AGTGCCAGTACCAGTGCCAGTGCAGGTGTGGGCGGACCATGACCGTGGTGAGAGAAACAGTAGGGGTTTGGCTTCCGAAAGCGACGCACA 
 631        .         .         .         .         .         .         .         .         . 
   TCTCCCACCGCACTTCAAAGAGTCTTCACAAACACCAACGCACAATTTTAGCAAAGACTTTGTAAACGGTATCAAGCTTCAAGAGCCACC 
 721        .         .         .         .         .         .         .         .         . 
   ACTCAAACTCATAAGCGATATCGACGAGAGGCTGTTTCCTACCAAAGCACAGTCGCAGCAGGACATTCTCGCCAAGACGCAGAGGCCGTT 
 811        .         .         .         .         .         .         .         .         . 
   TGTGGTTGCGCGCTTCAACTTTTTAAAGTACTTTAACCAGCACGAACAGTTGTGCCTCGATCTCTCGCGAGACTTTCTTGTCAAGTCGCA 
 901        .         .         .         .         .         .         .         .         . 
   CTTCTGGATCATCCCGGGCGGCATCAAGGAGATCAACAGGACATACGTCGAAAAGCACCTGTTCATCACGAGCGTTTTCACCATCATTCG 
 991        .         .         .         .         .         .         .         .         . 
   AATGGGGTTTGACGAAAACAACAAGTACGAGAAGGAACAGGAGCAGCTGTACCCGCTGGTCGAGCGGTTTCTCACAAACACTCTGACCAT 
1081        .         .         .         .         .         .         .         .         . 
   GTTCGAGAAGCTGACTGACCACGACATCGAGGCCATCCTCTACTGCTCCATGTTCAACATTTCGCGCAAATCCAAGCGGCACAGGCAGCT 
1171        .         .         .         .         .         .         .         .         . 
   CAAGTTCAACTCGCTGGTGCTGTGCAACTTTGCCGTCAATAGCGTGCTGAACATTGTGGACTTTCACAAGATCAAGGAAAGAGTGCTGAT 
1261        .         .         .         .         .         .         .         .         . 
   CAACGAAGAGTACTCTGCGCTCGACCTGTACCACCTGCGGATCCTGAACTCGCTGACGGCGTGCAGGCTGCAGTATTCCATCGGATCCGG 
1351        .         .         .         .         .         .         .         .         . 
   CAACTTCACCATCCAGGACGACATGCTCAAGGAGTTCAACAACCTGACTGCAAAGTTTCCCCAAGCCAACTTTGGCGATGACATCAAGAT 
1441        .         .         .         .         .         .         .         .         . 
   CAGCGAGATCAACCTGGCCGACATTGTCAATGGCATCTTTTTGAACTTCAAGGCGTATTTTAAAGGTTTTTCCAAGAGGTTCAGGGCAGA 
1531        .         .         .         .         .         .         .         .         . 
   AACGCGCGGCCACGCGGACAGAAACCGGGACGTTGCTGGTGGAGCCACCGACGATGGTGGCAAAGGCGGCAAAGACGGCAACGGCAACAA 
1621        .         .         .         .         .         .         .         .         . 
   CGGTCACAATGGAAACAGACAACAGTGCCCTGGAACTGGAGTGCCTGGTGATCCCGGAGCTGGAGTACTGGCTCAAGAACTGGGACGAGC 
1711        .         .         .         .         .         .         .         .         . 
   TTCTGTCAAAGGACGGCGGTGGTGTGCTGCTTTTTGCGTACGACTTTTACTACAGCATGATATGCCGCTCCTTCCTGACCGAGTTTTTCG 
1801        .         .         .         .         .         .         .         .         . 
   AAGAGGAGTTCCAAAACGACGTTGTGTATTTCAAGTGCGCGCTAAAGACGATGAAGCGCTATTGCTTCTCGCTTCTCGACGGTTTTTTGA 
1891        .         .         .         .         .         .         .         .         . 
   AACTGCCGCCATCACTGATCAAGGGAGCACCAACAATTACACTGCACCAGCTAGTATATGCGTGTCTAACGCTATGCGACTTCCTGCACT 
1981        .         .         .         .         .         .         .         .         . 
   GCTTTGACGTTGCGGAAAGACAGCAAGTGTTGAACTTGTGCACCAAGATTTACTGGCACTTGAACACCATTGGCGAAAAGCTAAACGAGG 
2071        .         .         .         .         .         .         .         .         . 
   CCACCGACAACGTTGGCAAGATCATCAAGTCGCTAATCGACACCAGCAAGAGGAAGGCCCAGGTGTCCGGCCGCTTGGCGGTTCCAAGAA 
2161        .         .         .         .         .         .         .         .         . 
   ACACCAAGCGGGGGAGCCCATCCATGACGCCGGGATTTCAGCAGTCGGTGCAAAGCTCCTCTGCACTGCAGGGTAGCAAAGCGGGGTCTC 
2251        .         .         .         .         .         .         .         .         . 
   CGCAGAGTGCAAGGTCTGTCAACTCGCAAGGCAGCGGTGCCGACAGTCTTGCCGCAGCCAGCTTCAACATGCCTGATGTGGCTCAGTTTA 
2341        .         .         .         .         .         .         .         .         . 
   ACTCATTTGAGGACTTTTTTCAGGACTTTTTTGACAACTTGAAGCCCACTACGCAGAGCATGTTTTCGACACTGCAGCAGCAGCAGCAGT 
2431    
   AG 
Saccharomyces kluyveri PYD12 mRNA 
   1        .         .         .         .         .         .         .         .         . 
   ATGGCCTCCGACAACAGCCAGACCCAAACACGCACGAAAAAGCCTCGCAAAAAGAGAAAGACATACAGCTGTGGGGTTTGCCGCAAGTTC 
    M  A  S  D  N  S  Q  T  Q  T  R  T  K  K  P  R  K  K  R  K  T  Y  S  C  G  V  C  R  K  F      
  91        .         .         .         .         .         .         .         .         . 
   AAGACCCGGTGCGACTTTGAGCCGCTGGTTGGCAAGTGCCACCGTTGTAACGTGCTGAGGTTGGAGTGCTCTTTGACCAAGGAGCGGGAA 
    K  T  R  C  D  F  E  P  L  V  G  K  C  H  R  C  N  V  L  R  L  E  C  S  L  T  K  E  R  E      
 181        .         .         .         .         .         .         .         .         . 
   GAGGAAATACTTGCCGCCGTCGAAAGCACATCAAAGTCAACCCTAGCGCCCGCTTCTCTAGTCTCTGGCCAGTTACCTGCTTTGGCTGCT 
    E  E  I  L  A  A  V  E  S  T  S  K  S  T  L  A  P  A  S  L  V  S  G  Q  L  P  A  L  A  A      
 271        .         .         .         .         .         .         .         .         . 
   GCCAACCCCGTGGTGGCAAACGACGCTGTCGTGGTTGCTCCCGTGGCAGCGACCCTGAGCAGCCGGTTGAACAAGTTGGAGTCTTCTGTG 
    A  N  P  V  V  A  N  D  A  V  V  V  A  P  V  A  A  T  L  S  S  R  L  N  K  L  E  S  S  V      
 361        .         .         .         .         .         .         .         .         . 
   GGCAGTTTGAATAGCAAGCTGGATCTGGCGCTGATGCTTTTGCAGGGCTCCAACTCTGCCATCAGCAATTTGAAAAACCTGACCTCGAGC 
    G  S  L  N  S  K  L  D  L  A  L  M  L  L  Q  G  S  N  S  A  I  S  N  L  K  N  L  T  S  S      
 451        .         .         .         .         .         .         .         .         . 
   AAGGCGGGCATGGGCGACCGCAACGCTACCTACGACGACGATGACGACGGCGACGACGACGGCCATGACCACAGCGATAGTGACAACTTT 
    K  A  G  M  G  D  R  N  A  T  Y  D  D  D  D  D  G  D  D  D  G  H  D  H  S  D  S  D  N  F      
 541        .         .         .         .         .         .         .         .         . 
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   GTAAACGGTATCAAGCTTCAAGAGCCACCACTCAAACTCATAAGCGATATCGACGAGAGGCTGTTTCCTACCAAAGCACAGTCGCAGCAG 
    V  N  G  I  K  L  Q  E  P  P  L  K  L  I  S  D  I  D  E  R  L  F  P  T  K  A  Q  S  Q  Q      
 631        .         .         .         .         .         .         .         .         . 
   GACATTCTCGCCAAGACGCAGAGGCCGTTTGTGGTTGCGCGCTTCAACTTTTTAAAGTACTTTAACCAGCACGAACAGTTGTGCCTCGAT 
    D  I  L  A  K  T  Q  R  P  F  V  V  A  R  F  N  F  L  K  Y  F  N  Q  H  E  Q  L  C  L  D      
 721        .         .         .         .         .         .         .         .         . 
   CTCTCGCGAGACTTTCTTGTCAAGTCGCACTTCTGGATCATCCCGGGCGGCATCAAGGAGATCAACAGGACATACGTCGAAAAGCACCTG 
    L  S  R  D  F  L  V  K  S  H  F  W  I  I  P  G  G  I  K  E  I  N  R  T  Y  V  E  K  H  L      
 811        .         .         .         .         .         .         .         .         . 
   TTCATCACGAGCGTTTTCACCATCATTCGAATGGGGTTTGACGAAAACAACAAGTACGAGAAGGAACAGGAGCAGCTGTACCCGCTGGTC 
    F  I  T  S  V  F  T  I  I  R  M  G  F  D  E  N  N  K  Y  E  K  E  Q  E  Q  L  Y  P  L  V      
 901        .         .         .         .         .         .         .         .         . 
   GAGCGGTTTCTCACAAACACTCTGACCATGTTCGAGAAGCTGACTGACCACGACATCGAGGCCATCCTCTACTGCTCCATGTTCAACATT 
    E  R  F  L  T  N  T  L  T  M  F  E  K  L  T  D  H  D  I  E  A  I  L  Y  C  S  M  F  N  I      
 991        .         .         .         .         .         .         .         .         . 
   TCGCGCAAATCCAAGCGGCACAGGCAGCTCAAGTTCAACTCGCTGGTGCTGTGCAACTTTGCCGTCAATAGCGTGCTGAACATTGTGGAC 
    S  R  K  S  K  R  H  R  Q  L  K  F  N  S  L  V  L  C  N  F  A  V  N  S  V  L  N  I  V  D      
1081        .         .         .         .         .         .         .         .         . 
   TTTCACAAGATCAAGGAAAGAGTGCTGATCAACGAAGAGTACTCTGCGCTCGACCTGTACCACCTGCGGATCCTGAACTCGCTGACGGCG 
    F  H  K  I  K  E  R  V  L  I  N  E  E  Y  S  A  L  D  L  Y  H  L  R  I  L  N  S  L  T  A      
1171        .         .         .         .         .         .         .         .         . 
   TGCAGGCTGCAGTATTCCATCGGATCCGGCAACTTCACCATCCAGGACGACATGCTCAAGGAGTTCAACAACCTGACTGCAAAGTTTCCC 
    C  R  L  Q  Y  S  I  G  S  G  N  F  T  I  Q  D  D  M  L  K  E  F  N  N  L  T  A  K  F  P      
1261        .         .         .         .         .         .         .         .         . 
   CAAGCCAACTTTGGCGATGACATCAAGATCAGCGAGATCAACCTGGCCGACATTGTCAATGGCATCTTTTTGAACTTCAAGGCGTATTTT 
    Q  A  N  F  G  D  D  I  K  I  S  E  I  N  L  A  D  I  V  N  G  I  F  L  N  F  K  A  Y  F      
1351        .         .         .         .         .         .         .         .         . 
   AAAGGTTTTTCCAAGAGGTTCAGGGCAGAAACGCGCGGCCACGCGGACAGAAACCGGGACTGCCTGGTGATCCCGGAGCTGGAGTACTGG 
    K  G  F  S  K  R  F  R  A  E  T  R  G  H  A  D  R  N  R  D  C  L  V  I  P  E  L  E  Y  W      
1441        .         .         .         .         .         .         .         .         . 
   CTCAAGAACTGGGACGAGCTTCTGTCAAAGGACGGCGGTGGTGTGCTGCTTTTTGCGTACGACTTTTACTACAGCATGATATGCCGCTCC 
    L  K  N  W  D  E  L  L  S  K  D  G  G  G  V  L  L  F  A  Y  D  F  Y  Y  S  M  I  C  R  S      
1531        .         .         .         .         .         .         .         .         . 
   TTCCTGACCGAGTTTTTCGAAGAGGAGTTCCAAAACGACGTTGTGTATTTCAAGTGCGCGCTAAAGACGATGAAGCGCTATTGCTTCTCG 
    F  L  T  E  F  F  E  E  E  F  Q  N  D  V  V  Y  F  K  C  A  L  K  T  M  K  R  Y  C  F  S      
1621        .         .         .         .         .         .         .         .         . 
   CTTCTCGACGGTTTTTTGAAACTGCCGCCATCACTGATCAAGGGAGCACCAACAATTACACTGCACCAGCTAGTATATGCGTGTCTAACG 
    L  L  D  G  F  L  K  L  P  P  S  L  I  K  G  A  P  T  I  T  L  H  Q  L  V  Y  A  C  L  T      
1711        .         .         .         .         .         .         .         .         . 
   CTATGCGACTTCCTGCACTGCTTTGACGTTGCGGAAAGACAGCAAGTGTTGAACTTGTGCACCAAGATTTACTGGCACTTGAACACCATT 
    L  C  D  F  L  H  C  F  D  V  A  E  R  Q  Q  V  L  N  L  C  T  K  I  Y  W  H  L  N  T  I      
1801        .         .         .         .         .         .         .         .         . 
   GGCGAAAAGCTAAACGAGGCCACCGACAACGTTGGCAAGATCATCAAGTCGCTAATCGACACCAGCAAGAGGAAGGCCCAGGTGTCCGGC 
    G  E  K  L  N  E  A  T  D  N  V  G  K  I  I  K  S  L  I  D  T  S  K  R  K  A  Q  V  S  G      
1891        .         .         .         .         .         .         .         .         . 
   CGCTTGGCGGTTCCAAGAAACACCAAGCGGGGGAGCCCATCCATGACGCCGGGATTTCAGCAGTCGGTGCAAAGCTCCTCTGCACTGCAG 
    R  L  A  V  P  R  N  T  K  R  G  S  P  S  M  T  P  G  F  Q  Q  S  V  Q  S  S  S  A  L  Q      
1981        .         .         .         .         .         .         .         .         . 
   GGTAGCAAAGCGGGGTCTCCGCAGAGTGCAAGGTCTGTCAACTCGCAAGGCAGCGGTGCCGACAGTCTTGCCGCAGCCAGCTTCAACATG 
    G  S  K  A  G  S  P  Q  S  A  R  S  V  N  S  Q  G  S  G  A  D  S  L  A  A  A  S  F  N  M      
2071        .         .         .         .         .         .         .         .         . 
   CCTGATGTGGCTCAGTTTAACTCATTTGAGGACTTTTTTCAGGACTTTTTTGACAACTTGAAGCCCACTACGCAGAGCATGTTTTCGACA 
    P  D  V  A  Q  F  N  S  F  E  D  F  F  Q  D  F  F  D  N  L  K  P  T  T  Q  S  M  F  S  T      
2161        .         .    
   CTGCAGCAGCAGCAGCAGTAG 
    L  Q  Q  Q  Q  Q         
Saccharomyces kluyveri Pyd12p sequence 
  1 MASDNSQTQT RTKKPRKKRK TYSCGVCRKF KTRCDFEPLV GKCHRCNVLR LECSLTKERE 
 61 EEILAAVEST SKSTLAPASL VSGQLPALAA ANPVVANDAV VVAPVAATLS SRLNKLESSV 
121 GSLNSKLDLA LMLLQGSNSA ISNLKNLTSS KAGMGDRNAT YDDDDDGDDD GHDHSDSDNF 
181 VNGIKLQEPP LKLISDIDER LFPTKAQSQQ DILAKTQRPF VVARFNFLKY FNQHEQLCLD 
241 LSRDFLVKSH FWIIPGGIKE INRTYVEKHL FITSVFTIIR MGFDENNKYE KEQEQLYPLV 
301 ERFLTNTLTM FEKLTDHDIE AILYCSMFNI SRKSKRHRQL KFNSLVLCNF AVNSVLNIVD 
361 FHKIKERVLI NEEYSALDLY HLRILNSLTA CRLQYSIGSG NFTIQDDMLK EFNNLTAKFP 
421 QANFGDDIKI SEINLADIVN GIFLNFKAYF KGFSKRFRAE TRGHADRNRD CLVIPELEYW 
481 LKNWDELLSK DGGGVLLFAY DFYYSMICRS FLTEFFEEEF QNDVVYFKCA LKTMKRYCFS 
541 LLDGFLKLPP SLIKGAPTIT LHQLVYACLT LCDFLHCFDV AERQQVLNLC TKIYWHLNTI 
601 GEKLNEATDN VGKIIKSLID TSKRKAQVSG RLAVPRNTKR GSPSMTPGFQ QSVQSSSALQ 
661 GSKAGSPQSA RSVNSQGSGA DSLAAASFNM PDVAQFNSFE DFFQDFFDNL KPTTQSMFST 
721 LQQQQQ 
Number of amino acids: 726 
Molecular weight: 82177.7 
Conserved Domain Search (Marchler-Bauer A, Bryant SH (2004), "CD-Search: 
protein domain annotations on the fly.", Nucleic Acids Res. 32:W327-331): 
Area: 18 – 59 
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CDD: smart00066, GAL4-like Zn(II)2Cys6 binuclear cluster DNA-binding domain  
  1 RRVSKACDRC RKRKIKCDGK KPPCSNCIKR GLECTYSDSK 
Saccharomyces kluyveri PYD13,15 gene 
     .        .         .         .         .         .         .         .         .         .         . 
   1 ATGTCTGTTGACACTTTGGGCTGGTCCGCCCAAGACTGGATAGATTTCCATGGTAAATCTACGCCAGAACACTCTTACAATACTCTACTTTCTTTGCTAA 
 101 AATCTCAAAAATCTGCACCTGAAGATCCTGCTTGGATCTCTCTGATTAATGAAGCCAACCTGGCACACCAATGGAAGGTTTTACAGAGTAAAGCCAATAA 
 201 GCAACAGTTGCCATTGTACGGTGTTCCGATCGCCGTTAAAGACAACATTGACTCCAAGGGCTCGCCAACTACTGCTGCTTGCCCAGCCTTTGAGTACAAC 
 301 CCTTCGGCTGATTCTACCGTCGTGGCCCTGTTAAAAGATGCAGGTGCTATCGTTATCGGTAAGACTAACTTGGATCAGTTCGCCACGGGTTTGGTTGGTA 
 401 CCAGATCTCCTTACGGAAAGACTCCTTGTGTTTTCAGTGATAAACATGTCTCTGGTGGATCTTCTGCAGGTAGTGCATCTGCAGTTGGCAGAGGTATTGT 
 501 TCCAATTGCACTAGGTACTGATACTGCTGGCTCCGGTAGAGTCCCAGCAGCCTTGAACAACTTGATCGGCTTAAAACCAACGAAAGGCCTCTTTTCCTGC 
 601 TCAGGCGTTGTTCCAGCCTGTAAATCTTTGGACTGTGTTTCCGTTTTTGCCATGAATTTGAGTGACGCTGAGCGCTGCTTTAAGGTCATGGCCAAGCCTG 
 701 ACTTGGAAAACGATGAATATTCTAGACCTTTACCTTCTAACCCACTTCAAAAATACCCTAAAAATGTTACTATTGCTATTCCAAAAGAAGTGCCATGGTA 
 801 TGGCGAAACCGAGAACCCAAAACTGTACGCTAAGGCTATCGAAAACCTAAAAGTAGCAGGTGCTAGCATCGTTACTATTGATTTCGAACCACTTTTGGCG 
 901 CTAGCTCGTTGTCTATATGAAGGTGCCTGGGTTGCTGAACGCTATGAAGCTACTAAAGATTTTTTTGCCACAAACCCACCAGAATCTTCTTTAGATCCAA 
1001 CTGTGACATCAATCATCAAAACTGCTACTAAATATGATGCCGCTGATTCTTTCAGGTATGAATATCAAAGACAAGGCATTTTACAAAAAGTCGACCAAAC 
1101 GCTAAAAGATATTGACGTTTTGTGTGTCCCAACTTGTCCTTTGAATCCAACATTCGAGGAAGTCGCAGCAGAACCAGTATTGGTTAACTCTAGACAAGGC 
1201 ACATGGACCAACTTTGTCAACCTGGCTGACATGGCAGCTTTGGCTGTTCCAGCAGGCTTTAGACCTGATGGTCTGCCTCAGGGTGTTACCTTGATTGGTA 
1301 AAAAATTTACCGATTTTGCATTATTAGAATTGGCTAACAGATACTTCAAAGTGGCATTTCCTCAAGGTTCCAGAACTTTTGGTAAGTTTATAGATAGACA 
1401 AGTAACCACTAAAGACGATGAGTTGAGAGGGCCTGATATTTCACCTGAGGATTCTGTAAAATTGGCTGTCGTCGGTGCTCATTTAAAGGGTTTACCATTG 
1501 TATTGGCAATTGGAAAAGGTCAATGCTACGTATCTGGGATCTCCAAAGACTTCAAAAAATTATAAATTGTACGCTCTACCGAAAACTGGTCCTATTTTGA 
1601 AACCAGGGTTGAGAAGAGTTGGTGAAGAAACGGGTTCTCAGATCCAATTAGAAGTTTACAGCGTTCCAAAGGAAAATTTTGGTGAATTTATTTCTATGGT 
1701 TCCTGAACCACTAGGTATTGGTTCTGTGGAACTGGAATCTGGTGAATGGGTGAAATCTTTTATCTGTGAAGAGTTTGGCTACACCCAAAAGGGCACCGTT 
1801 GATATTACCAAGTATGGTGGTTTCAAGAAGTACATCGATTTTTTGAAGCAAGAAGAGGCCAAGGTTAAGAAACCATTTGAAACTGTCTTGATTGCCAATA 
1901 GAGGTGAAATTGCTGTTCGTATCATTAAAACTCTGAAAAAATTGAACATTAGATCGGTAGCCGTCTATTCTGATCCGGACAAATACTCTCAACACGTTAT 
2001 TGATGCTGATTTAGGTGTTGCACTAAACGGTAGAACTGCTGCAGAAACTTACCTCGACATTGACAAAATTATTAAAGCCGCCAAGGACACTAATGCCCAG 
2101 GCAATTATTCCAGGTTATGGTTTCTTATCGGAAAACGCTGAATTTGCCGATAAGTGTGTTGAAGAAGGCATTGTCTTTGTTGGTCCATCCGGCGAAGCTA 
2201 TCAGAAAGTTGGGTCTGAAGCACTCCGCCAGAGAAATTGCCGAAAAGGCCGGTGTTCCTTTAGTTCCAGGTTCTGGTTTGGTTACTAGTGCTAAAGAGGC 
2301 CAAGGAAATTGCCAATAAACTAGAATATCCAGTGATGGTCAAGTCTACCGCTGGTGGTGGTGGTATTGGTTTGCAGAAGGTTGACTCGGAAAATGAAATT 
2401 GAACGTGTTTTCGAAACTGTTCAACATCAAGGTAAAGCTTACTTCGGCGATTCTGGTGTTTTCTTGGAAAGATTTGTTGAAAATGCCAGACATGTAGAAA 
2501 TCCAAATGATGGGTGACGGTTACGGTAAAGCAATTGCTATTGGTGAACGTGACTGTTCTTTGCAACGTCGTAACCAAAAAATTATTGAAGAAACTCCGGC 
2601 ACCAAATTTGGGTGAGACTACCAGAACTAAGATGAGACAAGCTGCCGAAAGTTTGGGTTCATTGTTGAAGTACAAGTGTGCAGGTACTGTGGAATTTATT 
2701 TATGACGAAAGAAGGGACGAGTTTTACTTTTTGGAAGTGAATGCTAGGTTGCAAGTTGAACACCCAATCACGGAAATGGTTACTGGCCTGGACTTGGTTG 
2801 AATGGATGTTGAGAATTGCAGCCGACGATGCGCCAGATTTTGAATCTGCCAATATCGTTGTTACTGGTGCTTCGATCGAAGCTCGTTTGTACGCTGAAAA 
2901 CCCAGCTAAGGATTTCAGACCTTCACCAGGTCTTTTAACTGACGTTCACTTCCCAGAATGGGCTAGAGTTGACACTTGGGTTTCTAAAGGTACCACTGTT 
3001 TCTGCCGAATATGATCCAACATTAGCTAAGATCATCGTTCATGGTAAGGACCGTAACGATGCCATCATGAAAATGAATAAAGCCTTGAATGAAACTGTCG 
3101 TTTACGGCTGTATTACTAACATCGATTATTTAAGATCCATTGCTTCCTCTGAGATGTTTAAGACAGCCAAAGTTGCAACTAAGATTTTAGACTCTTACGA 
3201 TTACAAGCCATGTGCCTTTGAAGTTACCTCTCCGGGTGCATACACTACCGTCCAAGATTATCCGGGTAGAGTGGGTTACTGGAGAATTGGTGTTCCACCA 
3301 TCAGGTCCTATGGATGCCTACTCATTTAGGTTAGCCAATAGAATTGTTGGTAACCACTACAAGGCTCCAGCTATTGAACTAACTTTGAATGGTCCAAAGA 
3401 TTCTATTCCATACTGAAACCATCATTGCTATATCTGGTGGTATTGCAGCATGCTCCTTAAACGATAAACCAATTGAGCAAAACAAACCAATTCAAGTTAA 
3501 TAGAGGCGATCATTTGGCAATTGGCAAATTATCTGTCGGTTGTAGGGCTTACTTGGCTATCAGAGGTGGTATCGATGTTCCTGAATACTTGGGATCCAGA 
3601 TCTACGTTTGCTTTGGGTAATATGGGTGGTTACAACGGCAGGGTGCTGAAGCTGGGTGACGTTTTATTTTTGAACCAACCAGAATTGGCTTCTTCCTCTT 
3701 TACCAGGTCCAGCCTATGAACCTCAGGCCCCACCAGCTAACTTGTTACCTAAGATTTCTGATGACAAGGAATGGACCATCGGGGTTACTTGTGGTCCACA 
3801 CGGCTCTCCAGATTTCTTCAAACCTGAATCCGTGGAAGAATTCTTCAGCGAGAAATGGAAGGTCCATTACAATTCCAACAGATTTGGTGTTAGACTAATT 
3901 GGTCCAAAACCAAAATGGGCTAGAAAAGACGGTGGTGAGGGTGGTTTGCATCCATCTAATGCTCATGACTATGTCTACTCTTTGGGTGCTATTAATTTCA 
4001 CCGGTGATGAACCCGTTATTATTACTTCAGACGGCCCATCGTTAGGTGGTTTTGTTTGCCAAGCAGTTGTTCCAGAAGCTGAGTTATGGAAGGTTGGTCA 
4101 AGTTAAACCAGGTGATTCTATCCAGTTTGTTCCAATTTCTTACCAAGTCGCTAGACAGCTGAAAGAATCTCAGGATGCAGCTATCGAAACTTTGGAAGAC 
4201 GGCAAACTACAAACTCTAACATCTGACCTCATTTTGCCTACTTACGAGGATCCGGTTTTGGTTCAACTACCTAAGAAATCCAATTTGTCTCCAAAGGTTA 
4301 CCTATCGCCAAGCTGGTGATCGTTACATACTGGTCGAATATGGTGAAAATCAGATGGATTTGAACATTGCTTACAGAATCAACCAGTTGATCAATCTGGT 
4401 TGGGAAACACAAAACCGTTGGCATTGTTGAAATGTCGCAAGGTGTCAGATCTGTCTTGATCGAATACGATGGTTACAAAATTTCTCAAGGGGCTTTGCTG 
4501 GACACCTTGGTGGCTTACGAGAGCGAAATTCAATTTGACAAAAATTGGTCTATCAAATCCAAAATCTTTAAGTTGCCTTTGGCCTTTGAGGATTCTAAAA 
4601 CTTTGGAATGTGTTACTCGTTACCAAGAAACTATTCGTTCTAAGGCTCCATGGTTACCAAATAATGTTGATTTTGTTGCTGAAGTTAACGATATCACTCA 
4701 TAAAGACGTGGAAAACATGTTGTACAGTGCTAGATTCTTGGTCTTAGGTTTAGGTGATGTATTTTTGGGTGCACCATGTGCTGTGCCTTTAGATCCCCGT 
4801 CACAGATTCCTAGGTTCAAAGTACAATCCTTCAAGAACATATACCAAAAATGGTGTTGTCGGTATTGGTGGGATGTACATGTGCATCTATGCTATGGATT 
4901 CACCAGGTGGTTATCAATTGGTTGGTAGAACCATTCCAATTTGGGACAAGTTGAAGTTGGGTTCTCACTCACAAGAACACCCTTGGTTGTTGACCCCATT 
5001 CGACCAAGTTGAATTTTATCCAGTCAGTGAAGAGGAGCTGGACAGATTTACCGAGGATTGCGAAAATGGTAAATTCCCAGTTCAAGTGGAAGAAAGTGTT 
5101 TTTGACCACAAGAACTACTTGAAGTGGATCAATGAAAACATTGAATCTATTACAGAATTCCAAAAGAGCCAAGGTGGTGCTAAAGCTGATGAATTCGCTA 
5201 GATTAATTCAAGTGGCTAACCAAGAACTAGAAAGTTCAACAACCAACAAGTCTGCTGTTGAGGAAGAATATCCTGAAGATGCTGAGATGGTTTACTCTGA 
5301 ATACTCGGGTCGTTTCTGGAAGCCTATGGTTTCCGCTGGGGACACCGTTACCAAGGGTGATGGTTTGGTTATTGTCGAAGCCATGAAAACCGAAATGGTT 
5401 GTGCCTGCTAAAAAATCCGGTAAGGTTTTGAAAATCGTTCACAAGAATGGTGACATGGTCGATGCCGGTGGCATAGTGGCTGTCATTCAGTAG 
Saccharomyces kluyveri Pyd13,15p sequence 
   1 MSVDTLGWSA QDWIDFHGKS TPEHSYNTLL SLLKSQKSAP EDPAWISLIN EANLAHQWKV 
  61 LQSKANKQQL PLYGVPIAVK DNIDSKGSPT TAACPAFEYN PSADSTVVAL LKDAGAIVIG 
 121 KTNLDQFATG LVGTRSPYGK TPCVFSDKHV SGGSSAGSAS AVGRGIVPIA LGTDTAGSGR 
 181 VPAALNNLIG LKPTKGLFSC SGVVPACKSL DCVSVFAMNL SDAERCFKVM AKPDLENDEY 
 241 SRPLPSNPLQ KYPKNVTIAI PKEVPWYGET ENPKLYAKAI ENLKVAGASI VTIDFEPLLA 
 301 LARCLYEGAW VAERYEATKD FFATNPPESS LDPTVTSIIK TATKYDAADS FRYEYQRQGI 
 361 LQKVDQTLKD IDVLCVPTCP LNPTFEEVAA EPVLVNSRQG TWTNFVNLAD MAALAVPAGF 
 421 RPDGLPQGVT LIGKKFTDFA LLELANRYFK VAFPQGSRTF GKFIDRQVTT KDDELRGPDI 
 481 SPEDSVKLAV VGAHLKGLPL YWQLEKVNAT YLGSPKTSKN YKLYALPKTG PILKPGLRRV 
 541 GEETGSQIQL EVYSVPKENF GEFISMVPEP LGIGSVELES GEWVKSFICE EFGYTQKGTV 
 601 DITKYGGFKK YIDFLKQEEA KVKKPFETVL IANRGEIAVR IIKTLKKLNI RSVAVYSDPD 
 661 KYSQHVIDAD LGVALNGRTA AETYLDIDKI IKAAKDTNAQ AIIPGYGFLS ENAEFADKCV 
 721 EEGIVFVGPS GEAIRKLGLK HSAREIAEKA GVPLVPGSGL VTSAKEAKEI ANKLEYPVMV 
 781 KSTAGGGGIG LQKVDSENEI ERVFETVQHQ GKAYFGDSGV FLERFVENAR HVEIQMMGDG 
 841 YGKAIAIGER DCSLQRRNQK IIEETPAPNL GETTRTKMRQ AAESLGSLLK YKCAGTVEFI 
 901 YDERRDEFYF LEVNARLQVE HPITEMVTGL DLVEWMLRIA ADDAPDFESA NIVVTGASIE 
 961 ARLYAENPAK DFRPSPGLLT DVHFPEWARV DTWVSKGTTV SAEYDPTLAK IIVHGKDRND 
1021 AIMKMNKALN ETVVYGCITN IDYLRSIASS EMFKTAKVAT KILDSYDYKP CAFEVTSPGA 
1081 YTTVQDYPGR VGYWRIGVPP SGPMDAYSFR LANRIVGNHY KAPAIELTLN GPKILFHTET 
1141 IIAISGGIAA CSLNDKPIEQ NKPIQVNRGD HLAIGKLSVG CRAYLAIRGG IDVPEYLGSR 
1201 STFALGNMGG YNGRVLKLGD VLFLNQPELA SSSLPGPAYE PQAPPANLLP KISDDKEWTI 
1261 GVTCGPHGSP DFFKPESVEE FFSEKWKVHY NSNRFGVRLI GPKPKWARKD GGEGGLHPSN 
1321 AHDYVYSLGA INFTGDEPVI ITSDGPSLGG FVCQAVVPEA ELWKVGQVKP GDSIQFVPIS 
1381 YQVARQLKES QDAAIETLED GKLQTLTSDL ILPTYEDPVL VQLPKKSNLS PKVTYRQAGD 
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1441 RYILVEYGEN QMDLNIAYRI NQLINLVGKH KTVGIVEMSQ GVRSVLIEYD GYKISQGALL 
1501 DTLVAYESEI QFDKNWSIKS KIFKLPLAFE DSKTLECVTR YQETIRSKAP WLPNNVDFVA 
1561 EVNDITHKDV ENMLYSARFL VLGLGDVFLG APCAVPLDPR HRFLGSKYNP SRTYTKNGVV 
1621 GIGGMYMCIY AMDSPGGYQL VGRTIPIWDK LKLGSHSQEH PWLLTPFDQV EFYPVSEEEL 
1681 DRFTEDCENG KFPVQVEESV FDHKNYLKWI NENIESITEF QKSQGGAKAD EFARLIQVAN 
1741 QELESSTTNK SAVEEEYPED AEMVYSEYSG RFWKPMVSAG DTVTKGDGLV IVEAMKTEMV 
1801 VPAKKSGKVL KIVHKNGDMV DAGGIVAVIQ 
Underlined sequence corrosponds to the ORF found on p638.  
Number of amino acids: 1830 (1046) 
Molecular weight: 201073.0 
Conserved Domain Search (Marchler-Bauer A, Bryant SH (2004), "CD-Search: 
protein domain annotations on the fly.", Nucleic Acids Res. 32:W327-331): 
Area: 28 – 442 
CDD: pfam01425, Amidase 
  1 TLLSLLKSQK SAPEDPAWIS LINEANLAHQ WKVLQSKANK QQLPLYGVPI AVKDNIDSKG 
 61 SPTTAACPAF EYNPSADSTV VALLKDAGAI VIGKTNLDQF ATGLVGTRSP YGKTPCVFSD 
121 KHVSGGSSAG SASAVGRGIV PIALGTDTAG SGRVPAALNN LIGLKPTKGL FSCSGVVPAC 
181 KSLDCVSVFA MNLSDAERCF KVMAKPDLEN DEYSRPLPSN PLQKYPKNVT IAIPKEVPWY 
241 GETENPKLYA KAIENLKVAG ASIVTIDFEP LLALARCLYE GAWVAERYEA TKDFFATNPP 
301 ESSLDPTVTS IIKTATKYDA ADSFRYEYQR QGILQKVDQT LKDIDVLCVP TCPLNPTFEE 
361 VAAEPVLVNS RQGTWTNFVN LADMAALAVP AGFRPDGLPQ GVTLIGKKFT DFALL 
Area: 626 – 1066 
CDD: COG0439, AccC, Biotin carboxylase 
  1 FETVLIANRG EIAVRIIKTL KKLNIRSVAV YSDPDKYSQH VIDADLGVAL NGRTAAETYL 
 61 DIDKIIKAAK DTNAQAIIPG YGFLSENAEF ADKCVEEGIV FVGPSGEAIR KLGLKHSARE 
121 IAEKAGVPLV PGSGLVTSAK EAKEIANKLE YPVMVKSTAG GGGIGLQKVD SENEIERVFE 
181 TVQHQGKAYF GDSGVFLERF VENARHVEIQ MMGDGYGKAI AIGERDCSLQ RRNQKIIEET 
241 PAPNLGETTR TKMRQAAESL GSLLKYKCAG TVEFIYDERR DEFYFLEVNA RLQVEHPITE 
301 MVTGLDLVEW MLRIAADDAP DFESANIVVT GASIEARLYA ENPAKDFRPS PGLLTDVHFP 
361 EWARVDTWVS KGTTVSAEYD PTLAKIIVHG KDRNDAIMKM NKALNETVVY GCITNIDYLR 
421 SIASSEMFKT AKVATKILDS Y 
Area: 1095 – 1394 
CDD: pfam02626, AHS2, Allophanate hydrolase subunit 2 
  1 RIGVPPSGPM DAYSFRLANR IVGNHYKAPA IELTLNGPKI LFHTETIIAI SGGIAACSLN 
 61 DKPIEQNKPI QVNRGDHLAI GKLSVGCRAY LAIRGGIDVP EYLGSRSTFA LGNMGGYNGR 
121 VLKLGDVLFL NQPELASSSL PGPAYEPQAP PANLLPKISD DKEWTIGVTC GPHGSPDFFK 
181 PESVEEFFSE KWKVHYNSNR FGVRLIGPKP KWARKDGGEG GLHPSNAHDY VYSLGAINFT 
241 GDEPVIITSD GPSLGGFVCQ AVVPEAELWK VGQVKPGDSI QFVPISYQVA RQLKESQDAA 
Area: 1437 – 1650 
CDD: pfam02682, AHS1, Allophanate hydrolase subunit 1 
  1 QAGDRYILVE YGENQMDLNI AYRINQLINL VGKHKTVGIV EMSQGVRSVL IEYDGYKISQ 
 61 GALLDTLVAY ESEIQFDKNW SIKSKIFKLP LAFEDSKTLE CVTRYQETIR SKAPWLPNNV 
121 DFVAEVNDIT HKDVENMLYS ARFLVLGLGD VFLGAPCAVP LDPRHRFLGS KYNPSRTYTK 
181 NGVVGIGGMY MCIYAMDSPG GYQLVGRTIP IWDK 
Area: 1678 - 1829 
CDD: COG0511, AccB, Biotin carboxyl carrier protein 
  1 EELDRFTEDC ENGKFPVQVE ESVFDHKNYL KWINENIESI TEFQKSQGGA KADEFARLIQ 
 61 VANQELESST TNKSAVEEEY PEDAEMVYSE YSGRFWKPMV SAGDTVTKGD GLVIVEAMKT 
121 EMVVPAKKSG KVLKIVHKNG DMVDAGGIVA VI 
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Saccharomyces kluyveri PYD14 gene 
   1        .         .         .         .         .         .         .         .         . 
   ATGACAGTTGATAACCCAGTATCCTATTTCAAATCCATCTCTTCTGTTCGTGAAACGACCAAGCAGGTCTTCGATTATGTTGAACAAAAC 
    M  T  V  D  N  P  V  S  Y  F  K  S  I  S  S  V  R  E  T  T  K  Q  V  F  D  Y  V  E  Q  N      
  91        .         .         .         .         .         .         .         .         . 
   GATGGTCAAGGCAATCACTTTAAAATGGAGCTGTCTAAAATGGACGACGTTGTTGATTTTTTGTGCTCAATAATTGCCCGTGATTACGGA 
    D  G  Q  G  N  H  F  K  M  E  L  S  K  M  D  D  V  V  D  F  L  C  S  I  I  A  R  D  Y  G      
 181        .         .         .         .         .         .         .         .         . 
   ACGGATTATTCTTCGATCCCACCTCATGGCCGTTGGCAACACTTGAACTGTGGAAATGTTCTCCGTGTCGAAAGCTTGATCGAGCAATGG 
    T  D  Y  S  S  I  P  P  H  G  R  W  Q  H  L  N  C  G  N  V  L  R  V  E  S  L  I  E  Q  W      
 271        .         .         .         .         .         .         .         .         . 
   TCTGGTGCCGGTATAGACGAAGTAGAAATTTCCCGCAAGCTAATTGATTTGTTCGTGTTTAGCGTATTGGTCGATGCCGGTGCGGGGAAT 
    S  G  A  G  I  D  E  V  E  I  S  R  K  L  I  D  L  F  V  F  S  V  L  V  D  A  G  A  G  N      
 361        .         .         .         .         .         .         .         .         . 
   ACCTGGAAGTACACCACTACGGAAGAGGGTAATAAGGCCTTTGACAGATCGGAAGGGTTAGCAGTAGCTTCTTACTACTTGTTTGTCCAG 
    T  W  K  Y  T  T  T  E  E  G  N  K  A  F  D  R  S  E  G  L  A  V  A  S  Y  Y  L  F  V  Q      
 451        .         .         .         .         .         .         .         .         . 
   GGCGCATTGTCTCAAGACACCAACGACAAGTTTAAGGTCAACGGCAAAAAATTGACGGAGCTTACCATGGATGAGTTTTGCCAAGGGTTT 
    G  A  L  S  Q  D  T  N  D  K  F  K  V  N  G  K  K  L  T  E  L  T  M  D  E  F  C  Q  G  F      
 541        .         .         .         .         .         .         .         .         . 
   CAGGTCAGCGACGCCAACCCACTAAACGGTACTGAAGGTAGATTGAAGTTGATCCAAAACCTGGGCGTTGCACTATCGACTAACCCAGCC 
    Q  V  S  D  A  N  P  L  N  G  T  E  G  R  L  K  L  I  Q  N  L  G  V  A  L  S  T  N  P  A      
 631        .         .         .         .         .         .         .         .         . 
   ATATTCGGCAAAGAGGGTAGACCAGGTTGTTTGGTGGATTATTTGTACTCAAAATGCACTAAGGATAATGGAACAGCAGTTGTCGATTTA 
    I  F  G  K  E  G  R  P  G  C  L  V  D  Y  L  Y  S  K  C  T  K  D  N  G  T  A  V  V  D  L      
 721        .         .         .         .         .         .         .         .         . 
   AATGACGTATGGAACGCGTTGATGGACGGGTTTACCTCCATCTGGCCTGCCGGTAGAACCTCAATCGATGGCGAACCTTTGGGAGATGCA 
    N  D  V  W  N  A  L  M  D  G  F  T  S  I  W  P  A  G  R  T  S  I  D  G  E  P  L  G  D  A      
 811        .         .         .         .         .         .         .         .         . 
   TGGGTCTTGGACACCAAGGCCAAGGCTAGTGGCAGTGATGCCTTCTTGGACAGCATTGTCACCTTCCATAAGTTAACGCAATGGTTATGC 
    W  V  L  D  T  K  A  K  A  S  G  S  D  A  F  L  D  S  I  V  T  F  H  K  L  T  Q  W  L  C      
 901        .         .         .         .         .         .         .         .         . 
   TACTCCCTACTTGTCCCATTGGAAAACTACGGCTACAAGTTCACTATTAAGAACAAGGATATGCAAACCGGGTTGCCAGAATATAGAAAC 
    Y  S  L  L  V  P  L  E  N  Y  G  Y  K  F  T  I  K  N  K  D  M  Q  T  G  L  P  E  Y  R  N      
 991        .         .         .         .         .         .         .         .         . 
   GGTGGCCTCTTTTACGATTTTGGCGTACTGACATTGACAGACGGTGCTTACAAACGTGGGTTGGCACTGACCCAAAAGCTAGGCGACAAC 
    G  G  L  F  Y  D  F  G  V  L  T  L  T  D  G  A  Y  K  R  G  L  A  L  T  Q  K  L  G  D  N      
1081        .         .         .         .         .         .         .         .         . 
   TCCTCCAAAATTCCAACTTTCACCCCTGAAGATGGTGCCATTGTCGAGTGGAGGTGCTTGACTATTGGATTGTTGGACTATTTGCTACCA 
    S  S  K  I  P  T  F  T  P  E  D  G  A  I  V  E  W  R  C  L  T  I  G  L  L  D  Y  L  L  P      
1171        .         .         .         .         .         .         .         .         . 
   CTGGTAAACAAAAAGCTGGACTACGATTTGGTGCTGCCACAGTTGATAGAAGCTGGTAGCTGGAAAGCCGGTAGAGAAATTGCAGCTATC 
    L  V  N  K  K  L  D  Y  D  L  V  L  P  Q  L  I  E  A  G  S  W  K  A  G  R  E  I  A  A  I      
1261        .         .         .         .         .         1320    
   AAAAGACCTGACACCAAGGGTCCACCAATCGAATTACACAGCGACGGTACAGTTTTTTGA 
    K  R  P  D  T  K  G  P  P  I  E  L  H  S  D  G  T  V  F         
Saccharomyces kluyveri Pyd14p sequence 
  1 MTVDNPVSYF KSISSVRETT KQVFDYVEQN DGQGNHFKME LSKMDDVVDF LCSIIARDYG 
 61 TDYSSIPPHG RWQHLNCGNV LRVESLIEQW SGAGIDEVEI SRKLIDLFVF SVLVDAGAGN 
121 TWKYTTTEEG NKAFDRSEGL AVASYYLFVQ GALSQDTNDK FKVNGKKLTE LTMDEFCQGF 
181 QVSDANPLNG TEGRLKLIQN LGVALSTNPA IFGKEGRPGC LVDYLYSKCT KDNGTAVVDL 
241 NDVWNALMDG FTSIWPAGRT SIDGEPLGDA WVLDTKAKAS GSDAFLDSIV TFHKLTQWLC 
301 YSLLVPLENY GYKFTIKNKD MQTGLPEYRN GGLFYDFGVL TLTDGAYKRG LALTQKLGDN 
361 SSKIPTFTPE DGAIVEWRCL TIGLLDYLLP LVNKKLDYDL VLPQLIEAGS WKAGREIAAI 
421 KRPDTKGPPI ELHSDGTVF 
Number of amino acids: 439 
Molecular weight: 48647.0 
Conserved Domain Search (Marchler-Bauer A, Bryant SH (2004), "CD-Search: protein domain 
annotations on the fly.", Nucleic Acids Res. 32:W327-331): 
Area: 1 - 439 
CDD: No hits found! 
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Saccharomyces kluyveri PYD16 gene 
  1        .         .         .         .         .         .         .         .         . 
  ATGTCCTCCGAACCTTTTAAAAACGTATACTTGCTTCCTCAAACCAACCAACTTTTGGGTCTTTACACTATTATCAGAGATAAGAAAACC 
   M  S  S  E  P  F  K  N  V  Y  L  L  P  Q  T  N  Q  L  L  G  L  Y  T  I  I  R  D  K  K  T      
 91        .         .         .         .         .         .         .         .         . 
  AAGAGACCTGATTTCGTTTTCTACTCTGATAGAATTATCAGATTGCTGGTTGAAGAAGGTTTAAACCATCTGCCCGTTACTCCAAACACT 
   K  R  P  D  F  V  F  Y  S  D  R  I  I  R  L  L  V  E  E  G  L  N  H  L  P  V  T  P  N  T      
181        .         .         .         .         .         .         .         .         . 
  GTTGAAACTGATACAAATCAATCTTTCGATGGTGTTTCTTTCTTGGGTAAAATCTGCGGTGTTTCAATTGTTAGAGCTGGTGAATCCATG 
   V  E  T  D  T  N  Q  S  F  D  G  V  S  F  L  G  K  I  C  G  V  S  I  V  R  A  G  E  S  M      
271        .         .         .         .         .         .         .         .         . 
  GAGCAAGGCTTGAGAGACTGCTGCAGATCTGTCCGCATTGGTAAGATTTTGATTCAAAGAGACGAAGAAACTGCTTTGCCAAAACTTTTC 
   E  Q  G  L  R  D  C  C  R  S  V  R  I  G  K  I  L  I  Q  R  D  E  E  T  A  L  P  K  L  F      
361        .         .         .         .         .         .         .         .         . 
  TATGAAAAGTTACCTGATGACATTGCTGATAGATTTGTTTTCTTGCTAGACCCAATGTTGGCTACTGGTGGTAGTGCTATCATGGCTACT 
   Y  E  K  L  P  D  D  I  A  D  R  F  V  F  L  L  D  P  M  L  A  T  G  G  S  A  I  M  A  T      
451        .         .         .         .         .         .         .         .         . 
  GAAGTCTTAATAAAGAGAGGTGTCAAACCAGAAAGAATATTCTTTTTGAACCTAATCTGCAGCAAAGAGGGTATTGAAAACTACCATGCC 
   E  V  L  I  K  R  G  V  K  P  E  R  I  F  F  L  N  L  I  C  S  K  E  G  I  E  N  Y  H  A      
541        .         .         .         .         .         .         .         .         . 
  AAGTTCCCAACTATTAAGATTGTCACCGGTGCCTTGGATAAGGGCTTGGACGCTAACAGGTATTTGATCCCAGGTCTAGGCGATTTTGGT 
   K  F  P  T  I  K  I  V  T  G  A  L  D  K  G  L  D  A  N  R  Y  L  I  P  G  L  G  D  F  G      
631        .         .651     
  GATAGATACTACTGTATCTGA 
   D  R  Y  Y  C  I         
Saccharomyces kluyveri Pyd16p sequence 
  1 MSSEPFKNVY LLPQTNQLLG LYTIIRDKKT KRPDFVFYSD RIIRLLVEEG LNHLPVTPNT 
 61 VETDTNQSFD GVSFLGKICG VSIVRAGESM EQGLRDCCRS VRIGKILIQR DEETALPKLF 
121 YEKLPDDIAD RFVFLLDPML ATGGSAIMAT EVLIKRGVKP ERIFFLNLIC SKEGIENYHA 
181 KFPTIKIVTG ALDKGLDANR YLIPGLGDFG DRYYCI 
Number of amino acids: 216 
Molecular weight: 24373.3 
Conserved Domain Search (Marchler-Bauer A, Bryant SH (2004), "CD-Search: protein domain 
annotations on the fly.", Nucleic Acids Res. 32:W327-331): 
Area: 6 – 215 
CDD: COG0035, Upp, Uracil phosphoribosyltransferase 
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Phylogenetic relationship among PYD16/FUR1 homologous genes found in 
PYD11, PYD12 and PYD14 containing organisms. S. cerevisiae Ura5,10 
proteins were used as the outgroup. Clustering in two groups is seen. Top 
cluster contains yeast FUR1-like proteins, bottom cluster contains bacterial/fungi 
UPP-like proteins. 
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ABSTRACT 
In humans, beta-alanine (BAL) and neurotransmitter gamma-aminobutyrate (GABA) 
are transaminated by a single aminotransferase (AT) enzyme, BAL-AT I/GABA-AT 
(EC 2.6.1.19). Apparently, yeast originally also had a single enzyme, but the 
corresponding gene was duplicated in the Saccharomyces/Candida albicans lineage. 
In S. kluyveri, SkUGA1 encodes a homolog of S. cerevisiae-specific GABA-AT and 
SkPYD4 encodes an enzyme involved in BAL and GABA transamination. SkPYD4 
and SkUGA1 were sub-cloned, over-expressed, purified and characterized. It was 
found that, like in other aminotransferases, the cofactor pyridoxal 5’phosphate (PLP) 
is needed for (enzymatic) activity. SkPyd4p uses preferentially BAL as the amino 
group donor (Vmax/Km = 0.78 U mg-1 mM-1), but can also use GABA (Vmax/Km = 0.42 
U mg-1 mM-1), while SkUga1p only uses GABA (Vmax/Km = 4.01 U mg-1 mM-1). Like 
other GABA-ATs, SkPyd4p and SkUga1p use alpha-ketoglutarate, and not pyruvate 
as the amino group acceptor.  
While mammals degrade BAL and GABA with only one enzyme, but in different 
tissues, a unicellular yeast has developed two different genes/enzymes, so that it can 
apparently distinguish between the two reactions in a single cell. 
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INTRODUCTION 
In biological systems, beta-alanine (BAL) plays a major role as a precursor of 
pantothenic acid, as constituent of dipeptides like anserine and carnosine, and as an 
intermediate in the reductive degradation of pyrimidines. Because of its chemical 
similarity to the major inhibitory neurotransmitters, gamma-aminobutyrate (GABA) 
and glycine, and its presence in the brain, BAL is thought to have a similar function in 
animals. In mammals, uracil is degraded to BAL via three consecutive enzymatic 
steps (dihydropyrimidine dehydrogenase [DPD, EC 1.3.1.2], dihydropyrimidine 
amidohydrolase [DHP, EC 3.5.2.2] and beta-ureidopropionase [UP, EC 3.5.1.6]). In 
microorganisms, also other biochemical pathways provide BAL, e.g. Escherichia coli 
produces BAL by direct decarboxylation of aspartate, while Saccharomyces 
cerevisiae uses the break-down of polyamines (putrescine, spermidine and spermine) 
(Cronan, Jr., 1980; White et al., 2001; White et al., 2003). 
Mammals degrade BAL to malonic semialdehyde (MSA) using either BAL:alpha-
ketoglutarate (aKG) aminotransferase [BAL-AT I, EC 2.6.1.19] or D-3-
aminoisobutyrate:pyruvate aminotransferase [BAL-AT II, D-BAIB-AT, EC 2.6.1.40]. 
Only BAL-AT I activity can be found in rat brain, and even though BAL-AT II 
activity is present in rat liver and kidney, BAL-AT I is the dominant enzyme also in 
these tissues (Kontani et al., 1999). The produced MSA is subsequently metabolized 
by methylmalonate semialdehyde dehydrogenase [EC 1.2.1.27] to acetyl-CoA 
(Goodwin et al., 1989; Tamaki et al., 1982; Ueno et al., 1990). 
In humans, BAL-AT I and GABA-AT are identical (Schor et al., 2001). The gene is 
primarily expressed in brain, liver, pancreas and kidney, and the actual function in 
these tissues could be related to substrate availability eg. GABA-AT in brain (high 
GABA concentration) and BAL-AT I in liver (high BAL concentration). In rat, a 
processing protease in the liver modifies the enzyme in this tissue, leading to higher 
affinity for BAL, while leaving GABA affinity unchanged (Kontani et al., 1999; 
Ohyama et al., 2004). 
Even though S. cerevisiae can synthezise BAL from polyamines, it cannot use it as 
sole nitrogen source (Di Carlo et al., 1952). GABA, on the other hand, is readily used 
as sole nitrogen source by the action of UGA1 and UGA2 encoding GABA-AT and 
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succinic semialdehyde dehydrogenase, respectively (Ramos et al., 1985). Transport of 
GABA across the cell membrane is facilitated by the UGA4 gene product (Vissers et 
al., 1989). The whole GABA catabolic pathway is regulated by the transcriptional 
activator UGA3 (Andre, 1990). Many yeast strains, like Saccharomyces kluyveri and 
Schizosaccharomyces pombe can utilize BAL as sole nitrogen source, while S. 
cerevisiae cannot (LaRue and Spencer, 1968). S. kluyveri has recently become a 
useful model to study the synthesis of BAL (Gojkovic et al., 1998; Lundgren et al., 
2003), and now this yeast is employed as a model for BAL degradation. A genetic and 
enzymatic characterization of a BAL-AT (encoded by PYD4) and a GABA-AT 
(encoded by UGA1) from S. kluyveri is presented. These two enzymes are compared 
with GABA-AT from S. pombe and S. cerevisiae. These are the first genetic and 
enzymatic data presented on BAL degradation in fungi. 
MATERIALS & METHODS 
Materials 
Uracil (U0570), dihydrouracil (D7628), beta-ureidopropionate (C3750), beta-alanine 
(146064) and gamma-aminobutyrate (A5835) were purchased from Sigma. Yeast 
nitrogen base w/o amino acids and ammonium sulfate were obtained from Difco. 
Oligos were purchased from DNA Technology, Denmark. Sequencing was done by 
MWG Biotech, Germany. 
 
Strains and growth media 
The yeast and bacterial strains used in this study are presented in Table 1. The strains 
were grown in YPD medium (1 % yeast extract, 2 % Bactopeptone, 2 % glucose) or 
synthetic defined (SD) medium (1 % succinic acid, 0.6 % sodium hydroxide, 2 % 
glucose, 0.67 % yeast nitrogen base w/o amino acids and ammonium sulfate) 
supplemented with different nitrogen sources (0.5 % ammonium sulfate, 0.1 % for all 
other types). For solid medium (plates) 2 % agar was added. All percentages are w/v. 
The Escherichia coli strain XL1-Blue (Stratagene) was used for plasmid rescue, 
TOP10 was used for cloning and BL21 StarTM (DE3) was used for overexpression of 
fusion proteins, respectively. All bacteria were grown at 37°C in Luria-Bertani 
medium supplemented with ampicillin (100 mg/liter) for selection (Sambrook et al., 
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1989). G418 selection media consisted of YPD supplemented with 75 mg/L of G418 
(SIGMA G5013). 
 
Mutagenesis 
Yeast mutants were generated from the strains Y156 and Y159 with ethyl 
methanesulfonate (EMS) as described in Gojkovic et al. (Gojkovic et al., 1998). 
Mutagenized cells were plated on YPD plates (100-200 colonies pr. plate) and grown 
for 2-3 days at 25°C. The plates were replicated onto new plates containing 
ammonium sulfate (control) or uracil (DHU) as sole nitrogen source. After 5-7 days at 
25°C colonies were selected based on their inability to grow on DHU plates compared 
to the control plates. Putative mutants were tested for growth on BUP and BAL as 
sole nitrogen source. 
 
Complementation of Y947 with genomic library 
The used S. kluyveri wild type genomic library was prepared by F. Lacroute and based 
on the shuttle vector pFL44S (Bonneaud et al., 1991). Y947 was transformed with the 
library DNA using the electroporation procedure (Gojkovic et al., 2000) and plated on 
media containing beta-alanine as sole nitrogen source for selection. A number of 
transformants were tested for plasmid loss, before rescue of the plasmid, P733, into E. 
coli strain XL1-Blue. Sequencing was done using the primers M13rev-29 and 
M13uni-21. 
 
DNA sequence analysis 
Nucleotide sequence analysis and protein alignments were done with WinSeqEZ ver. 
1.0 [F. G. Hansen unpublished] and ClustalX (Thompson et al., 1997). Database 
searches were performed using the BLAST network services of the National Center 
for Biotechnology Information (http://www.ncbi.nlm.nih.gov/BLAST/). 
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Table 1 : Strains description 
Saccharomyces kluyveri strains 
Designation Reference/origin Genotype Comment 
Y057 NRRL Y-12651 Diploid, prototroph  
Y090 L. Marsch, MYA-2152 MATα thr  
Y091 L. Marsch, MYA-2153 MATa his aux  
Y156 J. Strathern, GRY1175 MATα ura3  
Y159 J. Strathern, GRY1183 MATa ura3  
Y947 Y159 MATa ura3 pyd4 EMS 
Y1042 Y90 MATα thr uga1 ::KanMX3 Disruption 
Y1043 Y91 MATa his aux uga1 ::KanMX3 Disruption 
Y1044 Y156 MATα ura3 uga1 ::KanMX3 Disruption 
Y1047 Y90 MATα thr pyd4 ::KanMX3 Disruption 
Y1048 Y91 MATa his aux pyd4 ::KanMX3 Disruption 
Y1049 Y156 MATα ura3 pyd4 ::KanMX3 Disruption 
Y1050 Y159 MATα ura3 pyd4 ::KanMX3 Disruption 
Y1154 Y1042xY1048 haploid, thr uga1 ::KanMX3 pyd4 ::KanMX3 Random spore 
Y1155 Y1042xY1048 haploid, aux uga1 ::KanMX3 pyd4 ::KanMX3 Random spore 
Escherichia coli strains 
Designation Reference/origin Genotype Comment 
XL-1 Blue STRATAGENE recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZ∆M15 Tn10 
(TetR)] 
 
TOP10 INVITROGEN F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacΧ74 recA1 araD139 ∆(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG 
 
BL21 StarTM(DE3) INVITROGEN F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3) 
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Disruption of the PYD4 and UGA1 genes.  
Replacement cassettes with very long flanking homology regions (approx. 500 bp) 
within the ORF were used to disrupt the two genes. Upon correct integration approx. 
1/3 of the ORF (the middle part) would be exchanged with the resistance cassette. The 
dominant cassette KanMX3, which confers geneticin resistance was used. PCR 
amplification was performed with Pfu polymerase (Stratagene) from wild-type 
genomic DNA (Y057) with the oligonucleotides: 
PYD4 1-5’ (CCTCTTATTCTGTCGCTGAACTT) 
PYD4 1-3’ (GACCCGGCGGGGACGAGGCAAGCTTTCAGTGCTAAAAGACCTACCATTTC) 
PYD4 2-5’ (CGAGCCCTGCCACGGCTCTGCGCCCCATGAACACTGGAACCTAAGTAATC) 
PYD4 2-3’ (CTAACCGTAAAGTTGTCTCAATGTT) 
UGA1 1-5’ (ATGACTGTTTGCGAAAGCTACTACC) 
UGA1 1-3’ (GACCCGGCGGGGACGAGGCAAGCTTTCATTTTCTTCAGCAGAAAACTCAG) 
UGA1 2-5’ (CGAGCCCTGCCACGGCTCTGCGCCCACATCATTGATGAAGTTCAAACTGG) 
UGA1 2-3’ (TTCAAAGTGTCAACAAAGATGTCAG) 
and on pFA6-KanMX3 plasmid with the oligonucleotides  
KanMX3 5’ (AAGCTTGCCTCGTCCCCGCCGGGTC),  
KanMX3 3’ (GGGCGCAGAGCCGTGGCAGGGCTCG)  
generating four 500 bp DNA products corresponding to two parts of the genes, with 
25-bp extensions (underlined) homologous to the KanMX3 marker, and one 1500 bp 
DNA product corresponding to the KanMX3 cassette. In a second PCR amplification, 
the two 500 bp parts of the genes, were fused to the KanMX3 cassette using the outer 
primers. The two resulting linear fragments of each 2500 bp was used to transform S. 
kluyveri cells using electroporation as described in Gojkovic et al., 2000, and selected 
on G-418 plates. Correct integration was confirmed by PCR. 
 
Cloning, expression and purification procedures 
Proteins were expressed using the pET151/D-TOPO expression system (Invitrogen 
K151-01). The expression vector pET151 adds a 33 amino acid N-terminal his-tag 
(MHHHHHHGKPIPNPLLGLDSTENLYFQGIDPFT) to the expressed protein. Total 
DNA from S. kluyveri (NRRL Y-12651) and S. cerevisiae (NRRL 12632) and a 
commercial cDNA library from S. pombe were used as template. The cloning was 
done as described by the manufacturer, and clones were checked for correct insertion 
by PCR and restriction analysis, before sending for sequencing. The following 
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oligonucleotides for SkPYD4 (DQ512721), SkUGA1 (DQ512722), ScUGA1 
(NP_011533) and SpUGA1 (NP_594905) were used: 
SkPYD4-5’ CACCATGCCCTCTTATTCTG 
SkPYD4-3’ CTAACCGTAAAGTTGTCTCAATG 
SkUGA1-5’ CACCATGACTGTTTGCGAAAG 
SkUGA1-3’ CTATAGTTGAGGAACAACCTTTTTC 
ScUGA1-5’ CACCATGTCTATTTGTGAACAATAC 
ScUGA1-3’ TCATAATTCATTAACTGATTTGGC 
SpUGA1-5’ CACCATGTCTTCTACTGCCAC 
SpUGA1-3’ TTAAATCAATTCGTCAATCTTCTTGAG 
The resulting plasmids were termed pET151-SkPYD4 (P895), pET151-SkUGA1 
(P896), pET151-ScUGA1 (P897) and pET151-SpUGA1 (P898). 
 
Purification procedure (Pyd4 and Uga1 proteins) 
Expression: BL-21(DE3) were transformed as described by the manufacturer. A 
preculture was made by inoculation of the transformation in 10 mL LB media [100 
µg/mL ampicilin, 100 µM PLP] and overnight growth (37°C) with shaking. The 
preculture was transferred to 1 L LB media [100 µg/mL ampicilin, 100 µM PLP] and 
the culture was grown at 37°C with shaking till the OD600 was 0.5-0.6. The 
temperature was lowered to 25°C, IPTG was added to a final concentration of 100 
µM, and the culture was grown over night (25°C). Harvesting was done by 
centrifugation at 4,225 x g for 10 min, and the harvested cells were either stored at -
80°C or processed directly. All procedures past the harvesting were done in the cold 
(ice or 4°C).  
Cell disruption: The pellet was resuspended in 20 mL lysis buffer [50 mM potassium 
phosphate pH 7.0, 300 mM potassium chloride, 100 µM PLP, 1 mM dithiothreitol 
(DTT), Complete Minus EDTA Protease Inhibitor cocktail tablets (ROCHE 
Diagnostics)] and disrupted in a French Press (4 x 1,000 psi). Cell debris was 
removed by centrifugation (24,500 x g, 30 min). 
Streptomycin treatment: Streptomycin sulfate (10 %) was added dropwise to a final 
concentration of 2 % with stirring. The precipitate was removed by centrifugation 
(24,500 x g, 30 min). 
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Desalting: The solution was desalted on a G-25 column. The column was equilibrated 
and run with buffer A [50 mM potassium phosphate pH 7.0, 300 mM potassium 
chloride, 100 µM PLP]. 
Affinity chromatography: The desalted solution was applied to a 4.5 mL Ni2+-NTA 
(Chelating Sepharose Fast Flow from Amersham Biosciences). The column was 
equilibrated and washed with 200 mL buffer I [50 mM potassium phosphate pH 7.0, 
300 mM potassium chloride, 100 µM PLP, 20 mM imidazole]. The protein was eluted 
by stripping the column with buffer B [50 mM potassium phosphate pH 7.0, 300 mM 
potassium chloride, 100 µM PLP, 10 mM EDTA]. 
(NH4)2SO4 precipitation: The protein was concentrated by ammonium sulfate 
precipitation (and removal of Ni2+ and EDTA would also be achieved). Finely ground 
solid ammonium sulfate was slowly added to obtain 70 % saturation (0.472 g 
(NH4)2SO4/ml protein solution). The solution was stirred for 15 min prior to 
centrifugation (24,500 x g, 30 min). The precipitated protein was dissolved in 6 mL 
buffer S [100 mM potassium phosphate pH 7.0, 100 µM PLP]. 
Gel filtration: A final gel-filtration step was used to remove ammonium sulfate. The 
S-12 gel-filtration column was equilibrated and run with buffer S. Active fractions 
were pooled. Glycerol was added to a final concentration of 10 % (v/v), and protein 
was stored in 200 µL and 2 mL fractions at -80°C. 
 
Purification procedure (Malonic semialdehyde decarboxylase, MSADC) 
Expression, cell disruption, streptomycin treatment and desalting (G-25 column) is the 
same as above except all potassium was exchanged for sodium and no PLP was 
added. 
Affinity chromatography: The desalted solution was added slowly to a slurry of Ni2+-
NTA material (Chelating Sepharose Fast Flow from Amersham Biosciences) on ice. 
The content was slowly swirled around for approx. 5 min, before carefully removing 
buffer by vacuum filtration, without letting the Ni2+-NTA material run dry. Wash 
buffer [50 mM sodium phosphate pH 7.0, 300 mM sodium chloride, 10 % glycerol, 
25 mM imidazole] was added, and the mixture was swirled around and vacuum 
filtered. The washing procedure was repeated several times. The column material was 
scraped of the filter and mixed with 5 mL of elution buffer [50 mM sodium phosphate 
pH 7.0, 300 mM sodium chloride, 10 % glycerol, 500 mM imidazole, 20 mM EDTA]. 
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This mixture was then transferred to a 10 mL single use syringe, with a filter placed at 
the bottom. The mixture was placed at room temperature for half an hour with regular 
invertions of the syringe, before filtering the solution through the syringe The solution 
was dispensed in a dialysis tube (10 kDa cut-off), covered with absorbant gel matrix, 
and incubated under thin-foil at 4°C to concentrate the protein solution. The volume 
was reduced to 2 mL before running a final gel-filtration on a S-12 column. The S-12 
gel-filtration column was equilibrated and run with storage buffer [100 mM sodium 
phosphate pH 7.0, 10 % glycerol]. Protein fractions were pooled and stored in 200 µL 
and 2 mL fractions at -80°C. 
Protein concentrations were determined based on the calculated extinction coefficient 
at 280 nm (www.expasy.org/tools/protparam.html) or by the colorimetric method of 
Bradford using bovine serum albumin as standard (Bradford, 1976). 
Protein purity and molecular mass determination was done by SDS-PAGE (Laemmli, 
1970). Native protein mass was determined by running native gel electrophoresis at 
four different acrylamide concentrations (4, 6, 8 and 10 %). Gels were stained with 
Coomassie Blue [40 % ethanol, 1 % acetic acid, 1 g/L R-250 Coomassie Blue] and 
destained with 1 % acetic acid. Beta-amylase (200 kDa), bovine serum albumin, 
dimer (132 kDa), bovine serum albumin, monomer (66 kDa), and carbonic anhydrase 
(29 kDa) were used as protein standards. 
Spectroscopic measurements: 
All measurements were done on a Varian Cary3 UV/Visible spectrophotometer with 
Varian data analysis tools. The spectrometer was equipped with a temperature 
controled automatic multi-cell changer. 
 
Enzyme assays 
Glutamate dehydrogenase stopped assay with quenching (GDH assay) 
The enzymatic activity of BAL-AT I type enzymes was determined in a discontinued 
assay system based on a previously described method (Weber et al., 1992). The first 
reaction (1) is catalyzed by BAL-AT I type enzymes, which converts BAL/GABA 
and aKG to malonic semialdehyde (MSA) or succinic semialdehyde (SSA) and 
glutamate respectively. The second reaction (2) is catalyzed by glutamate 
dehydrogenase (SIGMA G2626), which stoichiometrically converts glutamate to aKG 
and ammonia while reducing NAD+ to NADH. In the second reaction, aKG 
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originating from the first reaction is quenched by hydrazine, allowing the conversion 
of glutamate to go to completion.  
The two reactions are: 
BAL/GABA + aKG  <=> MSA/SSA + glutamate (1) 
glutamate + NAD+ + H2O  <=> aKG + NADH + NH4+ (2) 
The standard reaction mixture consisted of 100 mM potassium phosphate (pH 8.0), 
100 µM pyridoxal 5’-phosphate (PLP, SIGMA P9255), aKG, BAL/GABA and 0.3 – 3 
µg PYD4/UGA1 enzyme. The reaction was carried out in a total volume of 200 µL at 
30°C for 5 min. The reaction was terminated by addition of 40 µL ice-cold stop mix 
(20 % TCA/0.6 M hydrazine) and placed on ice. After incubation on ice for 10 min, 
the reaction was neutralized with 20 µL 2 M potassium hydroxide. The second 
reaction mixture contained 260 µL first raction, 640 µL 0.5 M glycine buffer (pH 9.0), 
10 µL 0.5 mM ADP (SIGMA A5285), 80 µL 2 mM NAD+ (Boehringer Mannheim) 
and 10 µL glutamate dehydrogenase to a final volume of 1 mL. A measurement of the 
initial absorbance at 340 nm was taken before adding NAD+. The reaction was carried 
out until no further rise in absorbance at 340 nm was observed (approx. 1 hour). The 
amount of glutamate was calculated from the total change in absorbance at 340 nm 
using a molar extinction coefficient of NADH of 6.22 mM-1cm-1. One unit (U) of 
BAL/GABA-AT was defined as the amount of enzyme which catalyzed the formation 
of 1 µmol of glutamate in 1 min. 
Succinic semialdehyde dehydrogenase coupled assay (SSADH assay) 
In a continous assay, the succinic semialdehyde produced by GABA-AT (3) is 
converted by the NADP+-dependent SSADH (4), a E. coli gabD gene product, to 
NADPH and succinate. The absorbance change at 340 nm is monitored. The 
following enzymatic reactions are involved: 
aKG + GABA <=> glutamate + SSA (3) 
SSA + NADP+ + H2O <=> succinate + NADPH (4) 
The gabD gene cloned in the overexpression plasmid pET23a(+) (P899) was kindly 
provided by M.D. Toney (University of California, Davis), and the purification was 
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executed as described previously (Liu et al., 2004). The activity of the purified 
SSADH was determined at 30°C in a reaction mixture containing 10 µL 1/10 diluted 
SSADH, 10 µL 30 mM SSA (SIGMA S1505), 10 µL 20 mM NADP+ (SIGMA 
N0505), 970 µL 100 mM potassium phosphate (pH 7.0). One unit (U) of SSADH was 
defined as the amount of enzyme which catalyzed the formation of 1 µmol of 
succinate in 1 min. The SSADH activity was calculated to be 0.15 U µL-1 based on the 
change in absorbance at 340 nm and a molar extinction coefficient of NADPH of  
6.22 mM-1cm-1. The amount of SSADH in the assay was optimized, so SSADH was 
not limiting the reaction. One unit (U) of GABA-AT was defined as the amount of 
enzyme which catalyzed the formation of 1 µmol of SSA in 1 min.. Standard GABA-
AT assay conditions were 100 mM potassium phosphate (pH 8.0), 100 µM PLP, 0.3 
units/mL SSADH, 0.4 mM NADP+, aKG, GABA and 0.5 – 9 µg SkPYD4/SkUGA1 
enzyme. The assay could not be used to monitor the production of MSA from BAL-
AT reaction. 
Malonic semialdehyde decarboxylase coupled assay (MSADC assay) 
A continous assay coupling BAL-AT produced malonic semialdehyde (MSA) (5) 
with the reaction of Pseudomonas pavonaceae 170 MSADC (6) was developed. The 
MSADC-generated acetaldehyde (7) was monitored by following the depletion of 
NADH at 340 nm using a NADH-dependent alcohol dehydrogenase (ADH) 
(Poelarends et al., 2003). The three coupled reactions are: 
aKG + BAL <=> glutamate + MSA (5) 
MSA <=> acetaldehyde + CO2 (6) 
acetaldehyde + NADH <=> ethanol + NAD+ (7) 
The overexpression vector pET(130) containing the P. pavonaceae 170 orf130 
encoding MSADC was kindly provided by C.P. Whitman (University of Texas at 
Austin) (Poelarends et al., 2003). The gene was cloned into pET101/D-TOPO 
(Invitrogen), using the 5’ primer CACCATGCCACTTCTCAAG and the 3’ primer 
GACGAGGTCCCCAGTC. The resulting plasmid (P900) was sequenced. 
Transformation, expression and purification was done as described above. Amounts 
of MSADC and ADH were optimized to concentrations which are not limiting for the 
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reaction. One unit (U) of BAL-AT was defined as the amount of enzyme which 
catalyze the formation of 1 µmol MSA per min. Since the BAL-AT catalyzes the 
limiting reaction, the activity can be calculated from the amount of NADH reduced to 
NAD+ using the extinction coefficient of NADH of 6.22 mM-1cm-1. The standard 
BAL-AT assay conditions (1 mL total volume) were 100 mM potassium phosphate 
(pH 9.0), 0.2 mM NADH, 5 µL ADH (SIGMA A3263), 50 µL MSADC, aKG, BAL, 
2 – 30 µg SkPyd4p/SkUga1p. 
 
Data analysis 
All data analysis was done using the commercial curve-fitting EnzFitter version 2.0 
from Biosoft.  
RESULTS 
Identification of PYD4 gene encoding a beta-alanine aminotransferase 
While screening EMS mutagenized cells on dihydrouracil plates, a mutant, Y947 
(MATa ura3 pyd4), which could use neither dihydrouracil (DHU), beta-
ureidopropionate (BUP) nor beta-alanine (BAL), but uracil as sole nitrogen source, 
was isolated. This mutant would normally be considered a double mutant, since both 
BUP and BAL can serve as a direct nitrogen source via the action of UP or BAL-AT. 
However, the complementation with the genomic library yielded plasmid P733, which 
could grow on all three nitrogen sources (DHU, BUP and BAL). An ORF, termed 
PYD4 (DQ512721), encoding a protein with 55 % identity at the protein level to S. 
cerevisiae UGA1 gene product, GABA-AT, was identified. A BLAST search of 
ScUGA1 in the S. kluyveri genome (Cliften et al., 2003) revealed another homologous 
gene, termed SkUGA1 (DQ512722). Its gene product has 80 % identity to ScUga1p, 
and 57 % to SkPyd4p. Knock-out strains of both, PYD4 and UGA1, were constructed 
in different background strains (Table 1). Two double mutants (Y1154 and Y1155) 
were made from crossing and sporulation of Y1042 (∆uga1) and Y1048 (∆pyd4) 
(Table 1). Strains were tested for their ability to utilize DHU, BUP, BAL and GABA 
as nitrogen sources (Table 2). The Y1048 (∆pyd4) strain showed low growth on BAL. 
However, in contrast to Y947 (pyd4) it could grow on both DHU and BUP. Y1042 
(∆uga1) showed decreased growth on GABA, but was able to grow on the other 
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nitrogen sources tested. The double mutants Y1154 and Y1155 showed decreased 
growth on both BAL and GABA as sole nitrogen source. These results suggest that 
SkPYD4 is primarily involved in BAL degradation, but also has some influence on 
GABA degradation. SkUGA1, on the other hand, is only involved in GABA 
degradation. The remaining poor growth on BAL and GABA, when both genes are 
disrupted, indicates the presence of some unspecific background GABA-AT and 
BAL-AT activity in the cells.  
 
Sequence analysis 
Phylogenetic analysis of homologous proteins from yeast shows that the Pyd4p 
protein is only found in two other yeasts (Debaryomyces hansenii and Candida 
albicans). Both yeasts also contain a putative Uga1p encoding gene (Figure 1). When 
a search for Pyd2p and Pyd3p encoding genes was performed, it was found that S. 
kluyveri is the only yeast having all three genes, C. albicans and D. hansenii lack 
PYD2, and K. lactis has PYD2 and PYD3, but lacks PYD4 (Table 3). A phylogenetic 
tree of all Pyd4/Uga1 homologous proteins found in fungi with mammalian BAL-AT 
I and BAL-AT II (DBAIB-AT) is shown in Figure 2. ScCar2p and ScArg8p are 
included to illustrate general phylogenetic relationships. 
 
Table 2: Growth of pyd4 and uga1 mutant strains on uracil (URA), dihydrouracil (DHU), beta-ureidopropionate (BUP), 
beta-alanine (BAL) and gamma-aminobutyrate (GABA) media. +++ = good growth, + = growth, +/- = some growth, - = 
no growth 
Mutant URA DHU BUP BAL GABA 
Y-947 (pyd4) +++ - - - +++ 
Y-1042 (∆uga1) +++ +++ +++ +/- +++ 
Y-1048 (∆pyd4) +++ +++ +++ +++ + 
Y-1154 (∆uga1 ∆pyd4) +++ +++ +++ +/- +/- 
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Figure 1: Phylogenetic tree of yeast Pyd4p and Uga1p. Sk = S. kluyveri, Dh = D. 
hansenii, Ca = C. albicans, Yl = Y. lipolytica, Cg = C. glabrata, Eg = E. gossypii, 
Kl = K. lactis, Sc = S. cerevisiae, Sp = S. pombe. SpUga1p (NP_594905) was 
used as an outgroup. 
Table 3: Homologous proteins in K. lactis, D. hansenii and C. albicans. Numbers in brackets show percent identity to 
the S. kluyveri protein. 
Specie PYD2 PYD3 PYD4 
K. lactis XP_453052 (69 %) XP_453223 (77 %) No homolog 
C. albicans No homolog XP_714639 (54 %) XP_721100 (64 %) 
D. hansenii* No homolog XP_458518 (53 %) 
XP_460391 (53 %) 
XP_460765 (61 %) 
*There were two PYD3 homologous genes in D. hansenii (60 % identical to each other). 
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Cloning and expression 
The PYD4/UGA1 genes from S. kluyveri, S. cerevisiae and S. pombe, were sub-
cloned. Four expression plasmids (pET151-SkPYD4, pET151-SkUGA1, pET151-
ScUGA1 and pET151-SpUGA1, respectively) were constructed using the pET151/D-
TOPO cloning system. Sequencing confirmed correct cloning with no mutations, 
except for ScUGA1. Here a change (719 A->G) was found resulting in an amino acid 
change (H240R), when compared to the reference sequence NP_011533. In the 
original published sequence, position 719 is a guanine not adenine (Andre and 
Jauniaux, 1990). This is also noted in the SwissProt entry P17649 (even though the 
actual protein sequence in this entry has a histidine at position 240). The ScUGA1 
sequence was deposited in genbank (DQ512723). All the other yeast Uga1 proteins 
used in the phylogenetic analysis including S. pombe have an arginine at that position, 
 
Figure 2: Phylogenetic tree of eukaryotic BAL/GABA-AT. Ornithine-AT (ScCar2p) and 
acetylornithine-AT (ScArg2p) from S. cerevisiae are also shown. Sk = S. kluyveri, Dh = D. 
hansenii, Ca = C. albicans, Yl = Y. lipolytica, Cg = C. glabrata, Eg = E. gossypii, Kl = K. 
lactis, Sc = S. cerevisiae, Gz = G. zeae, An = A. nidulans, Af = A. fumigatus, Nc = N. crassa, 
Mg = M. grisea, Sp = S. pombe, Cn = C. neoformans, Um = U. maydis, Rn = rat, Bt = bull, 
Hs = human, Cf = dog. Note that some fungi have only one protein, while S. kluyveri and 
relatives have two. Apparently, the duplication took place after the separation of the S. 
kluyveri/C. albicans/D. hansenii lineage split from the rest of yeasts and fungi. 
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so it is most likely that the reference sequence is wrong, and the pET151-ScUGA1 
clone contains the wild-type sequence. 
A typical purification of SkPyd4p from 1 liter culture yields approx. 20 mg pure 
protein. The SDS-PAGE gel in Figure 3 shows the different fractions during the 
purification. The purified protein fractions show only minor impurities (Figure 4). The 
molecular weight of the protein was determined to be 56-57 kDa based on SDS-
PAGE gel, matching the calculated values of between 56.3-56.9 kDa. The purified 
proteins were dimers as determined by native gel. Some of the ScUga1 and SkUga1 
proteins were seen as tetramers.  
 
Absorption spectrum 
The spectrum of purified SkPyd4p showed two maxima (340 nm and 410 nm) besides 
the 280 nm absorbance. When the pH varied between 6.6 and 8.6, a pH dependent 
shift of these maxima was observed (Figure 5). When the protein was dialysed against 
3 times 1 L buffer S without PLP, the 340/410 nm absorption maxima disappeared 
(Figure 6). The protein without the 340/410 nm absorption was inactive.  
 
 
 
 Figure 4: SDS-PAGE of purified SkPyd4p (1-2), SkUga1p (3-4), 
ScUga1p (5-6) and SpUga1p (7-8). Benchmark Ladder (10). 
The 50 kDa reference is indicated 
Figure 3: SDS-PAGE showing different 
fractions of SkPyd4p purification. French Press 
(1), Streptomycin (2), G-25 col.(3), Ni2+ col. flow 
through (4), Ni2+ col. eluat (5), S-12 (6), 
Benchmark Ladder (7).  
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When PLP was added to the dialysed protein the 340/410 nm absorption reappeared 
and the protein becomes active again. When the reconstituted protein is compared to 
buffer containing PLP in the same concentration (10 µM), there is a shift in the 
maxima from 330/390 nm for PLP to 340/410 nm in the reconstituted SkPyd4p, 
 
Figure 5: Absorption spectra of SkPyd4p. The pH values used were 6.6, 7.0, 
7.5 and 8.6, as indicated on the graph. A decline at 410 nm and an increase at 
340 nm is seen when pH is increased. 
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Figure 6: Dialysis experiment. Full line = Dialysed SkPyd4p, Broken line = Dialysed SkPyd4p 
incubated 24 hours at 4°C with 100 µM PLP, Dotted line = 100 µM PLP. A shift from 390 nm to 
410 nm and an increase at 330 nm is seen upon PLP binding to the enzyme. 
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indicating the formation of the Schiff base of the formyl group of PLP with the ε-
amino group of a special lysine residue of the protein. From sequence alignment with 
E coli GABA-AT it can be deduced that the special lysine of SkPyd4p forming the 
Schiff base must be K329. 
 
Enzyme kinetic measurements 
Three assays were used in the kinetic measurements. The GDH assay has the 
advantage that it is based on the determination of the amino acceptor product, i.e. both 
BAL and GABA can be measured. But it has the disadvantage that hydrazine has to 
be added to remove aKG from the first reaction, and this influences the glutamate 
detection. The detection efficiency for glutamate was tested at different aKG 
concentrations, and it was found that for aKG concentrations higher than 5 mM the 
detected glutamate decreased. This is not a problem when determining relative 
activities at a fixed aKG concentration. For a full kinetic analysis a broad spectrum of 
concentrations is needed, and therefore the varying sensitivity of the GDH assay has 
disadvantages and it is very time-consuming. The lack of sensitivity could be 
overcome to some degree by adding GDH enzyme in amounts, which were not 
practical for large series of kinetic analysis experiments. The SSADH assay, on the 
other hand, is a very sensitive, continuous assay with no interference between first and 
second reaction. 
 
pH optimum and substrate specificity 
A series of measurements at different pH was done on SkPyd4p (Figure 7). The pH 
optimum was close to 8.0 with approximately 70 % activity at pH 7 and 9. This pH is 
in agreement with other GABA/BAL-AT, and was used for all assays. The enzyme’s 
stability at 4°C was tested and after 12 days 57 % activity was left. 
The purified enzymes were tested for their ability to use either BAL or GABA as 
amino donor (Table 4). There is a little inconsistency in the relative activities 
determined using the different methods, but in general it can be seen that SkPYD4 is 
more active with BAL, while the other three enzymes show only GABA-AT activity. 
In addition, SkPyd4p does not use pyruvate as amino acceptor. 
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Kinetic analysis of SkPyd4p and SkUga1p 
A full kinetic analysis on SkPyd4p and SkUga1p was done. Since SkUga1p had so 
little activity with BAL, only SkPyd4p was analyzed with BAL. A lot of effort was 
put into analysis using the GDH assay. At aKG concentration up to 2 mM, it was 
possible to produce data sets which could be fitted to Michaelis-Menten kinetics using 
equation 1 (Figure 8, A and C). When the inverted data was analysed (Figure 8, B and 
D) very poor fits were achieved. When the same data were subjected to a global non-
linear regression fit using commercial EnzFitter software it was clear that the data sets 
did not fit each other (Figure 9).  
Vi = Vmax[S]/(KM,S + [S])  (1) 
, where Vi = initial velocity, Vmax = maximal velocity, [S] = varied substrate (GABA, 
BAL or aKG), KM,S = Michaelis constant for S. The other assays (SSADH and 
MSADC) were much more reliable, and produced data sets that could be fitted to 
 
Figure 7: SkPyd4p activity at different pH. Standard conditions: GDH assay, 
5 minutes at 30°C, 50 mM BAL, 10 mM aKG, 100 µM PLP, 0.3 µg SkPYD4. 
Buffers (0.1 M): pH 5 (sodium acetate), pH 6 (potassium phosphate), pH 7 
(potasium phosphate), pH 8 potasium phosphate), pH 9 (glycine/sodium 
hydroxide). 
Table 4: Activity (U mg-1) of SkPyd4p, SkUga1p, ScUga1p and SpUga1p. Relative activities (%) are given in 
parentheses. The enzyme with the highest specific activity in each column is set to 100 %.  
 BAL* GABA* BAL** GABA*** 
SkPyd4p 4.5 (100) 1.6 (21) 3.52 (100) 0.75 (6) 
SkUga1p 0.13 (3) N.D. 0.10 (3) 12.8 (100) 
ScUga1p 0.00 (0) 3.6 (48) 0.15 (4) N.D. 
SpUga1p 0.00 (0) 7.5 (100) 0.14 (4) N.D. 
*Determined with GDH assay. **Determined with MSADC assay. ***Determined with SSADH assay. N.D. = not 
determined 
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EnzFitter algorithm (Figure 10, 11, 12). The GABA-AT data sets produced with the 
SSADH assay were fitted to equation 2.  
Vi = Vmax[S1][S2]/(KM,S1[S2] + KM,S2[S1] + [S1][S2])  (2) 
, where S1 = GABA or BAL, S2 = aKG. 
The BAL-AT data sets produced with the MSADC assay allowed usage of a higher 
concentrations of aKG (10 mM), revealing product inhibition by aKG. This data set 
was fitted to equation 3. 
Vi = Vmax[S1][S2]/(KM,S1[S2](1 + [S2]/Ki,S2) + KM,S2[S1] + [S1][S2])  (3) 
, where the inhibitor term 1+[S2]/Ki,S2 has been added to eq. 2. affecting KM,S1 in a 
S2-concentration dependent manor. The kinetic parameters for SkPyd4p and SkUga1p 
obtained from the fitting are presented in Table 5.  
 
 
Table 5: BAL-AT and GABA-AT analysis of SkPYD4 and SkUGA1.  
 Vmax 
(U mg-1) 
KM,BAL 
(mM) 
KM,GABA 
(mM) 
KM,aKG 
(mM) 
Ki,aKG 
(mM) 
SkPyd4p GDH assay 7.47 
(1.32) 
7.6 
(2.1) 
N.D. 2.1 
(0.6) 
N.D. 
SkPyd4p SSADH 
assay 
0.75 
(0.03) 
N.D. 1.8 
(0.2) 
0.18 
(0.02) 
N.D. 
SkUga1p SSADH 
assay 
12.83 
(0.27) 
N.D. 3.2 
(0.2) 
0.22 
(0.01) 
N.D. 
SkPyd4p MSADC 
assay 
6.43 
(0.21) 
8.2 
(0.4) 
N.D. 2.9 
(0.2) 
28.3 
(6.7) 
Standard errors of the fit are given in parentheses. One unit (U) is defined as the amount of enzyme needed to 
convert one µmole substrate into product per minute. N.D. = not determined. 
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Figure 8: Kinetic analysis of SkPyd4p BAL-AT activity (GDH assay). (A) Plot of activity (U mg-1) vs. BAL 
concentration (mM). aKG concentrations: 0.25 mM (RED), 0.5 mM (CYAN), 1 mM (GREEN), 2 mM (BLUE). (B) 
Plot of activity (U mg-1) vs. aKG concentration (mM). BAL concentrations: 2.5 mM (RED), 5 mM (CYAN), 10 mM 
(GREEN), 20 mM (BLUE), 40 mM (PINK). Curves in (A) and (B) are nonlinear regression fits of each data set to 
eq. 1. (C) Double reciprocal plot of activity (U mg-1) vs. BAL concentration (mM). aKG concentrations: see (A). (D) 
Double reciprocal plot of activity (U mg-1) vs. aKG concentration (mM). BAL concentrations: see (B). 
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Figure 9: Full kinetic analysis of SkPyd4p BAL-AT activity (GDH assay). (A) Plot of activity (U mg-1) vs. BAL 
concentration (mM). aKG concentrations: 0.25 mM (RED), 0.5 mM (CYAN), 1 mM (GREEN), 2 mM (BLUE). (B) 
Plot of activity (U mg-1) vs. aKG concentration (mM). BAL concentrations: 2.5 mM (RED), 5 mM (CYAN), 10 mM 
(GREEN), 20 mM (BLUE), 40 mM (PINK). Curves in (A) and (B) are global nonlinear regression fits of all data set 
to eq. 2. (C) Double reciprocal plot of activity (U mg-1) vs. BAL concentration (mM). aKG concentrations: see (A). 
(D) Double reciprocal plot of activity (U mg-1) vs. aKG concentration (mM). BAL concentrations: see (B). 
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Figure 10: Full kinetic analysis SkPyd4p GABA-AT activity (SSADH assay). (A) Plot of activity (U mg-1) vs. GABA 
concentration (mM). aKG concentrations: 0.1 mM (RED), 0.2 mM (CYAN), 0.4 mM (GREEN), 0.8 mM (BLUE), 1 
mM (PINK). (B) Plot of activity (U mg-1) vs. aKG concentration (mM). GABA concentrations: 1.5 mM (RED), 2.5 mM 
(CYAN), 5 mM (GREEN), 7.5 mM (BLUE). Curves in (A) and (B) are global nonlinear regression fits of all data set 
to eq. 2. (C) Double reciprocal plot of activity (U mg-1) vs. GABA concentration (mM). aKG concentrations: see (A). 
(D) Double reciprocal plot of activity (U mg-1) vs. aKG concentration (mM). GABA concentrations: see (B). 
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Figure 11: Full kinetic analysis SkUga1p GABA-AT activity (SSADH assay). (A) Plot of activity (U mg-1) vs. GABA 
concentration (mM). aKG concentrations: 0.1 mM (RED), 0.2 mM (CYAN), 0.4 mM (GREEN), 1 mM (BLUE), 2 mM 
(PINK). (B) Plot of activity (U mg-1) vs. aKG concentration (mM). GABA concentrations: 2 mM (RED), 4 mM 
(CYAN), 10 mM (GREEN), 20 mM (BLUE), 40 mM (PINK). Curves in (A) and (B) are global nonlinear regression 
fits of all data set to eq. 2. (C) Double reciprocal plot of activity (U mg-1) vs. GABA concentration (mM). aKG 
concentrations: see (A). (D) Double reciprocal plot of activity (U mg-1) vs. aKG concentration (mM). GABA 
concentrations: see (B). 
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Figure 12: Full kinetic analysis SkPyd4p BAL-AT activity (MSADC assay). (A) Plot of activity (U mg-1) vs. BAL 
concentration (mM). aKG concentrations: 0.5 mM (RED), 1 mM (CYAN), 2 mM (GREEN), 5 mM (BLUE), 10 mM 
(PINK). (B) Plot of activity (U mg-1) vs. aKG concentration (mM). BAL concentrations: 1 mM (RED), 2 mM (CYAN), 4 
mM (GREEN), 8 mM (BLUE), 20 mM (PINK). Curves in (A) and (B) are global nonlinear regression fits of all data set 
to eq. 2. (C) Double reciprocal plot of activity (U mg-1) vs. BAL concentration (mM). aKG concentrations: see (A). (D) 
Double reciprocal plot of activity (U mg-1) vs. aKG concentration (mM). BAL concentrations: see (B). 
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 DISCUSSION 
Identification of a novel BAL-AT encoding gene 
In S. cerevisiae only one gene encoding a GABA-AT (ScUGA1) is found, while S. 
kluyveri has two ScUGA1-like genes. This study identifies that one of these genes, 
SkPYD4 is a novel GABA-AT-like encoding gene involved in BAL degradation. It 
was isolated from a pyd4 mutant unable to grow on DHU, BUP and BAL as sole 
nitrogen source, but a strain with the gene disrupted (∆pyd4) could grow on DHU and 
BUP as sole nitrogen source. This contradictory result is difficult to explain, since the 
SkPYD4 gene complements all three growth defects. It could be that BAL and BAL 
derived compounds, which originate from DHU and BUP, are toxic to the pyd4 strain. 
Close homologues of SkPYD4 are found in two other yeast strains (D. hansenii and C. 
albicans), along with homologues of PYD3, but not PYD2. A more closely related 
species (K. lactis) does not have the PYD4 gene, but has both a PYD2 and a PYD3 
homologous gene. Apparently, the original PYD4/UGA1 gene was duplicated in one 
yeast lineage, but later on in some descendant lineages one of the duplicated genes 
was lost. The estimated time point for the gene duplication would be after Y. lipolitica 
split from the Saccharomyces/Candida/Debaryomyces lineages, approx. >200 mill. 
years ago. 
 
Gene duplication and speciation 
The other homologous gene (SkUGA1) is shown to be equivalent to ScUGA1, both by 
phylogenetically relationship and by the phenotype of a targeted disruption. In 
mammals, BAL-AT and GABA-AT activity derive from the same gene-product. In rat 
(but not in humans or pig) post transcriptional modification in the liver transforms the 
brain type GABA-AT to the liver type BAL-AT I (Kontani et al., 1999). The naming 
of the two types of enzymes is a little misleading since the kinetic parameters reported 
in the literature are almost the same. The presence of two separate genetic loci in S. 
kluyveri for enzymes with distinct substrate specificity indicates a recent duplication 
of a BAL/GABA-AT into the specialized PYD4 and UGA1 gene(s). The function of 
the preduplicated gene can either be BAL-AT, GABA-AT, or both. To test this 
theory, SkUga1p, SkPyd4p, ScUga1p and SpUga1p were characterized. The S. pombe 
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homolog was believed to be an example of a preduplicated unspecialized gene, 
because it is the only homologous gene in the genome and phylogenetically it falls 
outside the SkUGA1 and SkPYD4 branch (Figure 2). The purified proteins clearly fell 
into two groups (Table 6). SpUga1p only had GABA-AT activity, which then 
suggests that the duplicated gene was likely a GABA-AT, and SkPYD4 is a 
neofunctionalization of one of the two copies of the yeast BAL-AT I (Force et al., 
1999). The results with SpUga1p were a little surprizing since S. pombe, like S. 
kluyveri, can use BAL as sole nitrogen source (pers. com. Jürgen Stolz, Dept. of Cell 
Biology and Plant Physiology, University of Regensburg, Germany). However, 
alternative routes for BAL/GABA are also found in Ustilago maydis, where a 
disruption of the ugatA gene encoding a Uga1p homologous protein only influences 
the BAL but not GABA utilization ability (Straffon et al., 1996). 
 
Characterization of SkPyd4p and SkUga1p 
SkPyd4p is a PLP-dependent enzyme with the typical absorption maxima at 330 and 
410 nm corresponding to the ketoenamine and enolimine form of the prosthetic group. 
Dialysis removed the prosthetic group completely, which confirms the binding 
capacity of PLP to the apoenzyme is not very strong. Addition of PLP to the 
apoenzyme can fully restore the activity of the holoenzyme. 
The pH dependency of the absorption spectrum indicates that the internal aldimine is 
present in both the ketoenamine and enolimine form.  
Both SkPyd4p and ScUga1p show a reaction mechanism involving two half-reactions 
(8 and 9 respectively). In the first half-reaction, the amino-group is transferred from 
BAL or GABA to the internal aldimine (PLP), forming a semialdehyde and 
pyridoxamine 5’-phosphate (PMP). In the second half-reaction, the amino-group of 
PMP is moved to aKG, forming glutamate and restoring PLP. 
Table 6: Summary of enzymatic activity of Pyd4p and Uga1p. 
 BAL-AT GABA-AT 
SkPyd4p + + 
SkUga1p - + 
ScUga1p - + 
SpUga1p - + 
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BAL/GABA + E-PLP <=> MSA/SSA + E-PMP (8) 
E-PMP + aKG <=> E-PLP + glutamate (9) 
This ping-pong mechanism is evidenced by the parallel lines in the double-reciprocal 
Lineweaver-Burk plots. It was further found that at high aKG concentrations (10 mM) 
in the SkPyd4p (MSADC) experiments, a larger slope was observed when BAL was 
the varied substrate, and upwardly curving data, when aKG was the varied substrate. 
The latter is due to competitive binding of aKG to the E-PLP enzyme species. The 
inhibition constant of SkPyd4p for aKG (Ki,aKG) of 28.3 mM is almost three times as 
high as that of E. coli GABA-AT with a Ki,aKG of 10.2 mM (LIU 2005). This could be 
a consequence of the neofunctionalization of SkPYD4 into a BAL-AT, where the 
active site could be modified in a way that makes GABA (and aKG) less likely to 
bind to the E-PLP species.  
It seems though that the affinity (Km) for GABA is better in SkPyd4p than in 
SkUga1p (1.8 mM and 3.2 mM, respectively), but the real difference is in the catalytic 
efficiency. SkUga1p is 10-times more efficient than SkPyd4p (Vmax/Km of 4.0 versus 
0.4 U mg-1 mM-1, respectively. More detailed questions about substrate specificity and 
structure/function relationship will be investigated when the structure determination 
of SkPyd4p and SkUga1p is completed. 
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OUTLINE 
When this project started, one of the goals was to explain the genetic and enzymatic 
background of pyrimidine degradation (PYD genes) in the yeast, Saccharomyces 
kluyveri, and to study the origin of this pathway. It was believed that the pathway 
would be similar to the reductive pathway found in mammals, insects and bacteria, 
and that S. kluyveri could be used as a model to understand this pathway in any 
eukaryote. The two genes, PYD2 and PYD3, involved in this pathway, had already 
been characterized (Gojkovic et al., 2000; Gojkovic et al., 2001). The previous 
isolation of pyd2 and pyd3 mutants, both showing a clear genotype – phenotype 
relationship, e.g. both unable to grow on uracil, was very supportive towards the 
presence of an intact reductive pathway. So, in principle it was only the first piece of 
the puzzle, PYD1, coding for dihydropyrimidine dehydrogenase (DHPDH) catalyzing 
the reduction of uracil to dihydrouracil (DHU), that was missing. Besides its ability to 
utilize exogenous uracil, DHU and beta-ureidopropionate (BUP) as sole nitrogen 
source, S. kluyveri can also utilize exogenous beta-alanine (BAL), which is a product 
of the Pyd3p enzyme activity. Mutants in S. kluyveri unable to utilize BAL as nitrogen 
source (bac1) had also been identified previously (Gojkovic et al., 1998). Another 
goal of this project was to study the genetic and enzymatic basis of S. kluyveri’s 
ability to grow on BAL as nitrogen source.  
MY THREE YEARS IN THE LAB 
At the beginning it looked like a clear genotype - phenotype relationship between the 
presence of an active uracil reductive catabolic pathway and the ability to use 
intermediates of this pathway as sole nitrogen source (Chapter 3 and (LaRue and 
Spencer, 1968)). The ability to use uracil, DHU and BUP as nitrogen sources 
followed each other in most of the yeast species tested, which supports the existence 
of a linked pathway. A clear correlation between the loss of the ability to use uracil, 
DHU and BUP as sole nitrogen sources and the recent whole genome duplication was 
observed (Chapter 3). However, some of the tested yeast did not follow the path, like 
for example species of Torulaspora and Hanseniaspora (Chapter 3, Table 1). Another 
thing was, when the thirty-eight strains were tested; the loss of the ability to use BAL 
as nitrogen source was not linked to the whole genome duplication, but apparently 
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lost more or less randomly in several lineages (Chapter 3, Table 1). The genotype – 
phenotype relationship seen in Chapter 3, was not supported when more direct genetic 
methods were used (Chapter 4). Firstly, following an extensive mutagenesis of S. 
kluyveri strains, the screening was performed to find strains unable to grow on uracil 
as sole nitrogen source. When the novel mutants (pyd) were analysed, a very 
surprizing picture emerged. The organisms ability to utilize uracil, DHU, BUP and 
BAL as sole nitrogen source has for decades been used as indication of an active 
reductive catabolic pathway (LaRue and Spencer, 1968). When screening for mutants, 
it is simply more convenient to make growth experiments rather than to purify and 
characterize specific enzymatic activities. In this respect, one crucial fact was totally 
neglected, S. kluyveri grows very weakly with thymine as sole nitrogen source, even 
though the intermediates D-dihydrothymine (DHT), D-beta-ureidoisobuturate 
(DBUIB) and D-beta-aminoisobutyrate (DBAIB) all serve as good nitrogen sources. 
In bacteria, shown to posses either the reductive pathway (West, 2001) or oxidative 
pathway (Soong et al., 2001), thymine and uracil are equally good as a nitrogen 
source and as inducers of all the enzymes involved. The obtained pyd mutants could 
be divided into six groups, based on interallelic complementation, but none of the 
mutants were allelic with PYD2 or PYD3. All the pyd mutants could grow on DHU, 
BUP and BAL. When the PYD2 and PYD3 loci were disrupted, the resulting strains 
could grow on uracil as nitrogen source, showing the presence of two pathways, one 
for uracil and one for DHU degradation. The mutant loci of the uracil degradation 
were identified and the metabolic intermediates of the pathway were examined using 
HPLC (Chapter 4). 
Previous attempts to isolate the gene(s) involved in BAL catabolism were hindered by 
the bac1 mutants inability to be complemented by the S. kluyveri genomic library. The 
isolation of the gene PYD4 encoding a BAL aminotransferase (BAL-AT) did not 
come from a mutant with the same phenotype as the bac1 mutants. The gene was 
isolated from the pyd4 mutant Y947 which, unlike bac1 mutants, could not utilize 
exogenous DHU and BUP as sole nitrogen sources (Chapter 5, Table2). The SkPyd4p 
was found to be a classical PLP-dependent enzyme, which uses BAL or gamma-
aminobutyrate (GABA) as nitrogen donor and alpha-ketoglutarate (aKG), but not 
pyruvate as nitrogen acceptor. When SkPyd4p was compared with SkUga1p, 
ScUga1p and SpUga1p, it was found that while the latter enzymes all were highly 
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specific GABA-AT enzymes, SkPyd4p was a more broad and less efficient 
BAL/GABA-AT enzyme. 
GENETIC SPLIT OF URACIL AND DHU PATHWAYS 
Six loci were found to be involved in uracil degradation in S. kluyveri. They were 
termed PYD11,12,13,14,15,16 (Chapter 4) each complementing a specific pyd mutant. 
All PYD1X could grow on DHU as a sole nitrogen source, meaning either an 
extremely unlucky distribution of mutations in the genome obtained through EMS 
mutagenesis, or uracil and DHU degradation could be genetically and biochemically 
separated. Disruption of the previosly characterized PYD2 and PYD3 loci, showed 
that ∆pyd2 and ∆pyd3 can grow on uracil, indicating that the pyd2 and pyd3 strains, 
which were previously isolated, were likely double mutants (containing also a pyd1X 
mtutation). Another example of geno-/phenotype controversy was the isolation of the 
pyd4 mutant strain Y947 (Chapter 5). This strain was isolated by chance, when 
selecting for mutants unable to grow on DHU. However, a pyd4 genotype was 
expected to be able to grow on DHU (and BUP) as sole nitrogen source, because of 
the nitrogen liberated from the beta-ureidopropionase (UP) reaction. When the gene 
was disrupted, the resulting ∆pyd4 strain could grow (as expected) on DHU and BUP. 
An explanation could be that Pyd4p is a negative regulator of PYD2 and PYD3 when 
BAL is present at high concentrations, and that the pyd4 mutant locus produces a 
protein, which cannot catabolize BAL, but can be involved in negative regulation. 
When wild type PYD4 is introduced, it removes BAL, hereby restoring the whole 
pathway. In the ∆pyd4 strain the negative regulation is absent, therefore PYD2 and 
PYD3 are not regulated by high internal BAL concentration. S. kluyveri mutant, 
having the same phenotype as ∆pyd4, were isolated (bac1 mutants) previously by 
EMS mutagenesis (Gojkovic et al., 1998), but these mutants could not be 
complemented by the genomic library or the isolated PYD4 containing plasmid (data 
not shown). These findings on ”false” phenotypes strongly motivated the use of 
targeted disruption in the further studies to make sure that each phenotype is assigned 
the right genotype. Disruption was made of all PYD1X loci and the resulting mutants 
could not grow on uracil as sole nitrogen source (Chapter 4, Table 6). The ∆pyd16 
strain could not use either uracil or uridine as sole nitrogen source, while the original 
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Y811 (pyd16) grew well on uridine. Again, a discrepancy which could be due to a 
leaky mutation or presence of several additional mutations or a pleiotropic effect of a 
single mutation. Since Y811 is also ura3 it would be termed a synthetic lethal, since it 
cannot make pyrimidines de novo (ura3) and it cannot salvage pyrimidines (pyd16 is 
identical to fur1). Interestingly, when FUR1 was originally characterized, two 
recessive mutants were found in the same allele (fur1-1 and fur1-6) (Jund and 
Lacroute, 1970). The only difference was that fur1-1 mutants were as resistant to 5-
fluorouridine as the uridine transport mutants (fui1), while fur1-6 had wild type 
sensitivity. This could indicate that PYD16/FUR1 is also involved in uridine 
utilization/transport in general. While the pyd16 strain as mentioned is also ura3, the 
∆pyd16 is not, but such a strain has been constructed in S. cerevisae and therefore 
shown to be non-lethal (Seron et al., 1999). If utilization of uracil and uridine is 
blocked, then it must be exogenous cytidine (not cytosine), that serves as sole 
pyrimidine source in this strain (and maybe some unspecific transport of nucleotides). 
MASKING THE TWO PATHWAYS 
When the ability to utilize uracil, DHU and BUP was examined in different yeasts 
(Chapter 3), it seemed that the traits are ”linked”. Either a yeast can use none or all of 
the intermediates. This pattern is expected from intermediates belogning to a single 
pathway and not from two independent pathways. Apparently, the major metabolic 
rearrangements, that occured after the last whole genome duplication in yeast (Cliften 
et al., 2006), masked the split in the pathways, and both became redundant. Off 
course, this leads to speculations on the origin of the DHU degradation pathway. In 
nature, DHU comes from the reduction of uracil, either as an intermediate in the 
catabolic pathway or as a constituent of tRNA, where a special uracil gets reduced 
directly on the RNA molecule. All tRNAs isolated from S. cerevisiae have such a 
modification, and this modification is achieved by the DUS gene family encoding 
dihydrouridine synthases (Xing et al., 2004). The further fate of dihydrouracil from 
tRNA is not known, but it seems very unlikely, that S. kluyveri PYD2 and PYD3 
should be involved in this alone. Dihydrouracil could also originate from damaged 
DNA, where more or less efficient systems are involved in their removal 
(Venkhataraman et al., 2001). Yet another explanation could be the presence of DHU 
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in S. kluyveri natural habitats, e.g. fruit flies (Drosophila species) or trees (Barker and 
Miller, 1969).  
A NEW PATHWAY 
Deciphering the function of each PYD1X gene in the new pathway is hindered by the 
fact, that very little is known about any of the intermediates except the starting 
molecule, uracil, UMP and the almost final product, urea. The function of PYD12, 
PYD13, PYD15 and PYD16 was determined by homology searches, while function of 
PYD11 and PYD14 had to be speculated on. Eventually, a plausible pathway was 
constructed, giving an explanation for the role of all PYD1X genes found (Figure 1) 
(see also Chapter 4). 
 
First step (PYD16) 
The finding that pyd16 could grow on uridine, leads to the hypothesis, that a uracil 
nucleoside or nucleotide species is the first actual reaction intermediate. And with the 
disruption of uridine hydrolase gene (URH1) further evidence came, when the strain 
could still grow on uridine (and uracil) as sole nitrogen source. Apparently, uridine 
did not have to be changed into uracil, in order for the nitrogen to be extracted. This 
gave a strong indication that uridine or a phosphorylated product (UMP, UDP and 
UTP) is the starting and central point for the degradation, and that the first step in this 
pathway is equal to the first step in the salvage pathway of uracil (Reaction 1). 
uracil + PRPP <=> UMP + pyrophosphate 1 
 
Second step (PYD11) 
Pyd11p shares a common motif with GTP cyclohydrolase II (GCH2), which catalyses 
the first step in the biosynthesis of riboflavin. GCH2 uses GTP as substrate, by first 
covalently attaching GMP to the enzyme (releasing pyrophosphate), and then 
hydrolytic opening of a guanine ring. The structure of E. coli GCH2 was solved 
recently and shows a GTP analog bound in the active site with a Mg2+ and a Zn2+ 
atom pr. monomer (Ren et al., 2005). Pyd11p has a GCH2 motif, with many residues  
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conserved (Figure 2). These conserved residues are located in the active site, 
especially around the ribose and phosphate binding, but also two residues flanking 
each side of the guanine ring (Figure 3). At the same time the two residues, hydrogen-
binding with the pyrimidine part of the guanine ring, are different in Pyd11p. The 
residue believed to be involved in the first nucleophile attack on GTP in Ec GCH2, 
Arg128 is also conserved in all SkPyd11p-like proteins (Figure 2, residue 98). 
 
Figure 1: Proposed novel uracil degradation pathway. Firstly, uracil enters the 
cell and gets phosphoribosylated to UMP by Pyd16p. The entry point for the 
degradation pathway could be any of uridine, UMP, UDP or UTP (UriX). The 
usual cell enzymes convert UMP to UriX. UTP seems to be the most likely 
candidate as entry point, but the other uridine species are also possible. UriX is 
hydrolyzed by Pyd11p, and the product ureidomalonic semialdehyde–ribose–5-
monophosphate (UMSA-RX) is released. Unspecific or enzymatic hydrolysis 
splits the N-glucosidic bond of UMSA-RX to UMSA and Rib-X. Pyd14p 
hydrolyzes UMSA to urea and malonic semialdehyde (MSA). Urea gets 
degraded to ammonia and carbon dioxide in a two step reaction by the 
enzymatic reactons of Pyd13p and Pyd15p. The further fate of MSA is not 
known, but conversion to BAL through Pyd4p is a possibility. Pyd5p reaction 
could involve coupling to CoA (MSA dehydrogenase), oxidation (malonate 
dehydrogenase) or decarboxylating and reduction (MSA decarboxylase and 
alcohol dehydrogenase). 
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Figure 2: Sequence alignment of Pyd11 and GCH2 proteins. Only residues homologous to the Ec GCH2 R49 – K154 are shown. Comments are * = conserved and in substrate binding in Ec 
GCH2, # = conserved and not involved in substrate binding in Ec GCH2, X = not conserved and involved in substrate binding in Ec GCH2. Re_PYD11: R. eutropha gi:45517327, Lpp_PYD11: 
L. pneumophila gi:52629565, Po_PYD11: Polaromonas gi:54030739, Bb_PYD11: B. bacteriovorus HD100 gi:39575245, Kl PYD11: K. lactis gi:50307699, Yl PYD11: Y. lipolytica gi:50550185, 
Eg PYD11: E. gossypii gi:45200951, Gz PYD11: G. zeae gi:46126199, Sp PYD11: S. pombe gi:6689276, Rm PYD11: R. metallidurans gi:22975820, Bj PYD11: B. japonicum gi:27382348, Nc 
PYD11: N. crassa gi:32414817, Os GCH2 O. sativa gi:50946949, Sp GCH2: S. pombe gi:19114325, At GCH2: A. thaliana GCH2, Sc GCH2: S. cerevisiae GCH2, Eg GCH2: E. gossypii 
gi:2300724, Yl GCH2: Y. lipolytica gi:50551957, Kl GCH2: K. lactis gi:50304263, Ll GCH2: L. lactis Q9CGU7, Pp GCH2: P. putida Q88QH1, Ec GCH2: E. coli P25523 
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Substitution of the two non-conserved active site residues would predict a much 
smaller active site, making it impossible for a guanine ring to fit inside (Figure 3). It is 
possible that an uracil ring would fit in this active site indicating that Pyd11p uses a 
ribosylated uracil species (UriX) as substrate. The best candidate seems to be UTP, 
because the residues involved in stabilizing/binding the ribose-triphosphate part of 
GTP is conserved. The specific nucleophile, arginine, as mentioned above is also 
conserved, which indicates a similar reaction mechanism, with covalently bound 
UMP in the case of Pyd11p reaction.  
 
If cell free extracts from S. kluyveri cells pre-grown in media containing uracil as sole 
nitrogen source, are incubated with uridine, UMP, UDP or UTP, no decline in 
absorbance at 260 nm is seen (data not shown). In these cases, a decline would be 
expected from a cyclohydrolase reaction, but even though none is seen, the reaction 
could be dependent on specific co-factors or buffer conditions. Overexpression, 
purification and characterization of SkPyd11p would help in the identification of the 
  
Figure 3: Top view (left) and side view (right) of the active site of E. coli GCH2 (PDB entry: 2BZ0). 
The GTP analogue is located in the center of the pictures. The pictures are based on the sequence 
alignment of Pyd11p and GCH2 (Figure 2). Purple: residues marked with *, Green: residues 
marked with X, Red: mutation of the GCH2 residue into the Pyd11p residue, White: Mg2+-atom, 
Cyan: Zn2+-atom. 
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substrates (under investigation). The novel compounds, UMSA-RX and UMSA, are 
not found in the literature, but a similar compound (ureidomalonate, UMAL) is an 
intermediate in the oxidative degradation of uracil. UMAL gets hydrolysed to urea 
and malonate by ureidomalonase (Soong et al., 2001). Since urea should be formed at 
a latter point, the N-glucosidic bond between the ureido group and the ribose needs to 
be hydrolysed. This could happen in in-vivo by some unspecific reaction (enzymatic 
or non-enzymatic).  
 
Third step (PYD14): 
Pyd14 was the only protein which had no homology to any known protein motifs. 
This makes it a candidate as a novel enzymatic catalyst, which use the 
uncharacterized UMSA as substrate. The proposed mechanism for Pyd14p is to 
hydrolyse UMSA to yeild urea and MSA (Figure 1). 
 
Fourth, fifth step (PYD13,15): 
It seems that the 1-N, 2-C and 3-N atoms eventually become urea and then through 
the carboxylase and hydrolase activity of Pyd13,15p get mineralized to ammonia and 
carbon dioxide. Urea formation from uracil degradation has been reported or 
hypothezised a number of times (Di Carlo et al., 1952; Reinbothe, 1964; Thwaites et 
al., 1979), and was also found in extracts from both, pyd13 and pyd15 mutants. 
Not all steps from the entry of uracil into the cells to the final ammonia are accounted 
for by the action of the PYD1X genes. The rest of the genes must either have been 
missed by the mutagenesis and screening procedure or be essential in normal cell 
metabolism (and a mutation in the gene would be lethal). 
 
Regulation (PYD12) 
Pyd12p has strong homology to zinc-finger transcription factors from fungi, which 
strongly indicates a regulatory, rather than an enzymatic role of this protein (Todd and 
Andrianopoulos, 1997). The function of these proteins is to regulate gene expression 
either positively or negatively, this would highly likely be Pyd12p’s function. S. 
cerevisiae has a protein (YDR520Cp) which is homologous to Pyd12p, which 
indicates that these proteins have a similar function in both S. cerevisiae and S. 
kluyveri. Since S. cerevisiae does not have homologs of Pyd11p and Pyd14p (and 
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cannot use uracil as sole nitrogen source), the function of YDR520Cp/Pyd12p could 
be to regulate pyrimidine metabolism in a more general fashion, including both, 
biosynthetic and salvage pathways.  
WHAT IS THE FUNCTION OF THE URACIL PATHWAY? 
The organisms (presented in Chapter 4), which have the PYD11 and PYD14 genes, 
may represent only a fraction of the organisms having the ”new” degradation 
pathway. This pathway was lost in the yeast lineage which underwent the whole 
genome duplication event, but it remained to be present in many, if not all, other fungi 
(see Appendix). Therefore, it must play an important role in the fungal metabolism. 
From the deduced pathway uracil is catabolized to urea and MSA, but it needs to go to 
the ribosylated state, UriX, using at least one PRPP molecule in the process. Why 
”waste” energy to get urea and MSA? If the environment has limited nitrogen sources, 
then the ability to degrade any exogenous nitrogen-containing compounds is an 
advantage. Pyrimidines are widely distributed in nature, and might be a dominant 
nitrogen source in some places where yeast live. The ”novel” pathway would likely be 
under control of the nitrogen catabolite repression system and be induced by uracil 
and uridine. Another function could be regulation of the intracellular pyrimidine 
nucleotide pool under nitrogen-limiting conditions. Break-down of pyrimidines might 
help the cells adapt to a slower growth rate when going from rich to poor conditions. 
The presence of a reductive uracil catabolism in plants (Katahira and Ashihara, 2002) 
also argues that the progenitor of fungi likely had the first reductive uracil degradation 
step (PYD1). Apparently, while the ”novel” pathway (through UriX to urea) evolved 
during the evolutionary history, the uracil to DHU step was lost. However, could there 
remain any traces of the ”novel” pathway in plants? 
If MSA is really an intermediate, then the possibility of producing BAL from a 
reverse BAL-AT (Pyd4p) reaction, could also be one of the functions. In S. cerevisiae, 
BAL is produced from polyamine break-down, while for example S. pombe cannot 
generate BAL in this way. Instead, S. pombe can convert BUP and uracil, (but not 
DHU) to BAL, as was shown in a mutant unable to import exogenous pantothenate 
(Stolz et al., 2004). If BAL comes from uracil in S. pombe it could then explain the 
presence of Pyd11p and Pyd14p, and the pathway could look like the proposed one 
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(Figure 1). Even though the SpUga1p enzyme is a specific GABA-AT, with very little 
BAL-AT activity (Chapter 5), the reverse reaction might be enough to supply the cells 
with BAL from MSA, as proposed for A. nidulans (Arst, Jr., 1978). There might also 
be a specific BAL-AT protein in S. pombe, not homologous to Uga1p or Pyd4p, since 
S. pombe can use BAL as sole nitrogen source. A BLAST search in the S. kluyveri 
genome sequence at NCBI showed that 9 of 11 S. cerevisiae proteins involved in 
pantothenate biosynthesis are present. The two missing genes were a second copy of 
ALD2/ALD3 (which is known to be a recent duplication), and ECM31, which is 
involved in the (R)-pantoate synthesis. It could be that ECM31 is present in the part of 
the S. kluyveri genome not sequenced (<5%). All the homologous proteins indicate an 
intact pantothenate pathway with BAL supplied from the polyamine breakdown. If the 
novel uracil degradation pathway can produce BAL, then S. kluyveri would seem to 
have an overflow of possibilities to make BAL (Figure 4).  
DUPLICATION AND SPECIATION OF UGA1/PYD4 
GENES 
Duplications are one of the main sources of new genes. While the majority of 
duplicated copies, sooner or later are lost from the genome, both copies can be 
preserved if they develop a different expression pattern (regulation) or they divide the 
original function between them or one of the copies develop a new function. 
Mammals only have one gene encoding a GABA-AT with both BAL-AT I and 
GABA-AT activities. A post transcriptional modification process modifies the 
enzyme into a liver type BAL-AT I and a brain type enzyme GABA-AT (Kontani et 
al., 1999). This maturation causes a minor but significant change in the enzyme 
affinity regarding BAL (KM,BAL = 5.3 mM and 6.1 mM, Vmax = 0.83 U mg-1 and 1.00 
U mg-1 for liver type BAL-AT I and brain type GABA-AT respectively), which could 
have a metabolic influence. In S. kluyveri these two functions are split between two 
genes. One, SkUGA1, encodes a specialized GABA-AT, which has high homology to 
UGA1 from S. cerevisiae, and is needed for normal utilization of GABA as sole 
nitrogen source. The other gene, SkPYD4, encodes a non-specialized GABA/BAL-
AT, which is absent in the S. cerevisiae genome. The difference in substrate  
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specificity can be seen from targeted gene disruption of the two loci. The PYD4 
disruption causes a cell to grow very weakly on BAL as sole nitrogen source, while 
UGA1 disruption still results in moderate growth on GABA as sole nitrogen source 
(Chapter 5, Table 2). Double disruption results in very weak growth on both 
substrates. This shows that SkPyd4p is the only specialized BAL catabolizing enzyme 
in S. kluyveri, while GABA gets metabolized primarily by SkUga1p, and to some 
degree by SkPyd4p. The weak background growth, could be a result of unspecific 
AT-activity from some of the other AT in the cells.  
Homologs of the UGA1 gene are found in all annotated fungi species from the NCBI 
databank, so its function seems to be preserved. But what is the reason that the UGA1 
gene is present in fungi? GABA comes from decarboxylation of glutamate and gets 
metabolised into succinate and thereby enters the TCA cycle. The best explanation for 
preservation of this pathway should be natural sources of GABA in the fungal 
habitats.  
 
 
 
Figure 4: Production of BAL in yeast. S. 
cerevisiae (top left) fully rely on polyamines 
(putrescine, spermine, spermidine) for BAL 
production, while S. pombe (top right) can use 
either uracil or BUP, but not DHU or 
polyamines. In S. kluyveri (bottom left) all three 
pathways are intact. 
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From the phylogeny of the Uga1/Pyd4 enzymes it is deduced that the duplication into 
Uga1p and Pyd4p took place after Y. lipolytica branched out. However, in the fungal 
group both G. zeae and C. neoformans have two Uga1p encoding genes (Chapter 5, 
Figure 2). In the basidiomycete Ustilago maydis only one gene is present with 
homology to UGA1 from S. cerevisiae (Straffon et al., 1996). Interestingly enough the 
gene is induced by both GABA and BAL, but disruption of the gene only alters the 
BAL utilization (five fold decrease in growth rate on BAL as nitrogen source) and not 
GABA utilization (same growth rate as parent strain) (Straffon et al., 1996). U. 
maydis Uga1p (XP_757227) groups phylogenetically with the SpUga1p characterized 
to be a specific GABA-AT. Apparently, omega-acid transamination is greatly 
shrouded by the over-lapping specificities from other transaminases, and it is difficult 
to rely only on genetical data, but the enzyme activity needs to be measured on 
purified enzymes. While most other yeast have only one gene (UGA1), why does S. 
kluyveri need two? It could simply be to achieve fine tuning of utilization of different 
nitrogen sources.  
SPECULATIONS ON THE PYD5 MEDIATED REACTION 
Since S. kluyveri (and many other species) can utilize BAL as sole nitrogen source, an 
efficient system for metabolising BAL and the product MSA, needs to be present, too. 
In mammals and bacteria, MSA is converted to acetyl-CoA by methylmalonic 
semaldehyde dehydrogenase (MMSADH), normally associated with valine 
metabolism (Goodwin et al., 1989; Zhang et al., 1996). In the soil bacterium P. 
pavonaceae 170 a MSA decarboxylase (MSAD) was recently identified as one of the 
enzymes involved in trans-1,3-dichloropropene catabolism (Poelarends et al., 2003). 
MSAD converts MSA into acetaldehyde and CO2 (note that this enzymatic reaction 
was utilized in BAL-AT assay in Chapter 5) and the acetaldehyde could get reduced 
to ethanol by alcohol dehydrogenase. Homologs of MMSADH or MSAD are not 
found in the S. kluyveri genome sequence. Another possibility would be oxidation of 
MSA to malonate by a MSA dehydrogenase in a reaction similar to SSA to succinate 
by SSADH (Figure 5). There are two S. kluyveri ScUGA2 homologous genes in the 
genome nucleotide sequence at NCBI (termed UGA2a and termed UGA2b with the 
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accesion no. AACE02000036:11053..12537 and AACE02000070:4699..6216, 
respectively).  
 
A BLAST search of ScUga2p identified many homologs in all fungi, and some had, 
like S. kluyveri, two genes. A phylogenetic tree of Pyd4/Uga1 proteins and Uga2 
proteins in yeast shows that the UGA2 gene was duplicated at approximately the same 
time as the PYD4/UGA2 ancestor gene, and that both pairs likely evolved in parallel 
(Figure 6). 
 
Figure 5: GABA and BAL pathways. GABA gets metabolized first to succinic semialdehyde 
(SSA) by Uga1p (GABA-AT) and then SSA gets oxidized to succinate by Uga2p (SSA 
dehydrogenase). BAL could be metabolized in a similar fashion with first product being MSA by 
the action of Pyd4p (BAL-AT) and then MSA gets oxidized by Pyd5p (MSA dehydrogenase). 
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Figure 6: Phylogenetic trees of Uga1 (left) and Uga2 (right) proteins in 
yeast. Left: The split into Uga1p and Pyd4p group is seen, and Y. lipolytica 
Uga1p being the closest to a preduplication form. Right: The split into Uga2p 
(S. cerevisiae-like) and Pyd5p (putative MSA dehydrogenase) group is seen, 
and Y. lipolytica Uga2p being the closest to a preduplication form. In both 
trees, S. pombe proteins (SpUga1p and SpUga2p) were used as an 
outgroup. 
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CONCLUDING REMARKS 
The work presented here opens a whole new area of research. The genetic foundation 
for a new pathway has opened interesting questions to be answered. What are the 
actual intermediates? This would definitely help solving the question as to what the 
function is. A putative gene regulating protein was identified (Pyd12p), but its role is 
difficult to deduce, since even though the rest of the pathway got redundant after the 
whole genome duplication, Pyd12p did not (and is present in S. cerevisiae). 
Microarray for S. kluyveri are available now, and could prove a valuable tool to 
identify even further genes involved in uracil and BAL degradation. 
 
Note added in proof: Just recently a PNAS paper reported that operon b1012 in E. coli 
K12 is involved in a ”novel” pyrimidine degradation pathway (Loh et al., 2006). The 
operon is composed of seven unidentified ORF’s (none with homology to any of 
PYD1X genes presented in this thesis) and the end-products were determined to be 3-
hydroxypropionate, ammonia and carbon dioxide. Urea was not an intermediate. 
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LIST OF ORGANISMS 
Organisms were selected based on a BLAST search for the presence of PYD11 and 
PYD14 homologous genes using TBLASTN into translated nucleotide database at 
NCBI. If only one of the genes was found this is mentioned after the species name (in 
the brackets). In the fungi group all 42 strains are shown. 
 
Bacteria having PYD11 and PYD14 (of 545 genomes) 
1. Proteobacteria α Bradyrhizobium japonicum 
2. Proteobacteria α Bradyrhizobium sp. BTAi1 
3. Proteobacteria β Polaromonas 
4. Proteobacteria β Ralstonia eutropha 
5. Proteobacteria β Ralstonia metallidurans 
6. Proteobacteria γ Legionella pneumophila str. Lens 
7. Proteobacteria γ Legionella pneumophila str. Paris 
8. Proteobacteria γ Legionella pneumophila str. Philadelphia 1 
9. Proteobacteria δ/ε Bdellovibrio bacteriovorus 
10. Cyanobacteria Synechococcus sp. JA-2-3B’a(2-13) 
11. Actinobacteria Mycobacterium vanbaalenii PYR-1 
12. Actinobacteria Mycobacterium flavescens PYR-GCK 
 
 
Eukaryota (diatoms) 
1. Bacillariophyta Coscinodiscophyceae Thalassiosira pseudonana (PYD11 only) 
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Fungi having PYD11 and PYD14 (of 42 genomes) 
1. Ajellomyces capsulatus 
2. Aspergillus clavatus 
3. Aspergillus flavus 
4. Aspergillus fumigatus 
5. Aspergillus nidulans 
6. Aspergillus terreus 
7. Botryotinia fuckeliana 
8. Chaetomium globosum 
9. Coccidioides immitis 
10. Gibberella moniliformis 
11. Gibberella zeae 
12. Magnaporthe grisea 
13. Neosartorya fischeri 
14. Neurospora crassa 
15. Phaeosphaeria nodorum 
16. Sclerotinia sclerotiorum 
17. Trichoderma reesei 
18. Uncinocarpus reesii 
19. Eremothecium gossypii 
20. Kluyveromyces lactis 
21. Kluyveromyces waltii 
22. Saccharomyces kluyveri 
23. Yarrowia lipolytica 
24. Schizosaccharomyces pombe 
25. Coprinopsis cinerea okayama 
26. Cryptococcus neoformansvar.neoformans 
27. Phanerochaete chrysosporium 
28. Ustilago maydis 
29. Rhizopus oryzae 
 
Fungi not having PYD11 and PYD14 (of 42 genomes) 
1. Candida albicans 
2. Candida glabrata 
3. Candida tropicalis 
4. Clavispora lusitaniae 
5. Debaryomyces hansenii 
6. Pichia guilliermondii 
7. Saccharomyces bayanus 
8. Saccharomyces castellii 
9. Saccharomyces cerevisiae 
10. Saccharomyces kudriavzevii 
11. Saccharomyces mikatae 
12. Saccharomyces paradoxus 
13. Encephalitozoon cuniculi 
